U.S. patent application number 17/325937 was filed with the patent office on 2022-03-17 for methods of treating cancers.
The applicant listed for this patent is Foghorn Therapeutics Inc.. Invention is credited to Ammar ADAM, Richard C. CENTORE, David LAHR, Lan XU.
Application Number | 20220079940 17/325937 |
Document ID | / |
Family ID | 1000006037690 |
Filed Date | 2022-03-17 |
United States Patent
Application |
20220079940 |
Kind Code |
A1 |
CENTORE; Richard C. ; et
al. |
March 17, 2022 |
METHODS OF TREATING CANCERS
Abstract
The present invention relates to methods and compositions for
the treatment of BAF-related disorders such as acute myeloid
leukemia.
Inventors: |
CENTORE; Richard C.;
(Wakefield, MA) ; XU; Lan; (Wellesley, MA)
; LAHR; David; (Watertown, MA) ; ADAM; Ammar;
(Cambridge, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Foghorn Therapeutics Inc. |
Cambridge |
MA |
US |
|
|
Family ID: |
1000006037690 |
Appl. No.: |
17/325937 |
Filed: |
May 20, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
63027759 |
May 20, 2020 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 35/04 20180101;
A61K 45/06 20130101; A61K 31/501 20130101; A61P 35/02 20180101 |
International
Class: |
A61K 31/501 20060101
A61K031/501; A61K 45/06 20060101 A61K045/06; A61P 35/04 20060101
A61P035/04; A61P 35/02 20060101 A61P035/02 |
Claims
1. A method of treating acute myeloid leukemia in a subject in need
thereof, the method comprising administering to the subject an
effective amount of an agent that reduces the level and/or activity
of BRG1 and/or BRM.
2-6. (canceled)
7. The method of claim 1, wherein the acute myeloid leukemia is
metastatic.
8. The method of claim 1, wherein the AML is acute promyelocytic
leukemia, arises from a pre-existing myelodysplastic syndrome or
myeloproliferative disease, treatment-related AML, AML with
recurrent genetic abnormalities, AML with myelodysplasia-related
changes, therapy-related myeloid neoplasms, myeloid sarcoma,
myeloid proliferations related to Down syndrome, blastic
plasmacytoid dendritic cell neoplasm, AML minimally differentiated,
AML without maturation, AML with granulocytic maturation,
myelomonocytic together with bone marrow eosinophilia, acute
monoblastic leukemia, acute erythroid leukemia, acute
megakaryoblastic leukemia, or acute basophilic leukemia.
9. The method of claim 1, wherein the AML harbors a DNMT3A
mutation, an FLT3-ITD mutation, a NPM1 mutation, a CEBPA mutation,
a c-KIT mutation, a RUNX1 mutation, an ASXL1 mutation, an IDH1
mutation, or an IDH2 mutation.
10. The method of claim 1, wherein the method further comprises
administering induction chemotherapy.
11. The method of claim 10, wherein the induction chemotherapy
comprises cytarabine, an anthracycline such as daunorubicin,
arsenic trioxide, all-trans-retinoic acid, or combinations
thereof.
12. The method of claim 1, wherein the method further comprises
administering consolidation therapy.
13. The method of claim 12, wherein the consolidation therapy
comprises an allogenic stem cell transplantation and/or
immunotherapy.
14. The method of claim 1, wherein the method further comprises
administering a hemopoietic stem cell transplant, gemtuzumab
ozogamicin, or a combination thereof.
15. The method of claim 1, wherein the subject or cancer has and/or
has been identified as having a BRG1 or BRM loss of function
mutation.
16. (canceled)
17. The method of claim 1, wherein the acute myeloid leukemia has
failed to respond to or progressed after administration of one or
more chemotherapeutic or cytotoxic agents.
18. The method of claim 1, wherein the acute myeloid leukemia is
resistant to, or predicted to be resistant to one or more
chemotherapeutic agents.
19. The method of claim 17, wherein the one or more
chemotherapeutic or cytotoxic agents is cytarabine, an
anthracycline such as daunorubicin, arsenic trioxide,
all-trans-retionic acid, histamine dihydrochloride, interleukin 2,
and/or gemtuzumab ozogamicin.
20. The method of claim 1, wherein the effective amount of the
agent reduces the level and/or activity of BRG1 and/or BRM by at
least 5% as compared to a reference.
21. The method of claim 1, wherein the agent that reduces the level
and/or activity of BRG1 and/or BRM in a cell is a small molecule
compound, an antibody, an enzyme, and/or a polynucleotide.
22-28. (canceled)
29. The method of 21, wherein the agent that reduces the level
and/or activity of BRG1 and/or BRM in a cell is a small molecule
BRG1 and/or BRM inhibitor of any one of Formula I-V.
30-33. (canceled)
34. The method of claim 29, wherein the small molecule BRG and/or
BRM inhibitor has the structure of any one of compounds 1-20.
35. The method of claim 21, wherein the agent that reduces the
level and/or activity of BRG1 and/or BRM in a cell is a small
molecule compound of Formula VI.
Description
SEQUENCE LISTING
[0001] The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Nov. 5, 2021 is named 51121-049002_Sequence_Listing_9_13_21_ST25
and is 43,669 bytes in size.
BACKGROUND
[0002] The invention relates to methods for modulating BRG1- or
BRM-associated factors (BAF) complexes for use in the treatment of
acute myeloid leukemia (AML). In particular, the invention relates
to methods for treatment of disorders associated with BAF complex
function.
[0003] Chromatin regulation is essential for gene expression, and
ATP-dependent chromatin remodeling is a mechanism by which such
gene expression occurs. The human Switch/Sucrose Non-Fermentable
(SWI/SNF) chromatin remodeling complex, also known as BAF complex,
has two SWI2-like ATPases known as BRG1 (Brahma-related gene-1) and
BRM (Brahma). The transcription activator BRG1, also known as
ATP-dependent chromatin remodeler SMARCA4, is encoded by the
SMARCA4 gene on chromosome 19. BRG1 is overexpressed in some cancer
tumors and is needed for cancer cell proliferation. BRM, also known
as probable global transcription activator SNF2L2 and/or
ATP-dependent chromatin remodeler SMARCA2, is encoded by the
SMARCA2 gene on chromosome 9 and has been shown to be essential for
tumor cell growth in cells characterized by loss of BRG1 function
mutations. Deactivation of BRG and/or BRM results in downstream
effects in cells, including cell cycle arrest and tumor
suppression.
[0004] AML is a cancer of the myeloid line of blood cells. AML is
characterized by the rapid growth of abnormal cells that build up
in the bone marrow and blood and interfere with normal blood cells.
AML is generally considered incurable in about 65% of subjects
under 60 years old and about 90% of subjects over 60 years old.
Typical survival of older subjects with health too poor for
intensive chemotherapy is 5-to 10-months. The five-year survival
rate for AML is about 25% overall.
SUMMARY OF THE INVENTION
[0005] The present invention features methods to treat AML, e.g.,
in a subject in need thereof.
[0006] In one aspect, the invention features a method of treating
AML in a subject in need thereof, the method including
administering to the subject an effective amount of an agent that
reduces the level and/or activity of BRG1 and/or BRM.
[0007] In another aspect, the invention features a method of
reducing proliferation of AML in a subject in need thereof, the
method including administering (e.g., oral administration) to the
subject an effective amount of an agent that reduces the level
and/or activity of BRG1 and/or BRM in the tumor.
[0008] In another aspect, the invention features a method of
suppressing metastatic progression of AML in a subject, the method
including administering (e.g., oral administration) an effective
amount of an agent that reduces the level and/or activity of BRG1
and/or BRM.
[0009] In another aspect, the invention features a method of
suppressing metastatic colonization of AML in a subject, the method
including administering (e.g., oral administration) an effective
amount of an agent that reduces the level and/or activity of BRG1
and/or BRM.
[0010] In another aspect, the invention features a method of
reducing the level and/or activity of BRG1 and/or BRM in an AML
cell, the method including contacting the cell with an effective
amount of an agent that reduces the level and/or activity of BRG1
and/or BRM in the cell.
[0011] In some embodiments of any of the above aspects, the AML
cell is in a subject.
[0012] In some embodiments of any of the above aspects, the
effective amount of the agent reduces the level and/or activity of
BRG1 by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%,
35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%)
as compared to a reference. In some embodiments, the effective
amount of the agent that reduces the level and/or activity of BRG1
by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or
95%) as compared to a reference. In some embodiments, the effective
amount of the agent that reduces the level and/or activity of BRG1
by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or
99%).
[0013] In some embodiments, the effective amount of the agent
reduces the level and/or activity of BRG1 by at least 5% (e.g., 6%,
7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference
for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20
hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours,
or more). In some embodiments, the effective amount of the agent
that reduces the level and/or activity of BRG1 by at least 5%
(e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%,
55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a
reference for at least 4 days (e.g., 5 days, 6 days, 7 days, 14
days, 28 days, or more).
[0014] In some embodiments of any of the above aspects, the
effective amount of the agent reduces the level and/or activity of
BRM by at least 5% (e.g., 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%,
35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%)
as compared to a reference. In some embodiments, the effective
amount of the agent that reduces the level and/or activity of BRM
by at least 50% (e.g., 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or
95%) as compared to a reference. In some embodiments, the effective
amount of the agent that reduces the level and/or activity of BRM
by at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or
99%).
[0015] In some embodiments, the effective amount of the agent
reduces the level and/or activity of BRM by at least 5% (e.g., 6%,
7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%,
65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a reference
for at least 12 hours (e.g., 14 hours, 16 hours, 18 hours, 20
hours, 22 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours,
or more). In some embodiments, the effective amount of the agent
that reduces the level and/or activity of BRM by at least 5% (e.g.,
6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%,
60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%) as compared to a
reference for at least 4 days (e.g., 5 days, 6 days, 7 days, 14
days, 28 days, or more).
[0016] In some embodiments, the AML expresses BRG1 and/or BRM
protein and/or the cell or subject has been identified as
expressing BRG1 and/or BRM. In some embodiments, the AML has an
elevated expression of BRG1 and/or BRM. In some embodiments, the
AML expresses BRG1 protein and/or the cell or subject has been
identified as expressing BRG1. In some embodiments, the AML has an
elevated expression of BRG1. In some embodiments, the AML expresses
BRM protein and/or the cell or subject has been identified as
expressing BRM. In some embodiments, the AML has an elevated
expression of BRM.
[0017] In some embodiments, the AML is acute promyelocytic leukemia
(APL). In some embodiments, the AML arises from a pre-existing
myelodysplastic syndrome or myeloproliferative disease. In some
embodiments, the AML is treatment-related AML, e.g., AML arising
after chemotherapy for another previous malignancy. In some
embodiments, the AML is AML with recurrent genetic abnormalities.
In some embodiments, the AML is AML with myelodysplasia-related
changes. In some embodiments, the AML is therapy-related myeloid
neoplasms. In some embodiments, the AML is myeloid sarcoma. In some
embodiments, the AML is myeloid proliferations related to Down
syndrome. In some embodiments, the AML is blastic plasmacytoid
dendritic cell neoplasm. In some embodiments, the AML is AML
minimally differentiated. In some embodiments, the AML is AML
without maturation. In some embodiments, the AML is AML with
granulocytic maturation. In some embodiments, the AML is
myelomonocytic together with bone marrow eosinophilia. In some
embodiments, the AML is acute monoblastic leukemia. In some
embodiments, the AML is acute erythroid leukemia, e.g.,
erythroleukemia or pure erythroid leukemia. In some embodiments,
the AML is acute megakaryoblastic leukemia. In some embodiments,
the AML is acute basophilic leukemia.
[0018] In some embodiments, the cytogenetics of the AML are
t(8;21), t(15;17), or inv(16). In some embodiments the cytogenetics
of the AML are normal, +8, +21, +22, del(7q), del(9q), or abnormal
11q23. In some embodiments, the cytogenetics of the AML are -5, -7,
del(5q), abnormal 3q, or complex cytogenetics.
[0019] In some embodiments, the cancer is metastatic (e.g., the
cancer has spread to the liver). The metastatic cancer can include
cells exhibiting migration and/or invasion of migrating cells
and/or include cells exhibiting endothelial recruitment and/or
angiogenesis. In some embodiments, the effective amount of an agent
that reduces the level and/or activity of BRG1 and/or BRM is an
amount effective to inhibit metastatic colonization of the AML to
the liver.
[0020] In some embodiments, the AML harbors a DNMT3A mutation. In
some embodiments, the AML harbors an FLT3-ITD mutation. In some
embodiments, the AML harbors a NPM1 mutation. In some embodiments,
the AML harbors a CEBPA mutation (e.g., a biallelic CEBPA
mutation). In some embodiments, the AML harbors a c-KIT mutation.
In some embodiments, the AML harbors a RUNX1 mutation. In some
embodiments, the AML harbors an ASXL1 mutation. In some
embodiments, the AML harbors a TP53 mutation. In some embodiments,
the AML harbors a DNMT3A mutation. In some embodiments, the AML
harbors an IDH1 mutation. In some embodiments, the AML harbors an
IDH2 mutation.
[0021] In some embodiments, the subject is over 60 years old. In
some embodiments, the subject has elevated levels of lactate
dehydrogenase.
[0022] In some embodiments, the anticancer therapy and the agent
that reduces the level and/or activity of BRG1 and/or BRM in a cell
are administered within 28 days of each other and each in an amount
that together are effective to treat the subject.
[0023] In some embodiments, the subject or cancer has and/or has
been identified as having a BRG1 loss of function mutation. In some
embodiments, the subject or cancer has and/or has been identified
as having a BRM loss of function mutation. In some embodiments, the
cancer harbors a BRG1 T910M mutation.
[0024] In some embodiments, the method further includes
administering induction chemotherapy (e.g., cytarabine, an
anthracycline such as daunorubicin, arsenic trioxide,
all-trans-retinoic acid, or combinations thereof). In some
embodiments, the method includes administering a 7-day infusion of
cytarabine and a 3-day intravenous push of an anthracycline such as
daunorubicin. In some embodiments, the method further includes
administering consolidation therapy (e.g., an allogenic stem cell
transplantation, immunotherapy such as histamine dihydrochloride
and interleukin 2, or combinations thereof. In some embodiments,
the method further includes administering a hemapoietic stem cell
transplant, gemtuzumab ozogamicin, or combinations thereof. In some
embodiments, the method further includes administering venetoclax,
gilteritinib, or combinations thereof.
[0025] In some embodiments, the cancer is resistant to one or more
chemotherapeutic or cytotoxic agents (e.g., the cancer has been
determined to be resistant to chemotherapeutic or cytotoxic agents
such as by genetic markers, or is likely to be resistant, to
chemotherapeutic or cytotoxic agents such as a cancer that has
failed to respond to a chemotherapeutic or cytotoxic agent). In
some embodiments, the cancer has failed to respond to one or more
chemotherapeutic or cytotoxic agents. In some embodiments, the
cancer is resistant or has failed to respond to cytarabine, an
anthracycline such as daunorubicin, arsenic trioxide,
all-trans-retionic acid, histamine dihydrochloride, interleukin 2,
gemtuzumab ozogamicin, dacarbazine, temozolomide, cisplatin,
treosulfan, fotemustine, IMCgp100, a CTLA-4 inhibitor (e.g.,
ipilimumab), a PD-1 inhibitor (e.g., Nivolumab or pembrolizumab), a
PD-L1 inhibitor (e.g., atezolizumab, avelumab, or durvalumab), a
mitogen-activated protein kinase (MEK) inhibitor (e.g.,
selumetinib, binimetinib, or tametinib), and/or a protein kinase C
(PKC) inhibitor (e.g., sotrastaurin or LXS196, also known as
IDE196). In some embodiments, the cancer is resistant or has failed
to respond to cytarabine, an anthracycline such as daunorubicin,
arsenic trioxide, all-trans-retionic acid, histamine
dihydrochloride, interleukin 2, and/or gemtuzumab ozogamicin. In
some embodiments, the cancer is resistant or has failed to respond
to venetoclax, gilteritinib, or combinations thereof.
[0026] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM in a cell is a small molecule compound,
an antibody, an enzyme, and/or a polynucleotide.
[0027] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM in a cell is an enzyme, e.g., a
clustered regularly interspaced short palindromic repeats
(CRISPR)-associated protein such as CRISPR-associated protein 9
(Cas9), CRISPR-associated protein 12a (Cas12a), a zinc finger
nuclease (ZFN), a transcription activator-like effector nuclease
(TALEN), or a meganuclease.
[0028] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM in a cell is a polynucleotide, e.g., an
antisense nucleic acid, a short interfering RNA (siRNA), a short
hairpin RNA (shRNA), a microRNA (miRNA), a CRISPR/Cas 9 nucleotide,
or a ribozyme.
[0029] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM in a cell is a small molecule compound,
e.g., a small molecule BRG1 and/or BRM inhibitor. In some
embodiments, the agent that reduces the level and/or activity of
BRG1 and/or BRM in a cell is a small molecule compound, e.g., a
small molecule BRG1 inhibitor. In some embodiments, the agent that
reduces the level and/or activity of BRG1 and/or BRM in a cell is a
small molecule compound, e.g., a small molecule BRM inhibitor or a
degrader.
[0030] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula I:
##STR00001##
wherein m is 0, 1, 2, 3, or 4; X.sup.1 is N or CH; and each R.sup.1
is, independently, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino.
[0031] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula II:
##STR00002##
wherein R.sup.2 is phenyl that is substituted with hydroxy and that
is optionally substituted with one or more groups independently
selected from the group consisting of halo, cyano, trifluoromethyl,
trifluoromethoxy, C.sub.1-3 alkyl, and C.sub.1-3 alkoxy; R.sup.3 is
selected from the group consisting of --R.sup.a, --O--R.sup.a,
--N(R.sup.a).sub.2, --S(O).sub.2R.sup.a, and
--C(O)--N(R.sup.a).sub.2; each R.sup.a is, independently, selected
from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl, wherein each C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl is optionally substituted with one or more
groups independently selected from the group consisting of R.sup.b,
oxo, halo, --NO.sub.2, --N(R.sup.b).sub.2, --CN,
--C(O)--N(R.sup.b).sub.2, --S(O)--N(R.sup.b).sub.2,
--S(O).sub.2--N(R.sup.b).sub.2, --O--R.sup.b, --S--R.sup.b,
--O--C(O)--R.sup.b, --C(O)-- R.sup.b, --C(O)--OR.sup.b,
--S(O)--R.sup.b, --S(O).sub.2--R.sup.b, --N(R.sup.b)--C(O)--
R.sup.b, --N(R.sup.b)--S(O)--R.sup.b,
--N(R.sup.b)--C(O)--N(R.sup.b).sub.2, and
--N(R.sup.b)--S(O).sub.2--R.sup.b; each R.sup.b is, independently,
selected from the group consisting of hydrogen, C.sub.1-6 alkyl,
C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, 3-15
membered carbocyclyl, and 3-15 membered heterocyclyl, wherein each
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.1-6
alkoxy, 3-15 membered carbocyclyl, and 3-15 membered heterocyclyl
is optionally substituted with one or more groups independently
selected from RC; or two R.sup.b are taken together with the
nitrogen to which they are attached to form a heterocyclyl that is
optionally substituted with one or more groups independently
selected from the group consisting of oxo, halo and C.sub.1-3 alkyl
that is optionally substituted with one or more groups
independently selected from the group consisting of oxo and halo;
each RC is, independently, selected from the group consisting of
oxo, halo, --NO.sub.2, --N(R.sup.d).sub.2, --CN,
--C(O)--N(R.sup.d).sub.2, --S(O)--N(R.sup.d).sub.2,
--S(O).sub.2--N(R.sup.d).sub.2, --S--R.sup.d, --O--C(O)--R.sup.d,
--C(O)--R.sup.d, --C(O)--OR.sup.d, --S(O)-- R.sup.d,
--S(O).sub.2--R.sup.d, --N(R.sup.d)--C(O)--R.sup.d,
--N(R.sup.d)--S(O)-- R.sup.d, --N(R.sup.d)--C(O)--N(R.sup.d).sub.2,
--N(R.sup.d)--S(O).sub.2-- R.sup.d, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl, wherein any C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl is optionally substituted with one or more
groups independently selected from the group consisting of R.sup.d,
oxo, halo, --NO.sub.2, --N(R.sup.d).sub.2, --CN,
--C(O)--N(R.sup.d).sub.2, --S(O)--N(R.sup.d).sub.2,
--S(O).sub.2--N(R.sup.d).sub.2, --O--R.sup.d, --S--R.sup.d,
--O--C(O)--R.sup.d, --C(O)-- R.sup.d, --C(O)-- R.sup.d, --S(O)--
R.sup.d, --S(O).sub.2--R.sup.d, --N(R.sup.d)--C(O)-- R.sup.d,
--N(R.sup.d)--S(O)-- R.sup.d, --N(R.sup.d)--C(O)--N(R.sup.d).sub.2,
and --N(R.sup.d)--S(O).sub.2--R.sup.d; each R.sup.d is,
independently, selected from the group consisting of hydrogen,
C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, carbocyclyl,
and carbocyclyl(C.sub.1-3 alkyl)-; R.sup.4 is H, C.sub.1-6 alkyl,
or --C(.dbd.O)--C.sub.1-6 alkyl; and R.sup.5 is H or C.sub.1-6
alkyl.
[0032] Compounds of Formula II may be synthesized by methods known
in the art, e.g., those described in U.S. Patent Publication No.
2018/0086720, the synthetic methods of which are incorporated by
reference.
[0033] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula III:
##STR00003##
wherein R.sup.6 is halo, e.g., fluoro or chloro; R.sup.7 is
hydrogen, optionally substituted amino, or optionally substituted
C.sub.1-6 alkyl; and R.sup.8 is optionally substituted C.sub.6-10
aryl or optionally substituted C.sub.2-9 heteroaryl.
[0034] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of any one of compounds 1-16:
##STR00004## ##STR00005## ##STR00006##
[0035] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula IV:
##STR00007##
wherein R.sup.1 is absent, H, optionally substituted
C.sub.1-C.sub.6 acyl, optionally substituted C.sub.1-C.sub.6 alkyl,
optionally substituted C.sub.3-C.sub.8 cycloalkyl, optionally
substituted C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, or --SO.sub.2R.sup.6;
##STR00008##
is 5- or 6-membered heteroarylene; each of R.sup.2 and R.sup.5 is,
independently, H or optionally substituted C.sub.1-C.sub.6 alkyl;
R.sup.3 is H or optionally substituted C.sub.1-C.sub.6 alkyl; and
R.sup.4 is H, optionally substituted C.sub.1-C.sub.6 alkyl, or
optionally substituted C.sub.1-C.sub.6 heteroalkyl; or R.sup.3 and
R.sup.4, together with the carbon atom to which each is attached,
form an optionally substituted C.sub.3-C.sub.6 cycloalkyl; R.sup.6
is optionally substituted C.sub.1-C.sub.6 alkyl or
--NR.sup.7R.sup.8; R.sup.7 and R.sup.8 are, independently,
optionally substituted C.sub.1-C.sub.6 alkyl; Het is optionally
substituted 5-membered heteroarylene, optionally substituted
6-membered heteroarylene, or
##STR00009##
A is optionally substituted C.sub.6-C.sub.10 arylene, optionally
substituted C.sub.2-C.sub.9 heterocyclylene, or optionally
substituted C.sub.2-C.sub.9 heteroarylene; L is absent, --O--,
optionally substituted C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.1-C.sub.6 heteroalkylene, optionally substituted
C.sub.2-C.sub.6 alkenylene, optionally substituted C.sub.2-C.sub.6
heteroalkenylene, optionally substituted C.sub.2-C.sub.6
alkynylene, optionally substituted C.sub.2-C.sub.6
heteroalkynylene, optionally substituted C.sub.2-C.sub.9
heterocyclylene, optionally substituted C.sub.2-C.sub.9
heterocyclyl C.sub.1-C.sub.6 alkylene, optionally substituted
C.sub.2-C.sub.9 heteroarylene, or optionally substituted
C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene; and B is H,
halogen, cyano, optionally substituted C.sub.6-C.sub.10 aryl,
optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally
substituted C.sub.2-C.sub.9 heterocyclyl, or optionally substituted
C.sub.2-C.sub.9 heteroaryl, or a pharmaceutically acceptable salt
thereof.
[0036] In some embodiments,
##STR00010##
is 6-membered heteroarylene. In some embodiments,
##STR00011##
is 5-membered heteroarylene.
[0037] In some embodiments,
##STR00012##
where each of X, Y, and Z is, independently, N or CH.
[0038] In some embodiments, the compound of Formula IV has the
structure of Formula IVa:
##STR00013##
wherein each of X, Y, and Z is, independently, N or CH; R.sup.1 is
H, optionally substituted C.sub.1-C.sub.6 acyl, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted C.sub.3-C.sub.8
cycloalkyl, optionally substituted C.sub.2-C.sub.9 heterocyclyl, or
--SO.sub.2R.sup.6; each of R.sup.2, R.sup.3, and R.sup.5 is,
independently, H or optionally substituted C.sub.1-C.sub.6 alkyl;
R.sup.4 is H, optionally substituted C.sub.1-C.sub.6 alkyl, or
optionally substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.6 is
optionally substituted C.sub.1-C.sub.6 alkyl or --NR.sup.7R.sup.8;
each of R.sup.7 and R.sup.8 is, independently, optionally
substituted C.sub.1-C.sub.6 alkyl; Het is optionally substituted
5-membered heteroarylene, optionally substituted 6-membered
heteroarylene, or
##STR00014##
A is optionally substituted C.sub.6-C.sub.10 arylene, optionally
substituted C.sub.2-C.sub.9 heterocyclylene, or optionally
substituted C.sub.2-C.sub.9 heteroarylene; L is absent, --O--,
optionally substituted C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.1-C.sub.6 heteroalkylene, optionally substituted
C.sub.2-C.sub.6 alkenylene, optionally substituted C.sub.2-C.sub.6
heteroalkenylene, optionally substituted C.sub.2-C.sub.6
alkynylene, optionally substituted C.sub.2-C.sub.6
heteroalkynylene, optionally substituted C.sub.2-C.sub.9
heterocyclylene, optionally substituted C.sub.2-C.sub.9
heterocyclyl C.sub.1-C.sub.6 alkylene, optionally substituted
C.sub.2-C.sub.9 heteroarylene, or optionally substituted
C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene; and B is H,
halogen, cyano, optionally substituted C.sub.6-C.sub.10 aryl,
optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally
substituted C.sub.2-C.sub.9 heterocyclyl, or optionally substituted
C.sub.2-C.sub.9 heteroaryl, or a pharmaceutically acceptable salt
thereof.
[0039] In some embodiments, X, Y, and Z are CH; X is N and Y and Z
are CH; Z is N and X and Y are CH; Y is N and X and Z are CH; X is
CH and Y and Z are N; Z is CH and X and y are N; Y is CH and X and
Z are N; or X, Y, and Z are N.
[0040] In some embodiments, the compound of Formula IV has the
structure of Formula IVb:
##STR00015##
or a pharmaceutically acceptable salt thereof.
[0041] In some embodiments, the compound of Formula IV has the
structure of Formula IVc:
##STR00016##
or a pharmaceutically acceptable salt thereof.
[0042] In some embodiments, the compound of Formula IV has the
structure of Formula Ic:
##STR00017##
or a pharmaceutically acceptable salt thereof.
[0043] In some embodiments, the compound of Formula IV has the
structure of Formula IVe:
##STR00018##
or a pharmaceutically acceptable salt thereof.
[0044] In some embodiments,
##STR00019##
where X' is O or S; Y' is N or CH; and Z' is N or CH.
[0045] In some embodiments, the compound of Formula IVa has the
structure of Formula V:
##STR00020##
wherein W is C or N; X' is O, S, or N--CH.sub.3; Y' is N or CH; Z'
is N or CH; R.sup.1 is absent, H, optionally substituted
C.sub.1-C.sub.6 acyl, optionally substituted C.sub.1-C.sub.6 alkyl,
optionally substituted C.sub.1-C.sub.6 heteroalkyl, optionally
substituted C.sub.3-C.sub.8 cycloalkyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, or --SO.sub.2R.sup.6; each of
R.sup.2, R.sup.3, and R.sup.5 is, independently, H or optionally
substituted C.sub.1-C.sub.6 alkyl; R.sup.4 is H, optionally
substituted C.sub.1-C.sub.6 alkyl, or optionally substituted
C.sub.1-C.sub.6 heteroalkyl; R.sup.6 is optionally substituted
C.sub.1-C.sub.6 alkyl or --NR.sup.7R.sup.8; each of R.sup.7 and
R.sup.8 is, independently, optionally substituted C.sub.1-C.sub.6
alkyl; Het is optionally substituted 5-membered heteroarylene,
optionally substituted 6-membered heteroarylene, or
##STR00021##
A is optionally substituted C.sub.6-C.sub.10 arylene, optionally
substituted C.sub.2-C.sub.9 heterocyclylene, or optionally
substituted C.sub.2-C.sub.9 heteroarylene; L is absent, --O--,
optionally substituted C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.1-C.sub.6 heteroalkylene, optionally substituted
C.sub.1-C.sub.6 alkenylene, optionally substituted C.sub.2-C.sub.6
heteroalkenylene, optionally substituted C.sub.2-C.sub.6
alkynylene, optionally substituted C.sub.2-C.sub.6
heteroalkynylene, optionally substituted C.sub.2-C.sub.9
heterocyclylene, optionally substituted C.sub.2-C.sub.9
heterocyclyl C.sub.1-C.sub.6 alkylene, optionally substituted
C.sub.2-C.sub.9 heteroarylene, or optionally substituted
C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene; and B is H,
halogen, cyano, optionally substituted C.sub.6-C.sub.10 aryl,
optionally substituted C.sub.3-C.sub.10 cycloalkyl, optionally
substituted C.sub.2-C.sub.9 heterocyclyl, or optionally substituted
C.sub.2-C.sub.9 heteroaryl, or a pharmaceutically acceptable salt
thereof.
[0046] In some embodiments, X' is O, Y' is CH, and Z' is N; X' is
S, Y' is CH, and Z' is N; X' is O, Y' is N, and Z' is CH; X' is S,
Y' is N, and Z' is CH; X' is O, Y' is N, and Z' is N; or X' is S,
Y' is N, and Z' is N.
[0047] In some embodiments, the compound of Formula V has the
structure of Formula Va:
##STR00022##
or a pharmaceutically acceptable salt thereof.
[0048] In some embodiments, the compound of Formula II has the
structure of Formula Vb:
##STR00023##
or a pharmaceutically acceptable salt thereof.
[0049] In some embodiments, the small molecule compound, or
pharmaceutically acceptable salt thereof is any one of compounds
17-20 having the structure:
##STR00024##
[0050] In some embodiments, the small molecule compound, or a
pharmaceutically acceptable salt thereof is a degrader. In some
embodiments, the degrader has the structure of Formula VI:
C-L-D Formula VI
wherein C is a BRG1 and/or BRM binding moiety; L is a linker; and D
is a degradation moiety, or a pharmaceutically acceptable salt
thereof. In some embodiments, the degradation moiety is a ubiquitin
ligase moiety. In some embodiments, the ubiquitin ligase binding
moiety includes Cereblon ligands, IAP (Inhibitors of Apoptosis)
ligands, mouse double minute 2 homolog (MDM2), hydrophobic tag, or
von Hippel-Lindau ligands, or derivatives or analogs thereof.
[0051] In some embodiments, A includes the structure of any one of
Formula I-V, or any one of compounds 1-20.
[0052] In some embodiments, the hydrophobic tag includes a
diphenylmethane, adamantine, or tri-Boc arginine, i.e., the
hydrophobic tag includes the structure:
##STR00025##
[0053] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula A:
##STR00026##
wherein X.sup.1 is CH.sub.2, O, S, or NR.sup.1, wherein R.sup.1 is
H, optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; X.sup.2 is C.dbd.O,
CH.sub.2, or
##STR00027##
R.sup.3 and R.sup.4 are, independently, H, optionally substituted
C.sub.1-C.sub.6 alkyl, or optionally substituted C.sub.1-C.sub.6
heteroalkyl; m is 0, 1, 2, 3, or 4; and each R.sup.2 is,
independently, halogen, optionally substituted C.sub.1-C.sub.6
alkyl, optionally substituted C.sub.1-C.sub.6 heteroalkyl,
optionally substituted C.sub.3-C.sub.10 carbocyclyl, optionally
substituted C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino, or a pharmaceutically
acceptable salt thereof.
[0054] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00028##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0055] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula B:
##STR00029##
wherein each R.sup.4, R.sup.4', and R.sup.7 is, independently, H,
optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.5 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; R.sup.6 is H,
optionally substituted C.sub.1-C.sub.6 alkyl, optionally
substituted C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; n is 0, 1, 2, 3, or 4;
each R.sup.8 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; and each R.sup.9
and R.sup.10 is, independently, H, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, or optionally substituted C.sub.6-C.sub.10
aryl, wherein R.sup.4' or R.sup.5 includes a bond to the linker, or
a pharmaceutically acceptable salt thereof.
[0056] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00030##
or is a derivative or analog thereof, or a pharmaceutically
acceptable salt thereof.
[0057] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula C:
##STR00031##
wherein each R.sup.11, R.sup.13, and R.sup.15 is, independently, H,
optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.12 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; R.sup.14 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; p is 0, 1, 2, 3, or 4;
each R.sup.16 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; q is 0, 1, 2, 3,
or 4; and each R.sup.17 is, independently, halogen, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino, or a pharmaceutically
acceptable salt thereof.
[0058] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00032##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0059] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula D:
##STR00033##
wherein each R.sup.18 and R.sup.19 is, independently, H, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; r1 is 0, 1, 2, 3, or
4; each R.sup.20 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; r2 is 0, 1, 2, 3,
or 4; and each R.sup.21 is, independently, halogen, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino, or a pharmaceutically
acceptable salt thereof.
[0060] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00034##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0061] In some embodiments, the linker has the structure of Formula
V:
A.sup.1-(B.sup.1).sub.f--(C.sup.1).sub.g--(B.sup.2).sub.h-(D)-(B.sup.3).-
sub.i--(C.sup.2).sub.j--(B.sup.4).sub.k-A.sup.2 Formula V
wherein A.sup.1 is a bond between the linker and A; A.sup.2 is a
bond between B and the linker; B.sup.1, B.sup.2, B.sup.3, and
B.sup.4 each, independently, is selected from optionally
substituted C.sub.1-C.sub.2 alkyl, optionally substituted
C.sub.1-C.sub.3 heteroalkyl, O, S, S(O).sub.2, and NR.sup.N;
R.sup.N is hydrogen, optionally substituted C.sub.1-4 alkyl,
optionally substituted C.sub.2-4 alkenyl, optionally substituted
C.sub.2-4 alkynyl, optionally substituted C.sub.2-6 heterocyclyl,
optionally substituted C.sub.6-12 aryl, or optionally substituted
C.sub.1-7 heteroalkyl; C.sup.1 and C.sup.2 are each, independently,
selected from carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; f,
g, h, l, j, and k are each, independently, 0 or 1; and D is
optionally substituted C.sub.1-10 alkyl, optionally substituted
C.sub.2-10 alkenyl, optionally substituted C.sub.2-10 alkynyl,
optionally substituted C.sub.2-6 heterocyclyl, optionally
substituted C.sub.6-12 aryl, optionally substituted
C.sub.2-C.sub.10 polyethylene glycol, or optionally substituted
C.sub.1-10 heteroalkyl, or a chemical bond linking
A.sup.1-(B.sup.1).sub.f--(C.sup.1).sub.g--(B.sup.2).sub.h-- to
--(B.sup.3).sub.i--(C.sup.2).sub.l--(B.sup.4).sub.k-A.sup.2.
[0062] In some embodiments, D is optionally substituted
C.sub.2-C.sub.10 polyethylene glycol. In some embodiments, C.sup.1
and C.sup.2 are each, independently, a carbonyl or sulfonyl. In
some embodiments, B.sup.1, B.sup.2, B.sup.3, and B.sup.4 each,
independently, is selected from optionally substituted
C.sub.1-C.sub.2 alkyl, optionally substituted C.sub.1-C.sub.3
heteroalkyl, O, S, S(O).sub.2, and NR.sup.N; R.sup.N is hydrogen or
optionally substituted C.sub.1-4 alkyl. In some embodiments,
B.sup.1, B.sup.2, B.sup.3, and B.sup.4 each, independently, is
selected from optionally substituted C.sub.1-C.sub.2 alkyl or
optionally substituted C.sub.1-C.sub.3 heteroalkyl. In some
embodiments, j is 0. In some embodiments, k is 0. In some
embodiments, j and k are each, independently, 0. In some
embodiments, f, g, h, and i are each, independently, 1.
[0063] In some embodiments, the linker of Formula VII has the
structure of Formula Vila:
##STR00035##
wherein A.sup.1 is a bond between the linker and A, and A.sup.2 is
a bond between B and the linker.
[0064] In some embodiments, D is optionally substituted C.sub.1-10
alkyl. In some embodiments, C.sup.1 and C.sup.2 are each,
independently, a carbonyl. In some embodiments, B.sup.1, B.sup.2,
B.sup.3, and B.sup.4 each, independently, is selected from
optionally substituted C.sub.1-C.sub.2 alkyl, optionally
substituted C.sub.1-C.sub.3 heteroalkyl, 0, S, S(O).sub.2, and
NR.sup.N, wherein R.sup.N is hydrogen or optionally substituted
C.sub.1-4 alkyl. In some embodiments, B.sup.1, B.sup.2, B.sup.3,
and B.sup.4 each, independently, is selected from optionally
substituted C.sub.1-C.sub.2 alkyl, O, S, S(O).sub.2, and NR.sup.N,
wherein R.sup.N is hydrogen or optionally substituted C.sub.1-4
alkyl. In some embodiments, B.sup.1 and B.sup.4 each,
independently, is optionally substituted C.sub.1-C.sub.2 alkyl. In
some embodiments, B.sup.1 and B.sup.4 each, independently, is
C.sub.1 alkyl. In some embodiments, B.sup.2 and B.sup.4 each,
independently, is NR.sup.N, wherein R.sup.N is hydrogen or
optionally substituted C.sub.1-4 alkyl. In some embodiments,
B.sup.2 and B.sup.4 each, independently, is NH. In some
embodiments, f, g, h, l, j, and k are each, independently, 1.
[0065] In some embodiments, the linker of Formula VII has the
structure of Formula VIIb:
##STR00036##
wherein A.sup.1 is a bond between the linker and A, and A.sup.2 is
a bond between B and the linker.
Chemical Terms
[0066] For any of the following chemical definitions, a number
following an atomic symbol indicates that total number of atoms of
that element that are present in a particular chemical moiety. As
will be understood, other atoms, such as hydrogen atoms, or
substituent groups, as described herein, may be present, as
necessary, to satisfy the valences of the atoms. For example, an
unsubstituted C.sub.2 alkyl group has the formula
--CH.sub.2CH.sub.3. When used with the groups defined herein, a
reference to the number of carbon atoms includes the divalent
carbon in acetal and ketal groups but does not include the carbonyl
carbon in acyl, ester, carbonate, or carbamate groups. A reference
to the number of oxygen, nitrogen, or sulfur atoms in a heteroaryl
group only includes those atoms that form a part of a heterocyclic
ring.
[0067] The term "acyl," as used herein, represents a hydrogen or an
alkyl group that is attached to a parent molecular group through a
carbonyl group, as defined herein, and is exemplified by formyl
(i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl,
propionyl, and butanoyl. Exemplary unsubstituted acyl groups
include from 1 to 6, from 1 to 11, or from 1 to 21 carbons.
[0068] The term "alkyl," as used herein, refers to a branched or
straight-chain monovalent saturated aliphatic hydrocarbon radical
of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon
atoms, or 1 to 6 carbon atoms).
[0069] An alkylene is a divalent alkyl group. The term "alkenyl,"
as used herein, alone or in combination with other groups, refers
to a straight chain or branched hydrocarbon residue having a
carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2
to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon
atoms).
[0070] The term "alkynyl," as used herein, alone or in combination
with other groups, refers to a straight chain or branched
hydrocarbon residue having a carbon-carbon triple bond and having 2
to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon
atoms, 2 to 6, or 2 carbon atoms).
[0071] The term "amino," as used herein, represents
--N(R.sup.N1).sub.2, wherein each R.sup.N1 is, independently, H,
OH, NO.sub.2, N(R.sup.N2).sub.2, SO.sub.2OR.sup.N2,
SO.sub.2R.sup.N2, SOR.sup.N2, an N-protecting group, alkyl, alkoxy,
aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl,
or others described herein), wherein each of these recited R.sup.N1
groups can be optionally substituted; or two R.sup.N1 combine to
form an alkylene or heteroalkylene, and wherein each R.sup.N2 is,
independently, H, alkyl, or aryl. The amino groups of the compounds
described herein can be an unsubstituted amino (i.e., --NH.sub.2)
or a substituted amino (i.e., --N(R.sup.N1).sub.2).
[0072] The term "aryl," as used herein, refers to an aromatic mono-
or polycarbocyclic radical of 6 to 12 carbon atoms having at least
one aromatic ring. Examples of such groups include, but are not
limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl,
1,2-dihydronaphthyl, indanyl, and 1H-indenyl.
[0073] The term "arylalkyl," as used herein, represents an alkyl
group substituted with an aryl group. Exemplary unsubstituted
arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or
from 7 to 20 carbons, such as C.sub.1-C.sub.6 alkyl
C.sub.6-C.sub.10 aryl, C.sub.1-C.sub.10 alkyl C.sub.6-C.sub.10
aryl, or C.sub.1-C.sub.20 alkyl C.sub.6-C.sub.10 aryl), such as,
benzyl and phenethyl. In some embodiments, the alkyl and the aryl
each can be further substituted with 1, 2, 3, or 4 substituent
groups as defined herein for the respective groups.
[0074] The term "azido," as used herein, represents a --N3
group.
[0075] The term "bridged polycycloalkyl," as used herein, refers to
a bridged polycyclic group of 5 to 20 carbons, containing from 1 to
3 bridges.
[0076] The term "cyano," as used herein, represents a --CN
group.
[0077] The term "carbocyclyl," as used herein, refers to a
non-aromatic C.sub.3-C.sub.12 monocyclic, bicyclic, or tricyclic
structure in which the rings are formed by carbon atoms.
Carbocyclyl structures include cycloalkyl groups and unsaturated
carbocyclyl radicals.
[0078] The term "cycloalkyl," as used herein, refers to a
saturated, non-aromatic, monovalent mono- or polycarbocyclic
radical of 3 to 10, preferably 3 to 6 carbon atoms. This term is
further exemplified by radicals such as cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.
[0079] The term "halogen," as used herein, means a fluorine
(fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo)
radical.
[0080] The term "heteroalkyl," as used herein, refers to an alkyl
group, as defined herein, in which one or more of the constituent
carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In
some embodiments, the heteroalkyl group can be further substituted
with 1, 2, 3, or 4 substituent groups as described herein for alkyl
groups. An example of a heteroalkyl group is an "alkoxy", which, as
used herein, refers alkyl-O-- (e.g., methoxy and ethoxy). A
heteroalkylene is a divalent heteroalkyl group. The term
"heteroalkenyl," as used herein, refers to an alkenyl group, as
defined herein, in which one or more of the constituent carbon
atoms have been replaced by nitrogen, oxygen, or sulfur. In some
embodiments, the heteroalkenyl group can be further substituted
with 1, 2, 3, or 4 substituent groups as described herein for
alkenyl groups. Examples of heteroalkenyl groups are an "alkenoxy"
which, as used herein, refers alkenyl-O--. A heteroalkenylene is a
divalent heteroalkenyl group. The term "heteroalkynyl," as used
herein, refers to an alkynyl group, as defined herein, in which one
or more of the constituent carbon atoms have been replaced by
nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl
group can be further substituted with 1, 2, 3, or 4 substituent
groups as described herein for alkynyl groups. Examples of
heteroalkynyl groups are an "alkynoxy" which, as used herein,
refers alkynyl-O--. A heteroalkynylene is a divalent heteroalkynyl
group.
[0081] The term "heteroaryl," as used herein, refers to an aromatic
mono- or polycyclic radical of 5 to 12 atoms having at least one
aromatic ring containing 1, 2, or 3 ring atoms selected from
nitrogen, oxygen, and sulfur, with the remaining ring atoms being
carbon. One or two ring carbon atoms of the heteroaryl group may be
replaced with a carbonyl group. Examples of heteroaryl groups are
pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl,
imidazolyl, oxaxolyl, and thiazolyl.
[0082] The term "heteroarylalkyl," as used herein, represents an
alkyl group substituted with a heteroaryl group. Exemplary
unsubstituted heteroarylalkyl groups are from 7 to 30 carbons
(e.g., from 7 to 16 or from 7 to 20 carbons, such as
C.sub.1-C.sub.6 alkyl C.sub.2-C.sub.9 heteroaryl, C.sub.1-C.sub.10
alkyl C.sub.2-C.sub.9 heteroaryl, or C.sub.1-C.sub.20 alkyl
C.sub.2-C.sub.9 heteroaryl). In some embodiments, the alkyl and the
heteroaryl each can be further substituted with 1, 2, 3, or 4
substituent groups as defined herein for the respective groups.
[0083] The term "heterocyclyl," as used herein, refers a mono- or
polycyclic radical having 3 to 12 atoms having at least one ring
containing 1, 2, 3, or 4 ring atoms selected from N, O or S,
wherein no ring is aromatic. Examples of heterocyclyl groups
include, but are not limited to, morpholinyl, thiomorpholinyl,
furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl,
tetrahydropyranyl, tetrahydrofuranyl, and 1,3-dioxanyl.
[0084] The term "heterocyclylalkyl," as used herein, represents an
alkyl group substituted with a heterocyclyl group. Exemplary
unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons
(e.g., from 7 to 16 or from 7 to 20 carbons, such as
C.sub.1-C.sub.6 alkyl C.sub.2-C.sub.9 heterocyclyl,
C.sub.1-C.sub.10 alkyl C.sub.2-C.sub.9 heterocyclyl, or
C.sub.1-C.sub.20 alkyl C.sub.2-C.sub.9 heterocyclyl). In some
embodiments, the alkyl and the heterocyclyl each can be further
substituted with 1, 2, 3, or 4 substituent groups as defined herein
for the respective groups.
[0085] The term "hydroxyalkyl," as used herein, represents alkyl
group substituted with an --OH group.
[0086] The term "hydroxyl," as used herein, represents an --OH
group.
[0087] The term "N-protecting group," as used herein, represents
those groups intended to protect an amino group against undesirable
reactions during synthetic procedures. Commonly used N-protecting
groups are disclosed in Greene, "Protective Groups in Organic
Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999).
N-protecting groups include, but are not limited to, acyl, aryloyl,
or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl,
t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl,
trichloroacetyl, phthalyl, o-nitrophenoxyacetyl,
.alpha.-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl,
4-nitrobenzoyl, and chiral auxiliaries such as protected or
unprotected D, L, or D, L-amino acids such as alanine, leucine, and
phenylalanine; sulfonyl-containing groups such as benzenesulfonyl,
and p-toluenesulfonyl; carbamate forming groups such as
benzyloxycarbonyl, p-chlorobenzyloxycarbonyl,
p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl,
2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl,
3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl,
2,4-20 dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl,
2-nitro-4,5-dimethoxybenzyloxycarbonyl,
3,4,5-trimethoxybenzyloxycarbonyl,
1-(p-biphenylyl)-1-methylethoxycarbonyl,
.alpha.,.alpha.-dimethyl-3,5-dimethoxybenzyloxycarbonyl,
benzhydryloxy carbonyl, t-butyloxycarbonyl,
diisopropylmethoxycarbonyl, isopropyloxycarbonyl, ethoxycarbonyl,
methoxycarbonyl, allyloxycarbonyl, 2,2,2,-trichloroethoxycarbonyl,
phenoxycarbonyl, 4-nitrophenoxy carbonyl,
fluorenyl-9-methoxycarbonyl, cyclopentyloxycarbonyl,
adamantyloxycarbonyl, cyclohexyloxycarbonyl, and
phenylthiocarbonyl, arylalkyl groups such as benzyl,
triphenylmethyl, and benzyloxymethyl, and silyl groups, such as
trimethylsilyl. Preferred N-protecting groups are alloc, formyl,
acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl,
benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
[0088] The term "nitro," as used herein, represents an --NO.sub.2
group.
[0089] The term "thiol," as used herein, represents an --SH
group.
[0090] The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl,
heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl,
and heterocyclyl groups may be substituted or unsubstituted. When
substituted, there will generally be 1 to 4 substituents present,
unless otherwise specified. Substituents include, for example:
alkyl (e.g., unsubstituted and substituted, where the substituents
include any group described herein, e.g., aryl, halo, hydroxy),
aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl
(e.g., substituted and unsubstituted cycloalkyl), halogen (e.g.,
fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted
methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino
(e.g., NH2 or mono- or dialkyl amino), azido, cyano, nitro, or
thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and
heterocyclyl groups may also be substituted with alkyl
(unsubstituted and substituted such as arylalkyl (e.g., substituted
and unsubstituted benzyl)).
[0091] Compounds described herein can have one or more asymmetric
carbon atoms and can exist in the form of optically pure
enantiomers, mixtures of enantiomers such as, for example,
racemates, optically pure diastereoisomers, mixtures of
diastereoisomers, diastereoisomeric racemates, or mixtures of
diastereoisomeric racemates. The optically active forms can be
obtained for example by resolution of the racemates, by asymmetric
synthesis or asymmetric chromatography (chromatography with a
chiral adsorbent or eluant). That is, certain of the disclosed
compounds may exist in various stereoisomeric forms. Stereoisomers
are compounds that differ only in their spatial arrangement.
Enantiomers are pairs of stereoisomers whose mirror images are not
superimposable, most commonly because they contain an
asymmetrically substituted carbon atom that acts as a chiral
center. "Enantiomer" means one of a pair of molecules that are
mirror images of each other and are not superimposable.
Diastereomers are stereoisomers that are not related as mirror
images, most commonly because they contain two or more
asymmetrically substituted carbon atoms and represent the
configuration of substituents around one or more chiral carbon
atoms. Enantiomers of a compound can be prepared, for example, by
separating an enantiomer from a racemate using one or more
well-known techniques and methods, such as, for example, chiral
chromatography and separation methods based thereon. The
appropriate technique and/or method for separating an enantiomer of
a compound described herein from a racemic mixture can be readily
determined by those of skill in the art. "Racemate" or "racemic
mixture" means a compound containing two enantiomers, wherein such
mixtures exhibit no optical activity; i.e., they do not rotate the
plane of polarized light. "Geometric isomer" means isomers that
differ in the orientation of substituent atoms in relationship to a
carbon-carbon double bond, to a cycloalkyl ring, or to a bridged
bicyclic system. Atoms (other than H) on each side of a
carbon-carbon double bond may be in an E (substituents are on 25
opposite sides of the carbon-carbon double bond) or Z (substituents
are oriented on the same side) configuration. "R," "S," "S*," "R*,"
"E," "Z," "cis," and "trans," indicate configurations relative to
the core molecule. Certain of the disclosed compounds may exist in
atropisomeric forms. Atropisomers are stereoisomers resulting from
hindered rotation about single bonds where the steric strain
barrier to rotation is high enough to allow for the isolation of
the conformers. The compounds described herein may be prepared as
individual isomers by either isomer-specific synthesis or resolved
from an isomeric mixture. Conventional resolution techniques
include forming the salt of a free base of each isomer of an
isomeric pair using an optically active acid (followed by
fractional crystallization and regeneration of the free base),
forming the salt of the acid form of each isomer of an isomeric
pair using an optically active amine (followed by fractional
crystallization and regeneration of the free acid), forming an
ester or amide 35 of each of the isomers of an isomeric pair using
an optically pure acid, amine or alcohol (followed by
chromatographic separation and removal of the chiral auxiliary), or
resolving an isomeric mixture of either a starting material or a
final product using various well known chromatographic methods.
When the stereochemistry of a disclosed compound is named or
depicted by structure, the named or depicted stereoisomer is at
least 60%, 70%, 80%, 90%, 99%, or 99.9% by weight relative to the
other stereoisomers. When a single enantiomer is named or depicted
by structure, the depicted or named enantiomer is at least 60%,
70%, 80%, 90%, 99%, or 99.9% by weight optically pure. When a
single diastereomer is named or depicted by structure, the depicted
or named diastereomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9%
by weight pure. Percent optical purity is the ratio of the weight
of the enantiomer or over the weight of the enantiomer plus the
weight of its optical isomer. Diastereomeric purity by weight is
the ratio of the weight of one diastereomer or over the weight of
all the diastereomers. When the stereochemistry of a disclosed
compound is named or depicted by structure, the named or depicted
stereoisomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole
fraction pure relative to the other stereoisomers. When a single
enantiomer is named or depicted by structure, the depicted or named
enantiomer is at least 60%, 70%, 80%, 90%, 99%, or 99.9% by mole
fraction pure. When a single diastereomer is named or depicted by
structure, the depicted or named diastereomer is at least 60%, 70%,
80%, 90%, 99%, or 99.9% by mole fraction pure. Percent purity by
mole fraction is the ratio of the moles of the enantiomer or over
the moles of the enantiomer plus the moles of its optical isomer.
Similarly, percent purity by moles fraction is the ratio of the
moles of the diastereomer or over the moles of the diastereomer
plus the moles of its isomer. When a disclosed compound is named or
depicted by structure without indicating the stereochemistry, and
the compound has at least one chiral center, it is to be understood
that the name or structure encompasses either enantiomer of the
compound free from the corresponding optical isomer, a racemic
mixture of the compound, or mixtures enriched in one enantiomer
relative to its corresponding optical isomer. When a disclosed
compound is named or depicted by structure without indicating the
stereochemistry and has two or more chiral centers, it is to be
understood that the name or structure encompasses a diastereomer
free of other diastereomers, a number of diastereomers free from
other diastereomeric pairs, mixtures of diastereomers, mixtures of
diastereomeric pairs, mixtures of diastereomers in which one
diastereomer is enriched relative to the other diastereomer(s), or
mixtures of diastereomers in which one or more diastereomer is
enriched relative to the other diastereomers. The invention
embraces all of these forms.
[0092] Unless otherwise defined, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Methods
and materials are described herein for use in the present
disclosure; other, suitable methods and materials known in the art
can also be used. The materials, methods, and examples are
illustrative only and not intended to be limiting. All
publications, patent applications, patents, sequences, database
entries, and other references mentioned herein are incorporated by
reference in their entirety. In case of conflict, the present
specification, including definitions, will control.
Definitions
[0093] In this application, unless otherwise clear from context,
(i) the term "a" may be understood to mean "at least one"; (ii) the
term "or" may be understood to mean "and/or"; and (iii) the terms
"including" and "including" may be understood to encompass itemized
components or steps whether presented by themselves or together
with one or more additional components or steps.
[0094] As used herein, the terms "about" and "approximately" refer
to a value that is within 10% above or below the value being
described. For example, the term "about 5 nM" indicates a range of
from 4.5 to 5.5 nM.
[0095] As used herein, the term "administration" refers to the
administration of a composition (e.g., a compound or a preparation
that includes a compound as described herein) to a subject or
system. Administration to an animal subject (e.g., to a human) may
be by any appropriate route. For example, in some embodiments,
administration may be bronchial (including by bronchial
instillation), buccal, enteral, interdermal, intra-arterial,
intradermal, intragastric, intramedullary, intramuscular,
intranasal, intraperitoneal, intrathecal, intratumoral,
intravenous, intraventricular, mucosal, nasal, oral, rectal,
subcutaneous, sublingual, topical, tracheal (including by
intratracheal instillation), transdermal, vaginal, and vitreal.
[0096] As used herein, the term "BAF complex" refers to the
BRG1-associated or HBRM-associated factors complex in a human
cell.
[0097] As used herein, the term "BRG1 loss of function mutation"
refers to a mutation in BRG1 that leads to the protein having
diminished activity (e.g., at least 1% reduction in BRG1 activity,
for example 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1
activity). Exemplary BRG1 loss of function mutations include, but
are not limited to, a homozygous BRG1 mutation and a deletion at
the C-terminus of BRG1.
[0098] As used herein, the term "BRG1 loss of function disorder"
refers to a disorder (e.g., cancer) that exhibits a reduction in
BRG1 activity (e.g., at least 1% reduction in BRG1 activity, for
example 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRG1
activity).
[0099] As used herein, the term "BRM loss of function mutation"
refers to a mutation in BRM that leads to the protein having
diminished activity (e.g., at least 1% reduction in BRM activity,
for example 2%, 5%, 10%, 25%, 50%, or 100% reduction in BRM
activity). Exemplary BRM loss of function mutations include, but
are not limited to, a homozygous BRM mutation and a deletion at the
C-terminus of BRM. As used herein, the term "BRM loss of function
disorder" refers to a disorder (e.g., cancer) that exhibits a
reduction in BRM activity (e.g., at least 1% reduction in BRM
activity, for example 2%, 5%, 10%, 25%, 50%, or 100% reduction in
BRG1 activity).
[0100] As used herein, the terms "GBAF complex" and "GBAF" refer to
a SWI/SNF ATPase chromatin remodeling complex in a human cell. GBAF
complex subunits may include, but are not limited to, ACTB, ACTL6A,
ACTL6B, BICRA, BICRAL, BRD9, SMARCA2, SMARCA4, SMARCC1, SMARCD1,
SMARCD2, SMARCD3, and SS18.
[0101] The term "cancer" refers to a condition caused by the
proliferation of malignant neoplastic cells, such as tumors,
neoplasms, carcinomas, sarcomas, leukemias, and lymphomas.
[0102] As used herein, a "combination therapy" or "administered in
combination" means that two (or more) different agents or
treatments are administered to a subject as part of a defined
treatment regimen for a particular disease or condition. The
treatment regimen defines the doses and periodicity of
administration of each agent such that the effects of the separate
agents on the subject overlap. In some embodiments, the delivery of
the two or more agents is simultaneous or concurrent and the agents
may be co-formulated. In some embodiments, the two or more agents
are not co-formulated and are administered in a sequential manner
as part of a prescribed regimen. In some embodiments,
administration of two or more agents or treatments in combination
is such that the reduction in a symptom, or other parameter related
to the disorder is greater than what would be observed with one
agent or treatment delivered alone or in the absence of the other.
The effect of the two treatments can be partially additive, wholly
additive, or greater than additive (e.g., synergistic). Sequential
or substantially simultaneous administration of each therapeutic
agent can be effected by any appropriate route including, but not
limited to, oral routes, intravenous routes, intramuscular routes,
and direct absorption through mucous membrane tissues. The
therapeutic agents can be administered by the same route or by
different routes. For example, a first therapeutic agent of the
combination may be administered by intravenous injection while a
second therapeutic agent of the combination may be administered
orally.
[0103] As used herein, the term "BRG1" refers to ATP-dependent
chromatin remodeler SMARCA4. BRG1 is a component of the BAF
complex, a SWI/SNF ATPase chromatin remodeling complex. Human BRG1
is encoded by the SMARCA4 gene on chromosome 19, a nucleic acid
sequence of which is set forth in SEQ ID NO: 1 (GenBank Accession
No.: NM_001128849.1 (mRNA);
www.ncbi.nlm.nih.gov/nuccore/NM_001128849.1?report=fasta).
TABLE-US-00001
GGCGGGGGAGGCGCCGGGAAGTCGACGGCGCCGGCGGCTCCTGCAGGAGGCCACTGTCTGCAGCTCCCGT
GAAGATGTCCACTCCAGACCCACCCCTGGGCGGAACTCCTCGGCCAGGTCCTTCCCCGGGCCCTGGCCCT
TCCCCTGGAGCCATGCTGGGCCCTAGCCCGGGTCCCTCGCCGGGCTCCGCCCACAGCATGATGGGGCCCA
GCCCAGGGCCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCCTGGAGGGTACCCTCAGGACAACAT
GCACCAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCGGACGACCCGCGCTACAACCAG
ATGAAAGGAATGGGGATGCGGTCAGGGGGCCATGCTGGGATGGGGCCCCCGCCCAGCCCCATGGACCAGC
ACTCCCAAGGTTACCCCTCGCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCCAGCCAGTGGCCC
GTCTTCGGGGCCCCAGATGTCTTCCGGGCCAGGAGGTGCCCCGCTGGATGGTGCTGACCCCCAGGCCTTG
GGGCAGCAGAACCGGGGCCCAACCCCATTTAACCAGAACCAGCTGCACCAGCTCAGAGCTCAGATCATGG
CCTACAAGATGCTGGCCAGGGGGCAGCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCC
GATGCCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCT
GGCCCTGGCCCTGGCCCCGGCCCGGGTCCCGGCCCGGCACCTCCAAATTACAGCAGGCCTCATGGTATGG
GAGGGCCCAACATGCCTCCCCCAGGACCCTCGGGCGTGCCCCCCGGGATGCCAGGCCAGCCTCCTGGAGG
GCCTCCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCCACGAGCACCCCTCAGAAGCTG
ATTCCCCCGCAGCCAACGGGCCGCCCTTCCCCCGCGCCCCCTGCCGTCCCACCCGCCGCCTCGCCCGTGA
TGCCACCGCAGACCCAGTCCCCCGGGCAGCCGGCCCAGCCCGCGCCCATGGTGCCACTGCACCAGAAGCA
GAGCCGCATCACCCCCATCCAGAAGCCGCGGGGCCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTAC
AGGCTGCAGGCTCGCATCGCACACCGAATTCAGGAACTTGAAAACCTTCCCGGGTCCCTGGCCGGGGATT
TGCGAACCAAAGCGACCATTGAGCTCAAGGCCCTCAGGCTGCTGAACTTCCAGAGGCAGCTGCGCCAGGA
GGTGGTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAGCGCAGC
AAGCGCCAGTCCCTGCGCGAGGCCCGCATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGCAGGAGC
GCAAGCGCCGGCAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAAGGAATA
TCACAGATCCGTCACAGGCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAG
CGGGAGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGG
AGGGGTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCTACCTCTTGCAGCAGACAGACGA
GTACGTGGCTAACCTCACGGAGCTGGTGCGGCAGCACAAGGCTGCCCAGGTCGCCAAGGAGAAAAAGAAG
AAAAAGAAAAAGAAGAAGGCAGAAAATGCAGAAGGACAGACGCCTGCCATTGGGCCGGATGGCGAGCCTC
TGGACGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCCTCAC
AGGCACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCT
CCGAGGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAGGAAGAGCAGCCGCAGG
CAGCACAGCCTCCCACCCTGCCCGTGGAGGAGAAGAAGAAGATTCCAGATCCAGACAGCGATGACGTCTC
TGAGGTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTCGATGATGAATATGGCGTGTCCCAG
GCCCTTGCACGTGGCCTGCAGTCCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGT
CAGCGCTTATGGTCAATGGTGTCCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCCCTGTA
CAACAACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGGAAGACCATCCAGACCATCGCGCTC
ATCACGTACCTCATGGAGCACAAACGCATCAATGGGCCCTTCCTCATCATCGTGCCTCTCTCAACGCTGT
CCAACTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGC
AGCAAGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTAC
ATCATCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCACCGCA
TGAAGAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACTATGTGGCACCCCGCCGCCTGCTGCT
GACGGGCACACCGCTGCAGAACAAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCCTGCTGCCCACCATC
TTCAAGAGCTGCAGCACCTTCGAGCAGTGGTTTAACGCACCCTTTGCCATGACCGGGGAAAAGGTGGACC
TGAATGAGGAGGAAACCATTCTCATCATCCGGCGTCTCCACAAAGTGCTGCGGCCCTTCTTGCTCCGACG
ACTCAAGAAGGAAGTCGAGGCCCAGTTGCCCGAAAAGGTGGAGTACGTCATCAAGTGCGACATGTCTGCG
CTGCAGCGAGTGCTCTACCGCCACATGCAGGCCAAGGGCGTGCTGCTGACTGATGGCTCCGAGAAGGACA
AGAAGGGCAAAGGCGGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCC
CTACATGTTCCAGCACATCGAGGAGTCCTTTTCCGAGCACTTGGGGTTCACTGGCGGCATTGTCCAAGGG
CTGGACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCCAAACTCCGAGCAACCA
ACCACAAAGTGCTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCG
CGGCTTTAAATACCTCAGGCTTGATGGAACCACGAAGGCGGAGGACCGGGGCATGCTGCTGAAAACCTTC
AACGAGCCCGGCTCTGAGTACTTCATCTTCCTGCTCAGCACCCGGGCTGGGGGGCTCGGCCTGAACCTCC
AGTCGGCAGACACTGTGATCATTTTTGACAGCGACTGGAATCCTCACCAGGACCTGCAAGCGCAGGACCG
AGCCCACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCCTCTGCACCGTCAACAGCGTGGAGGAG
AAGATCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGTTCGACC
AGAAGTCCTCCAGCCATGAGCGGCGCGCCTTCCTGCAGGCCATCCTGGAGCACGAGGAGCAGGATGAGAG
CAGACACTGCAGCACGGGCAGCGGCAGTGCCAGCTTCGCCCACACTGCCCCTCCGCCAGCGGGCGTCAAC
CCCGACTTGGAGGAGCCACCTCTAAAGGAGGAAGACGAGGTGCCCGACGACGAGACCGTCAACCAGATGA
TCGCCCGGCACGAGGAGGAGTTTGATCTGTTCATGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCG
CAACCCCAAGCGGAAGCCGCGCCTCATGGAGGAGGACGAGCTCCCCTCGTGGATCATCAAGGACGACGCG
GAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAGGAGAAGATGTTCGGCCGTGGCTCCCGCCACCGCAAGG
AGGTGGACTACAGCGACTCACTGACGGAGAAGCAGTGGCTCAAGAAAATTACAGGAAAAGATATCCATGA
CACAGCCAGCAGTGTGGCACGTGGGCTACAATTCCAGCGTGGCCTTCAGTTCTGCACACGTGCGTCAAAG
GCCATCGAGGAGGGCACGCTGGAGGAGATCGAAGAGGAGGTCCGGCAGAAGAAATCATCACGGAAGCGCA
AGCGAGACAGCGACGCCGGCTCCTCCACCCCGACCACCAGCACCCGCAGCCGCGACAAGGACGACGAGAG
CAAGAAGCAGAAGAAGCGCGGGCGGCCGCCTGCCGAGAAACTCTCCCCTAACCCACCCAACCTCACCAAG
AAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGCAGTGGACGTCAGCTCAGCGAGG
TCTTCATCCAGCTGCCCTCGCGAAAGGAGCTGCCCGAGTACTACGAGCTCATCCGCAAGCCCGTGGACTT
CAAGAAGATAAAGGAGCGCATTCGCAACCACAAGTACCGCAGCCTCAACGACCTAGAGAAGGACGTCATG
CTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTATGAAGACTCCATCGTCTTGC
AGTCGGTCTTCACCAGCGTGCGGCAGAAAATCGAGAAGGAGGATGACAGTGAAGGCGAGGAGAGTGAGGA
GGAGGAAGAGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCAAAGTGAAGATCAAGCTTGGC
CGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGCCGGCGGCGGCCGAGCCGAGGGTCCCGAGCCAAGC
CGGTCGTGAGTGACGATGACAGTGAGGAGGAACAAGAGGAGGACCGCTCAGGAAGTGGCAGCGAAGAAGA
CTGAGCCCCGACATTCCAGTCTCGACCCCGAGCCCCTCGTTCCAGAGCTGAGATGGCATAGGCCTTAGCA
GTAACGGGTAGCAGCAGATGTAGTTTCAGACTTGGAGTAAAACTGTATAAACAAAAGAATCTTCCATATT
TATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCCTGGCATCAGTAGCATCTGTAACAGC
ATTAACTGTCTTAAAGAGAGAGAGAGAGAATTCCGAATTGGGGAACACACGATACCTGTTTTTCTTTTCC
GTTGCTGGCAGTACTGTTGCGCCGCAGTTTGGAGTCACTGTAGTTAAGTGTGGATGCATGTGCGTCACCG
TCCACTCCTCCTACTGTATTTTATTGGACAGGTCAGACTCGCCGGGGGCCCGGCGAGGGTATGTCAGTGT
CACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCCAAAAAAAAA
[0104] The term "BRG1" also refers to natural variants of the
wild-type human BRG1 protein, such as proteins having at least 85%
identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.9% identity, or more) to an amino acid
sequence of wild-type BRG1, which is set forth in SEQ ID NO: 2
(UniProt Accession No.: P51532;
www.uniprot.org/uniprot/P51532.fasta).
TABLE-US-00002 SEQ ID NO: 2
MSTPDPPLGGTPRPGPSPGPGPSPGAMLGPSPGPSPGSAHSMMGPSPGP
PSAGHPIPTQGPGGYPQDNMHQMHKPMESMHEKGMSDDPRYNQMKGMGM
RSGGHAGMGPPPSPMDQHSQGYPSPLGGSEHASSPVPASGPSSGPQMSS
GPGGAPLDGADPQALGQQNRGPTPFNQNQLHQLRAQIMAYKMLARGQPL
PDHLQMAVQGKRPMPGMQQQMPTLPPPSVSATGPGPGPGPGPGPGPGPA
PPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGPPKPWPEGPMANAAA
PTSTPQKLIPPQPTGRPSPAPPAVPPAASPVMPPQTQSPGQPAQPAPMV
PLHQKQSRITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGSL
AGDLRTKATIELKALRLLNFQRQLRQEVVVCMRRDTALETALNAKAYKR
SKRQSLREARITEKLEKQQKIEQERKRRQKHQEYLNSILQHAKDEKEYH
RSVTGKIQKLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYR
KLIDQKKDKRLAYLLQQTDEYVANLTELVRQHKAAQVAKEKKKKKKKKK
AENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTGTDAPKAG
QLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEE
KKKIPDPDSDDVSEVDARHIIENAKQDVDDEYGVSQALARGLQSYYAVA
HAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYNNNLNGILADEMGLG
KTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVS
YKGSPAARRAFVPQLRSGKENVLLTTYEYIIKDKHILAKIRWKYMIVDE
GHRMKNHHCKLTQVLNTHYVAPRRLLLTGTPLQNKLPELWALLNELLPT
IFKSCSTFEQWENAPFAMTGEKVDLNEEETILIIRRLHKVLRPFLLRRL
KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAKGVLLTDGSEKDKKGK
GGTKILMNTIMQLRKICNHPYMFQHIEESFSEHLGFTGGIVQGLDLYRA
SGKFELLDRILPKLRATNHKVLLFCQMTSLMTIMEDYFAYRGEKYLRLD
GITKAEDRGMLLKTFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDS
DWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVD
QKVIQAGMFDQKSSSHERRAFLQAILEHEEQDESRHCSTGSGSASFAHT
APPPAGVNPDLEEPPLKEEDEVPDDETVNQMIARHEEEFDLFMRMDLDR
RREEARNPKRKPRLMEEDELPSWIIKDDAEVERLICEEEEEKMFGRGSR
HRKEVDYSDSLTEKQWLKAIEEGTLEEIEEEVRQKKSSRKRKRDSDAGS
STPTTSTRSRDKDDESKKQKKRGRPPAEKLSPNPPNLTKKMKKIVDAVI
KYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKY
RSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKED
DSEGEESEEEEEGEEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPS
RGSRAKPVVSDDDSEEEQEEDRSGSGSEED.
[0105] As used herein, the term "BRM" refers to probable global
transcription activator SNF2L2. BRM is a component of the BAF
complex, a SWI/SNF ATPase chromatin remodeling complex. Human BRM
is encoded by the SMARCA2 gene on chromosome 9, a nucleic acid
sequence of which is set forth in SEQ ID NO: 3 (GenBank Accession
No.: NM_003070.4,
www.ncbi.nlm.nih.gov/nuccore/NM_003070.4?report=fasta).
TABLE-US-00003 SEQ ID NO: 3
GCGTCTTCCGGCGCCCGCGGAGGAGGCGAGGGTGGGACGCTGGGCGGAGCCCGAGTTTAGGAAGAGGAGG
GGACGGCTGTCATCAATGAAGTCATATTCATAATCTAGTCCTCTCTCCCTCTGTTTCTGTACTCTGGGTG
ACTCAGAGAGGGAAGAGATTCAGCCAGCACACTCCTCGCGAGCAAGCATTACTCTACTGACTGGCAGAGA
CAGGAGAGGTAGATGTCCACGCCCACAGACCCTGGTGCGATGCCCCACCCAGGGCCTTCGCCGGGGCCTG
GGCCTTCCCCTGGGCCAATTCTTGGGCCTAGTCCAGGACCAGGACCATCCCCAGGTTCCGTCCACAGCAT
GATGGGGCCAAGTCCTGGACCTCCAAGTGTCTCCCATCCTATGCCGACGATGGGGTCCACAGACTTCCCA
CAGGAAGGCATGCATCAAATGCATAAGCCCATCGATGGTATACATGACAAGGGGATTGTAGAAGACATCC
ATTGTGGATCCATGAAGGGCACTGGTATGCGACCACCTCACCCAGGCATGGGCCCTCCCCAGAGTCCAAT
GGATCAACACAGCCAAGGTTATATGTCACCACACCCATCTCCATTAGGAGCCCCAGAGCACGTCTCCAGC
CCTATGTCTGGAGGAGGCCCAACTCCACCTCAGATGCCACCAAGCCAGCCGGGGGCCCTCATCCCAGGTG
ATCCGCAGGCCATGAGCCAGCCCAACAGAGGTCCCTCACCTTTCAGTCCTGTCCAGCTGCATCAGCTTCG
AGCTCAGATTTTAGCTTATAAAATGCTGGCCCGAGGCCAGCCCCTCCCCGAAACGCTGCAGCTTGCAGTC
CAGGGGAAAAGGACGTTGCCTGGCTTGCAGCAACAACAGCAGCAGCAACAGCAGCAGCAGCAGCAGCAGC
AGCAGCAGCAGCAGCAGCAACAGCAGCCGCAGCAGCAGCCGCCGCAACCACAGACGCAGCAACAACAGCA
GCCGGCCCTTGTTAACTACAACAGACCATCTGGCCCGGGGCCGGAGCTGAGCGGCCCGAGCACCCCGCAG
AAGCTGCCGGTGCCCGCGCCCGGCGGCCGGCCCTCGCCCGCGCCCCCCGCAGCCGCGCAGCCGCCCGCGG
CCGCAGTGCCCGGGCCCTCAGTGCCGCAGCCGGCCCCGGGGCAGCCCTCGCCCGTCCTCCAGCTGCAGCA
GAAGCAGAGCCGCATCAGCCCCATCCAGAAACCGCAAGGCCTGGACCCCGTGGAAATTCTGCAAGAGCGG
GAATACAGACTTCAGGCCCGCATAGCTCATAGGATACAAGAACTGGAAAATCTGCCTGGCTCTTTGCCAC
CAGATTTAAGAACCAAAGCAACCGTGGAACTAAAAGCACTTCGGTTACTCAATTTCCAGCGTCAGCTGAG
ACAGGAGGTGGTGGCCTGCATGCGCAGGGACACGACCCTGGAGACGGCTCTCAACTCCAAAGCATACAAA
CGGAGCAAGCGCCAGACTCTGAGAGAAGCTCGCATGACCGAGAAGCTGGAGAAGCAGCAGAAGATTGAGC
AGGAGAGGAAACGCCGTCAGAAACACCAGGAATACCTGAACAGTATTTTGCAACATGCAAAAGATTTTAA
GGAATATCATCGGTCTGTGGCCGGAAAGATCCAGAAGCTCTCCAAAGCAGTGGCAACTTGGCATGCCAAC
ACTGAAAGAGAGCAGAAGAAGGAGACAGAGCGGATTGAAAAGGAGAGAATGCGGCGACTGATGGCTGAAG
ATGAGGAGGGTTATAGAAAACTGATTGATCAAAAGAAAGACAGGCGTTTAGCTTACCTTTTGCAGCAGAC
CGATGAGTATGTAGCCAATCTGACCAATCTGGTTTGGGAGCACAAGCAAGCCCAGGCAGCCAAAGAGAAG
AAGAAGAGGAGGAGGAGGAAGAAGAAGGCTGAGGAGAATGCAGAGGGTGGGGAGTCTGCCCTGGGACCGG
ATGGAGAGCCCATAGATGAGAGCAGCCAGATGAGTGACCTCCCTGTCAAAGTGACTCACACAGAAACCGG
CAAGGTTCTGTTCGGACCAGAAGCACCCAAAGCAAGTCAGCTGGACGCCTGGCTGGAAATGAATCCTGGT
TATGAAGTTGCCCCTAGATCTGACAGTGAAGAGAGTGATTCTGATTATGAGGAAGAGGATGAGGAAGAAG
AGTCCAGTAGGCAGGAAACCGAAGAGAAAATACTCCTGGATCCAAATAGCGAAGAAGTTTCTGAGAAGGA
TGCTAAGCAGATCATTGAGACAGCTAAGCAAGACGTGGATGATGAATACAGCATGCAGTACAGTGCCAGG
GGCTCCCAGTCCTACTACACCGTGGCTCATGCCATCTCGGAGAGGGTGGAGAAACAGTCTGCCCTCCTAA
TTAATGGGACCCTAAAGCATTACCAGCTCCAGGGCCTGGAATGGATGGTTTCCCTGTATAATAACAACTT
GAACGGAATCTTAGCCGATGAAATGGGGCTTGGAAAGACCATACAGACCATTGCACTCATCACTTATCTG
ATGGAGCACAAAAGACTCAATGGCCCCTATCTCATCATTGTTCCCCTTTCGACTCTATCTAACTGGACAT
ATGAATTTGACAAATGGGCTCCTTCTGTGGTGAAGATTTCTTACAAGGGTACTCCTGCCATGCGTCGCTC
CCTTGTCCCCCAGCTACGGAGTGGCAAATTCAATGTCCTCTTGACTACTTATGAGTATATTATAAAAGAC
AAGCACATTCTTGCAAAGATTCGGTGGAAATACATGATAGTGGACGAAGGCCACCGAATGAAGAATCACC
ACTGCAAGCTGACTCAGGTCTTGAACACTCACTATGTGGCCCCCAGAAGGATCCTCTTGACTGGGACCCC
GCTGCAGAATAAGCTCCCTGAACTCTGGGCCCTCCTCAACTTCCTCCTCCCAACAATTTTTAAGAGCTGC
AGCACATTTGAACAATGGTTCAATGCTCCATTTGCCATGACTGGTGAAAGGGTGGACTTAAATGAAGAAG
AAACTATATTGATCATCAGGCGTCTACATAAGGTGTTAAGACCATTTTTACTAAGGAGACTGAAGAAAGA
AGTTGAATCCCAGCTTCCCGAAAAAGTGGAATATGTGATCAAGTGTGACATGTCAGCTCTGCAGAAGATT
CTGTATCGCCATATGCAAGCCAAGGGGATCCTTCTCACAGATGGTTCTGAGAAAGATAAGAAGGGGAAAG
GAGGTGCTAAGACACTTATGAACACTATTATGCAGTTGAGAAAAATCTGCAACCACCCATATATGTTTCA
GCACATTGAGGAATCCTTTGCTGAACACCTAGGCTATTCAAATGGGGTCATCAATGGGGCTGAACTGTAT
CGGGCCTCAGGGAAGTTTGAGCTGCTTGATCGTATTCTGCCAAAATTGAGAGCGACTAATCACCGAGTGC
TGCTTTTCTGCCAGATGACATCTCTCATGACCATCATGGAGGATTATTTTGCTTTTCGGAACTTCCTTTA
CCTACGCCTTGATGGCACCACCAAGTCTGAAGATCGTGCTGCTTTGCTGAAGAAATTCAATGAACCTGGA
TCCCAGTATTTCATTTTCTTGCTGAGCACAAGAGCTGGTGGCCTGGGCTTAAATCTTCAGGCAGCTGATA
CAGTGGTCATCTTTGACAGCGACTGGAATCCTCATCAGGATCTGCAGGCCCAAGACCGAGCTCACCGCAT
CGGGCAGCAGAACGAGGTCCGGGTACTGAGGCTCTGTACCGTGAACAGCGTGGAGGAAAAGATCCTCGCG
GCCGCAAAATACAAGCTGAACGTGGATCAGAAAGTGATCCAGGCGGGCATGTTTGACCAAAAGTCTTCAA
GCCACGAGCGGAGGGCATTCCTGCAGGCCATCTTGGAGCATGAGGAGGAAAATGAGGAAGAAGATGAAGT
ACCGGACGATGAGACTCTGAACCAAATGATTGCTCGACGAGAAGAAGAATTTGACCTTTTTATGCGGATG
GACATGGACCGGCGGAGGGAAGATGCCCGGAACCCGAAACGGAAGCCCCGTTTAATGGAGGAGGATGAGC
TGCCCTCCTGGATCATTAAGGATGACGCTGAAGTAGAAAGGCTCACCTGTGAAGAAGAGGAGGAGAAAAT
ATTTGGGAGGGGGTCCCGCCAGCGCCGTGACGTGGACTACAGTGACGCCCTCACGGAGAAGCAGTGGCTA
AGGGCCATCGAAGACGGCAATTTGGAGGAAATGGAAGAGGAAGTACGGCTTAAGAAGCGAAAAAGACGAA
GAAATGTGGATAAAGATCCTGCAAAAGAAGATGTGGAAAAAGCTAAGAAGAGAAGAGGCCGCCCTCCCGC
TGAGAAACTGTCACCAAATCCCCCCAAACTGACAAAGCAGATGAACGCTATCATCGATACTGTGATAAAC
TACAAAGATAGGTGTAACGTGGAGAAGGTGCCCAGTAATTCTCAGTTGGAAATAGAAGGAAACAGTTCAG
GGCGACAGCTCAGTGAAGTCTTCATTCAGTTACCTTCAAGGAAAGAATTACCAGAATACTATGAATTAAT
TAGGAAGCCAGTGGATTTCAAAAAAATAAAGGAAAGGATTCGTAATCATAAGTACCGGAGCCTAGGCGAC
CTGGAGAAGGATGTCATGCTTCTCTGTCACAACGCTCAGACGTTCAACCTGGAGGGATCCCAGATCTATG
AAGACTCCATCGTCTTACAGTCAGTGTTTAAGAGTGCCCGGCAGAAAATTGCCAAAGAGGAAGAGAGTGA
GGATGAAAGCAATGAAGAGGAGGAAGAGGAAGATGAAGAAGAGTCAGAGTCCGAGGCAAAATCAGTCAAG
GTGAAAATTAAGCTCAATAAAAAAGATGACAAAGGCCGGGACAAAGGGAAAGGCAAGAAAAGGCCAAATC
GAGGAAAAGCCAAACCTGTAGTGAGCGATTTTGACAGCGATGAGGAGCAGGATGAACGTGAACAGTCAGA
AGGAAGTGGGACGGATGATGAGTGATCAGTATGGACCTTTTTCCTTGGTAGAACTGAATTCCTTCCTCCC
CTGTCTCATTTCTACCCAGTGAGTTCATTTGTCATATAGGCACTGGGTTGTTTCTATATCATCATCGTCT
ATAAACTAGCTTTAGGATAGTGCCAGACAAACATATGATATCATGGTGTAAAAAACACACACATACACAA
ATATTTGTAACATATTGTGACCAAATGGGCCTCAAAGATTCAGATTGAAACAAACAAAAAGCTTTTGATG
GAAAATATGTGGGTGGATAGTATATTTCTATGGGTGGGTCTAATTTGGTAACGGTTTGATTGTGCCTGGT
TTTATCACCTGTTCAGATGAGAAGATTTTTGTCTTTTGTAGCACTGATAACCAGGAGAAGCCATTAAAAG
CCACTGGTTATTTTATTTTTCATCAGGCAATTTTCGAGGTTTTTATTTGTTCGGTATTGTTTTTTTACAC
TGTGGTACATATAAGCAACTTTAATAGGTGATAAATGTACAGTAGTTAGATTTCACCTGCATATACATTT
TTCCATTTTATGCTCTATGATCTGAACAAAAGCTTTTTGAATTGTATAAGATTTATGTCTACTGTAAACA
TTGCTTAATTTTTTTGCTCTTGATTTAAAAAAAAGTTTTGTTGAAAGCGCTATTGAATATTGCAATCTAT
ATAGTGTATTGGATGGCTTCTTTTGTCACCCTGATCTCCTATGTTACCAATGTGTATCGTCTCCTTCTCC
CTAAAGTGTACTTAATCTTTGCTTTCTTTGCACAATGTCTTTGGTTGCAAGTCATAAGCCTGAGGCAAAT
AAAATTCCAGTAATTTCGAAGAATGTGGTGTTGGTGCTTTCCTAATAAAGAAATAATTTAGCTTGACAAA.
[0106] The term "BRM" also refers to natural variants of the
wild-type human BRM protein, such as proteins having at least 85%
identity (e.g., 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, 99%, 99.9% identity, or more) to an amino acid
sequence of wild-type BRM, which is set forth in SEQ ID NO: 4
(Uniprot Accession No.: P51531;
www.uniprot.org/uniprot/P51531.fasta).
TABLE-US-00004 SEQ ID NO: 4
MSTPTDPGAMPHPGPSPGPGPSPGPILGPSPGPGPSPGSVHSMMGPSPGP
PSVSHPMPTMGSTDFPQEGMHQMHKPIDGIHDKGIVEDIHCGSMKGTGMR
PPHPGMGPPQSPMDQHSQGYMSPHPSPLGAPEHVSSPMSGGGPTPPQMPP
SQPGALIPGDPQAMSQPNRGPSPFSPVQLHQLRAQILAYKMLARGQPLPE
TLQLAVQGKRTLPGLQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPQTQQ
QQQPALVNYNRPSGPGPELSGPSTPQKLPVPAPGGRPSPAPPAAAQPPAA
AVPGPSVPQPAPGQPSPVLQLQQKQSRISPIQKPQGLDPVEILQEREYRL
QARIAHRIQELENLPGSLPPDLRTKATVELKALRLLNFQRQLRQEVVACM
RRDTTLETALNSKAYKRSKRQTLREARMTEKLEKQQKIEQERKRRQKHQE
YLNSILQHAKDFKEYHRSVAGKIQKLSKAVATWHANTEREQKKETERIEK
ERMRRLMAEDEEGYRKLIDQKKDRRLAYLLQQTDEYVANLTNLVWEHKQA
QAAKEKKKRRRRKKKAEENAEGGESALGPDGEPIDESSQMSDLPVKVTHT
ETGKVLFGPEAPKASQLDAWLEMNPGYEVAPRSDSEESDSDYEEEDEEEE
SSRQETEEKILLDPNSEEVSEKDAKQIIETAKQDVDDEYSMQYSARGSQS
YYTVAHAISERVEKQSALLINGTLKHYQLQGLEWMVSLYNNNLNGILADE
MGLGKTIQTIALITYLMEHKRLNGPYLIIVPLSTLSNWTYEFDKWAPSVV
KISYKGTPAMRRSLVPQLRSGKENVLLTTYEYIIKDKHILAKIRWKYMIV
DEGHRMKNHHCKLIQVLNTHYVAPRRILLIGTPLQNKLPELWALLNFLLP
TIFKSCSTFEQWFNAPFAMTGERVDLNEEETILIIRRLHKVLRPFLLRRL
KKEVESQLPEKVEYVIKCDMSALQKILYRHMQAKGILLTDGSEKDKKGKG
GAKTLMNTIMQLRKICNHPYMFQHIEESFAEHLGYSNGVINGAELYRASG
KFELLDRILPKLRATNHRVLLFCQMTSLMTIMEDYFAFRNFLYLRLDGIT
KSEDRAALLKKENEPGSQYFIFLLSTRAGGLGLNLQAADTWIFDSDWNPH
QDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQA
GMFDQKSSSHERRAFLQAILEHEEENEEEDEVPDDETLNQMIARREEEFD
LFMRMDMDRRREDARNPKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEE
KIFGRGSRQRRDVDYSDALTEKQWLRAIEDGNLEEMEEEVRLKKRKRRRN
VDKDPAKEDVEKAKKRRGRPPAEKLSPNPPKLTKQMNAIIDTVINYKDRC
NVEKVPSNSQLEIEGNSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKK
IKERIRNHKYRSLGDLEKDVMLLCHNAQTFNLEGSQIYEDSIVLQSVFKS
ARQKIAKEEESEDESNEEEEEEDEEESESEAKSVKVKIKLNKKDDKGRDK
GKGKKRPNRGKAKPVVSDFDSDEEQDEREQSEGSGTDDE.
[0107] As used herein, the term "degrader" refers to a small
molecule compound including a degradation moiety, wherein the
compound interacts with a protein (e.g., BRG1 and/or BRM) in a way
which results in degradation of the protein, e.g., binding of the
compound results in at least 5% reduction of the level of the
protein, e.g., in a cell or subject.
[0108] As used herein, the term "degradation moiety" refers to a
moiety whose binding results in degradation of a protein, e.g.,
BRG1 and/or BRM. In one example, the moiety binds to a protease or
a ubiquitin ligase that metabolizes the protein, e.g., BRG1 and/or
BRM.
[0109] By "determining the level of a protein" is meant the
detection of a protein, or an mRNA encoding the protein, by methods
known in the art either directly or indirectly. "Directly
determining" means performing a process (e.g., performing an assay
or test on a sample or "analyzing a sample" as that term is defined
herein) to obtain the physical entity or value. "Indirectly
determining" refers to receiving the physical entity or value from
another party or source (e.g., a third-party laboratory that
directly acquired the physical entity or value). Methods to measure
protein level generally include, but are not limited to, western
blotting, immunoblotting, enzyme-linked immunosorbent assay
(ELISA), radioimmunoassay (RIA), immunoprecipitation,
immunofluorescence, surface plasmon resonance, chemiluminescence,
fluorescent polarization, phosphorescence, immunohistochemical
analysis, matrix-assisted laser desorption/ionization
time-of-flight (MALDI-TOF) mass spectrometry, liquid chromatography
(LC)-mass spectrometry, microcytometry, microscopy, fluorescence
activated cell sorting (FACS), and flow cytometry, as well as
assays based on a property of a protein including, but not limited
to, enzymatic activity or interaction with other protein partners.
Methods to measure mRNA levels are known in the art.
[0110] By "modulating the activity of a BAF complex" is meant
altering the level of an activity related to a BAF complex (e.g.,
GBAF), or a related downstream effect. The activity level of a BAF
complex may be measured using any method known in the art, e.g.,
the methods described in Kadoch et al, Cell 153:71-85 (2013), the
methods of which are herein incorporated by reference.
[0111] By "reducing the activity of BRG1 and/or BRM" is meant
decreasing the level of an activity related to a BRG1 and/or BRM,
or a related downstream effect. A non-limiting example of
inhibition of an activity of BRG1 and/or BRM is decreasing the
level of a BAF complex (e.g., GBAF) in a cell. The activity level
of BRG1 and/or BRM may be measured using any method known in the
art. In some embodiments, an agent which reduces the activity of
BRG1 and/or BRM is a small molecule BRG1 and/or BRM inhibitor By
"reducing the level of BRG1 and/or BRM" is meant decreasing the
level of BRG1 and/or BRM in a cell or subject. The level of BRG1
and/or BRM may be measured using any method known in the art.
[0112] As used herein, the term "inhibiting BRG and/or BRM" refers
to blocking or reducing the level or activity of the ATPase
catalytic binding domain or the bromodomain of the protein. BRG1
and/or BRM inhibition may be determined using methods known in the
art, e.g., a BRG and/or BRM ATPase assay, a Nano DSF assay, or a
BRG1 and/or BRM Luciferase cell assay.
[0113] By "level" is meant a level of a protein, or mRNA encoding
the protein, as compared to a reference. The reference can be any
useful reference, as defined herein. By a "decreased level" or an
"increased level" of a protein is meant a decrease or increase in
protein level, as compared to a reference (e.g., a decrease or an
increase by about 5%, about 10%, about 15%, about 20%, about 25%,
about 30%, about 35%, about 40%, about 45%, about 50%, about 55%,
about 60%, about 65%, about 70%, about 75%, about 80%, about 85%,
about 90%, about 95%, about 100%, about 150%, about 200%, about
300%, about 400%, about 500%, or more; a decrease or an increase of
more than about 10%, about 15%, about 20%, about 50%, about 75%,
about 100%, or about 200%, as compared to a reference; a decrease
or an increase by less than about 0.01-fold, about 0.02-fold, about
0.1-fold, about 0.3-fold, about 0.5-fold, about 0.8-fold, or less;
or an increase by more than about 1.2-fold, about 1.4-fold, about
1.5-fold, about 1.8-fold, about 2.0-fold, about 3.0-fold, about
3.5-fold, about 4.5-fold, about 5.0-fold, about 10-fold, about
15-fold, about 20-fold, about 30-fold, about 40-fold, about
50-fold, about 100-fold, about 1000-fold, or more). A level of a
protein may be expressed in mass/vol (e.g., g/dL, mg/mL, .mu.g/mL,
ng/mL) or percentage relative to total protein or mRNA in a
sample.
[0114] As used herein, the term "inhibitor" refers to any agent
which reduces the level and/or activity of a protein (e.g., BRG1
and/or BRM). Non-limiting examples of inhibitors include small
molecule inhibitors, degraders, antibodies, enzymes, or
polynucleotides (e.g., siRNA).
[0115] As used herein, the term "LXS196," refers to the PKC
inhibitor having the structure:
##STR00037##
[0116] or a pharmaceutically acceptable salt thereof.
[0117] As used herein, the terms "effective amount,"
"therapeutically effective amount," and "a "sufficient amount" of
an agent that reduces the level and/or activity of BRG1 and/or BRM
(e.g., in a cell or a subject) described herein refer to a quantity
sufficient to, when administered to the subject, including a human,
effect beneficial or desired results, including clinical results,
and, as such, an "effective amount" or synonym thereto depends on
the context in which it is being applied. For example, in the
context of treating cancer, it is an amount of the agent that
reduces the level and/or activity of BRG1 and/or BRM sufficient to
achieve a treatment response as compared to the response obtained
without administration of the agent that reduces the level and/or
activity of BRG1 and/or BRM. The amount of a given agent that
reduces the level and/or activity of BRG1 and/or BRM described
herein that will correspond to such an amount will vary depending
upon various factors, such as the given agent, the pharmaceutical
formulation, the route of administration, the type of disease or
disorder, the identity of the subject (e.g., age, sex, and/or
weight) or host being treated, and the like, but can nevertheless
be routinely determined by one of skill in the art. Also, as used
herein, a "therapeutically effective amount" of an agent that
reduces the level and/or activity of BRG1 and/or BRM of the present
disclosure is an amount which results in a beneficial or desired
result in a subject as compared to a control. As defined herein, a
therapeutically effective amount of an agent that reduces the level
and/or activity of BRG1 and/or BRM of the present disclosure may be
readily determined by one of ordinary skill by routine methods
known in the art. Dosage regimen may be adjusted to provide the
optimum therapeutic response.
[0118] The term "inhibitory RNA agent" refers to an RNA, or analog
thereof, having sufficient sequence complementarity to a target RNA
to direct RNA interference. Examples also include a DNA that can be
used to make the RNA. RNA interference (RNAi) refers to a
sequence-specific or selective process by which a target molecule
(e.g., a target gene, protein, or RNA) is down-regulated.
Generally, an interfering RNA ("iRNA") is a double-stranded
short-interfering RNA (siRNA), short hairpin RNA (shRNA), or
single-stranded micro-RNA (miRNA) that results in catalytic
degradation of specific mRNAs, and also can be used to lower or
inhibit gene expression.
[0119] The terms "short interfering RNA" and "siRNA" (also known as
"small interfering RNAs") refer to an RNA agent, preferably a
double-stranded agent, of about 10-50 nucleotides in length, the
strands optionally having overhanging ends comprising, for example
1, 2 or 3 overhanging nucleotides (or nucleotide analogs), which is
capable of directing or mediating RNA interference.
Naturally-occurring siRNAs are generated from longer dsRNA
molecules (e.g., >25 nucleotides in length) by a cell's RNAi
machinery (e.g., Dicer or a homolog thereof).
[0120] The term "shRNA", as used herein, refers to an RNA agent
having a stem-loop structure, comprising a first and second region
of complementary sequence, the degree of complementarity and
orientation of the regions being sufficient such that base pairing
occurs between the regions, the first and second regions being
joined by a loop region, the loop resulting from a lack of base
pairing between nucleotides (or nucleotide analogs) within the loop
region.
[0121] The terms "miRNA" and "microRNA" refer to an RNA agent,
preferably a single-stranded agent, of about 10-50 nucleotides in
length, preferably between about 15-25 nucleotides in length, which
is capable of directing or mediating RNA interference.
Naturally-occurring miRNAs are generated from stem-loop precursor
RNAs (i.e., pre-miRNAs) by Dicer. The term "Dicer" as used herein,
includes Dicer as well as any Dicer ortholog or homolog capable of
processing dsRNA structures into siRNAs, miRNAs, siRNA-like or
miRNA-like molecules. The term microRNA ("miRNA") is used
interchangeably with the term "small temporal RNA" ("stRNA") based
on the fact that naturally-occurring miRNAs have been found to be
expressed in a temporal fashion (e.g., during development).
[0122] The term "antisense," as used herein, refers to a nucleic
acid comprising a polynucleotide that is sufficiently complementary
to all or a portion of a gene, primary transcript, or processed
mRNA, so as to interfere with expression of the endogenous gene
(e.g., BRG1 and/or BRM). "Complementary" polynucleotides are those
that are capable of base pairing according to the standard
Watson-Crick complementarity rules. Specifically, purines will base
pair with pyrimidines to form a combination of guanine paired with
cytosine (G:C) and adenine paired with either thymine (A:T) in the
case of DNA, or adenine paired with uracil (A:U) in the case of
RNA. It is understood that two polynucleotides may hybridize to
each other even if they are not completely complementary to each
other, provided that each has at least one region that is
substantially complementary to the other.
[0123] The term "antisense nucleic acid" includes single-stranded
RNA as well as double-stranded DNA expression cassettes that can be
transcribed to produce an antisense RNA. "Active" antisense nucleic
acids are antisense RNA molecules that are capable of selectively
hybridizing with a primary transcript or mRNA encoding a
polypeptide having at least 80% sequence identity (e.g., 80%, 85%,
86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%, 99.9% identity, or more) with the targeted polypeptide
sequence (e.g., a BRG1 and/or BRM polypeptide sequence). The
antisense nucleic acid can be complementary to an entire coding
strand, or to only a portion thereof. In some embodiments, an
antisense nucleic acid molecule is antisense to a "coding region"
of the coding strand of a nucleotide sequence. The term "coding
region" refers to the region of the nucleotide sequence comprising
codons that are translated into amino acid residues. In some
embodiments, the antisense nucleic acid molecule is antisense to a
"noncoding region" of the coding strand of a nucleotide sequence.
The term "noncoding region" refers to 5' and 3' sequences that
flank the coding region that are not translated into amino acids
(i.e., also referred to as 5' and 3' untranslated regions). The
antisense nucleic acid molecule can be complementary to the entire
coding region of mRNA, or can be antisense to only a portion of the
coding or noncoding region of an mRNA. For example, the antisense
oligonucleotide can be complementary to the region surrounding the
translation start site. An antisense oligonucleotide can be, for
example, about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides
in length.
[0124] "Percent (%) sequence identity" with respect to a reference
polynucleotide or polypeptide sequence is defined as the percentage
of nucleic acids or amino acids in a candidate sequence that are
identical to the nucleic acids or amino acids in the reference
polynucleotide or polypeptide sequence, after aligning the
sequences and introducing gaps, if necessary, to achieve the
maximum percent sequence identity. Alignment for purposes of
determining percent nucleic acid or amino acid sequence identity
can be achieved in various ways that are within the capabilities of
one of skill in the art, for example, using publicly available
computer software such as BLAST, BLAST-2, or Megalign software.
Those skilled in the art can determine appropriate parameters for
aligning sequences, including any algorithms needed to achieve
maximal alignment over the full length of the sequences being
compared. For example, percent sequence identity values may be
generated using the sequence comparison computer program BLAST. As
an illustration, the percent sequence identity of a given nucleic
acid or amino acid sequence, A, to, with, or against a given
nucleic acid or amino acid sequence, B, (which can alternatively be
phrased as a given nucleic acid or amino acid sequence, A that has
a certain percent sequence identity to, with, or against a given
nucleic acid or amino acid sequence, B) is calculated as
follows:
100 multiplied by (the fraction X/Y)
where X is the number of nucleotides or amino acids scored as
identical matches by a sequence alignment program (e.g., BLAST) in
that program's alignment of A and B, and where Y is the total
number of nucleic acids in B. It will be appreciated that where the
length of nucleic acid or amino acid sequence A is not equal to the
length of nucleic acid or amino acid sequence B, the percent
sequence identity of A to B will not equal the percent sequence
identity of B to A.
[0125] The term "pharmaceutical composition," as used herein,
represents a composition containing a compound described herein
formulated with a pharmaceutically acceptable excipient, and
manufactured or sold with the approval of a governmental regulatory
agency as part of a therapeutic regimen for the treatment of
disease in a mammal. Pharmaceutical compositions can be formulated,
for example, for oral administration in unit dosage form (e.g., a
tablet, capsule, caplet, gelcap, or syrup); for topical
administration (e.g., as a cream, gel, lotion, or ointment); for
intravenous administration (e.g., as a sterile solution free of
particulate emboli and in a solvent system suitable for intravenous
use); or in any other pharmaceutically acceptable formulation.
[0126] A "pharmaceutically acceptable excipient," as used herein,
refers any ingredient other than the compounds described herein
(for example, a vehicle capable of suspending or dissolving the
active compound) and having the properties of being substantially
nontoxic and non-inflammatory in a patient. Excipients may include,
for example: antiadherents, antioxidants, binders, coatings,
compression aids, disintegrants, dyes (colors), emollients,
emulsifiers, fillers (diluents), film formers or coatings, flavors,
fragrances, glidants (flow enhancers), lubricants, preservatives,
printing inks, sorbents, suspensing or dispersing agents,
sweeteners, and waters of hydration. Exemplary excipients include,
but are not limited to: butylated hydroxytoluene (BHT), calcium
carbonate, calcium phosphate (dibasic), calcium stearate,
croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid,
crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl
cellulose, hydroxypropyl methylcellulose, lactose, magnesium
stearate, maltitol, mannitol, methionine, methylcellulose, methyl
paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl
pyrrolidone, povidone, pregelatinized starch, propyl paraben,
retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl
cellulose, sodium citrate, sodium starch glycolate, sorbitol,
starch (corn), stearic acid, sucrose, talc, titanium dioxide,
vitamin A, vitamin E, vitamin C, and xylitol.
[0127] As used herein, the term "pharmaceutically acceptable salt"
means any pharmaceutically acceptable salt of the compound of any
of the compounds described herein. For example, pharmaceutically
acceptable salts of any of the compounds described herein include
those that are within the scope of sound medical judgment, suitable
for use in contact with the tissues of humans and animals without
undue toxicity, irritation, allergic response and are commensurate
with a reasonable benefit/risk ratio. Pharmaceutically acceptable
salts are well known in the art. For example, pharmaceutically
acceptable salts are described in: Berge et al., J. Pharmaceutical
Sciences 66:1-19, 1977 and in Pharmaceutical Salts: Properties,
Selection, and Use, (Eds. P. H. Stahl and C. G. Wermuth),
Wiley-VCH, 2008. The salts can be prepared in situ during the final
isolation and purification of the compounds described herein or
separately by reacting a free base group with a suitable organic
acid.
[0128] The compounds described herein may have ionizable groups so
as to be capable of preparation as pharmaceutically acceptable
salts. These salts may be acid addition salts involving inorganic
or organic acids or the salts may, in the case of acidic forms of
the compounds described herein, be prepared from inorganic or
organic bases. Frequently, the compounds are prepared or used as
pharmaceutically acceptable salts prepared as addition products of
pharmaceutically acceptable acids or bases. Suitable
pharmaceutically acceptable acids and bases and methods for
preparation of the appropriate salts are well-known in the art.
Salts may be prepared from pharmaceutically acceptable non-toxic
acids and bases including inorganic and organic acids and bases.
Representative acid addition salts include acetate, adipate,
alginate, ascorbate, aspartate, benzenesulfonate, benzoate,
bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, fumarate, glucoheptonate, glycerophosphate,
hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride,
hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate,
laurate, lauryl sulfate, malate, maleate, malonate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate,
oleate, oxalate, palmitate, pamoate, pectinate, persulfate,
3-phenylpropionate, phosphate, picrate, pivalate, propionate,
stearate, succinate, sulfate, tartrate, thiocyanate,
toluenesulfonate, undecanoate, and valerate salts. Representative
alkali or alkaline earth metal salts include sodium, lithium,
potassium, calcium, and magnesium, as well as nontoxic ammonium,
quaternary ammonium, and amine cations, including, but not limited
to ammonium, tetramethylammonium, tetraethylammonium, methylamine,
dimethylamine, trimethylamine, triethylamine, and ethylamine.
[0129] By a "reference" is meant any useful reference used to
compare protein or mRNA levels. The reference can be any sample,
standard, standard curve, or level that is used for comparison
purposes. The reference can be a normal reference sample or a
reference standard or level. A "reference sample" can be, for
example, a control, e.g., a predetermined negative control value
such as a "normal control" or a prior sample taken from the same
subject; a sample from a normal healthy subject, such as a normal
cell or normal tissue; a sample (e.g., a cell or tissue) from a
subject not having a disease; a sample from a subject that is
diagnosed with a disease, but not yet treated with a compound
described herein; a sample from a subject that has been treated by
a compound described herein; or a sample of a purified protein
(e.g., any described herein) at a known normal concentration. By
"reference standard or level" is meant a value or number derived
from a reference sample. A "normal control value" is a
pre-determined value indicative of non-disease state, e.g., a value
expected in a healthy control subject. Typically, a normal control
value is expressed as a range ("between X and Y"), a high threshold
("no higher than X"), or a low threshold ("no lower than X"). A
subject having a measured value within the normal control value for
a particular biomarker is typically referred to as "within normal
limits" for that biomarker. A normal reference standard or level
can be a value or number derived from a normal subject not having a
disease or disorder (e.g., cancer); a subject that has been treated
with a compound described herein. In preferred embodiments, the
reference sample, standard, or level is matched to the sample
subject sample by at least one of the following criteria: age,
weight, sex, disease stage, and overall health. A standard curve of
levels of a purified protein, e.g., any described herein, within
the normal reference range can also be used as a reference.
[0130] As used herein, the term "subject" refers to any organism to
which a composition in accordance with the invention may be
administered, e.g., for experimental, diagnostic, prophylactic,
and/or therapeutic purposes. Typical subjects include any animal
(e.g., mammals such as mice, rats, rabbits, non-human primates, and
humans). A subject may seek or be in need of treatment, require
treatment, be receiving treatment, be receiving treatment in the
future, or be a human or animal who is under care by a trained
professional for a particular disease or condition.
[0131] As used herein, the terms "treat," "treated," or "treating"
mean both therapeutic treatment and prophylactic or preventative
measures wherein the object is to prevent or slow down (lessen) an
undesired physiological condition, disorder, or disease, or obtain
beneficial or desired clinical results. Beneficial or desired
clinical results include, but are not limited to, alleviation of
symptoms; diminishment of the extent of a condition, disorder, or
disease; stabilized (i.e., not worsening) state of condition,
disorder, or disease; delay in onset or slowing of condition,
disorder, or disease progression; amelioration of the condition,
disorder, or disease state or remission (whether partial or total),
whether detectable or undetectable; an amelioration of at least one
measurable physical parameter, not necessarily discernible by the
patient; or enhancement or improvement of condition, disorder, or
disease. Treatment includes eliciting a clinically significant
response without excessive levels of side effects. Treatment also
includes prolonging survival as compared to expected survival if
not receiving treatment.
[0132] As used herein, the terms "variant" and "derivative" are
used interchangeably and refer to naturally-occurring, synthetic,
and semi-synthetic analogues of a compound, peptide, protein, or
other substance described herein. A variant or derivative of a
compound, peptide, protein, or other substance described herein may
retain or improve upon the biological activity of the original
material.
[0133] The details of one or more embodiments of the invention are
set forth in the description below. Other features, objects, and
advantages of the invention will be apparent from the description
and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0134] FIG. 1 is a graph illustrating inhibition of cell
proliferation of several cancer cell lines by a BRG1/BRM inhibitor
(compound 17).
[0135] FIG. 2 is a graph illustrating inhibition of cell
proliferation of several cancer cell lines by a BRG1/BRM inhibitor,
compound 18.
[0136] FIG. 3 is a graph illustrating the area under the curves
(AUCs) calculated from dose-response curves for cancer cell lines
treated with a BRG1/BRM inhibitor.
[0137] FIG. 4 is a graph illustrating in vivo inhibition of AML
proliferation by a BRG1/BRM inhibitor.
[0138] FIG. 5 is a graph illustrating in vivo inhibition of AML
proliferation by a BRG1/BRM inhibitor.
[0139] FIG. 6 is a graph illustrating in vivo inhibition of AML
proliferation by a BRG1/BRM inhibitor.
DETAILED DESCRIPTION
[0140] The present inventors have found that depletion of BRG1
and/or BRM in AML results in decreased proliferation of the cancer
cells.
[0141] Accordingly, the invention features methods and compositions
useful for the inhibition of the activity of the BRG1 and/or BRM,
e.g., for the treatment of AML. The invention further features
methods and compositions useful for inhibition of the activity of
the BRG1 and/or BRM protein, e.g., for the treatment of AML, e.g.,
in a subject in need thereof. Exemplary methods are described
herein.
BRG1 and/or BRM-Reducing Agents
[0142] Agents described herein that reduce the level and/or
activity of BRG1 and/or BRM in a cell may be an antibody, a protein
(such as an enzyme), a polynucleotide, or a small molecule
compound. The agents reduce the level of an activity related to
BRG1 and/or BRM, or a related downstream effect, or reduce the
level of BRG1 and/or BRM in a cell or subject.
[0143] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM in a cell is an enzyme, a
polynucleotide, or a small molecule compound such as a small
molecule BRG1 and/or BRM inhibitor.
[0144] Antibodies
[0145] The agent that reduces the level and/or activity of BRG1
and/or BRM can be an antibody or antigen binding fragment thereof.
For example, an agent that reduces the level and/or activity of
BRG1 and/or BRM described herein is an antibody that reduces or
blocks the activity and/or function of BRG1 and/or BRM through
binding to BRG1 and/or BRM.
[0146] The making and use of therapeutic antibodies against a
target antigen (e.g., BRG1 and/or BRM) is known in the art. See,
for example, the references cited herein above, as well as Zhiqiang
An (Editor), Therapeutic Monoclonal Antibodies: From Bench to
Clinic. 1st Edition. Wiley 2009, and also Greenfield (Ed.),
Antibodies: A Laboratory Manual. (Second edition) Cold Spring
Harbor Laboratory Press 2013, for methods of making recombinant
antibodies, including antibody engineering, use of degenerate
oligonucleotides, 5'-RACE, phage display, and mutagenesis; antibody
testing and characterization; antibody pharmacokinetics and
pharmacodynamics; antibody purification and storage; and screening
and labeling techniques.
[0147] Polynucleotides
[0148] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM is a polynucleotide. In some
embodiments, the polynucleotide is an inhibitory RNA molecule,
e.g., that acts by way of the RNA interference (RNAi) pathway. An
inhibitory RNA molecule can decrease the expression level (e.g.,
protein level or mRNA level) of BRG1 and/or BRM. For example, an
inhibitory RNA molecule includes a short interfering RNA (siRNA),
short hairpin RNA (shRNA), and/or a microRNA (miRNA) that targets
full-length BRG1 and/or BRM. A siRNA is a double-stranded RNA
molecule that typically has a length of about 19-25 base pairs. A
shRNA is a RNA molecule including a hairpin turn that decreases
expression of target genes via RNAi. A microRNA is a non-coding RNA
molecule that typically has a length of about 22 nucleotides.
miRNAs bind to target sites on mRNA molecules and silence the mRNA,
e.g., by causing cleavage of the mRNA, destabilization of the mRNA,
or inhibition of translation of the mRNA. Degradation is caused by
an enzymatic, RNA-induced silencing complex (RISC).
[0149] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM is an antisense nucleic acid. Antisense
nucleic acids include antisense RNA (asRNA) and antisense DNA
(asDNA) molecules, typically about 10 to 30 nucleotides in length,
which recognize polynucleotide target sequences or sequence
portions through hydrogen bonding interactions with the nucleotide
bases of the target sequence (e.g., BRG1 and/or BRM). The target
sequences may be single- or double-stranded RNA, or single- or
double-stranded DNA.
[0150] In some embodiments, the polynucleotide decreases the level
and/or activity of a negative regulator of function or a positive
regulator of function. In other embodiments, the polynucleotide
decreases the level and/or activity of an inhibitor of a positive
regulator of function.
[0151] A polynucleotide of the invention can be modified, e.g., to
contain modified nucleotides, e.g., 2'-fluoro, 2'-o-methyl,
2'-deoxy, unlocked nucleic acid, 2'-hydroxy, phosphorothioate,
2'-thiouridine, 4'-thiouridine, 2'-deoxyuridine. Without being
bound by theory, it is believed that certain modification can
increase nuclease resistance and/or serum stability, or decrease
immunogenicity. The polynucleotides mentioned above, may also be
provided in a specialized form such as liposomes, microspheres, or
may be applied to gene therapy, or may be provided in combination
with attached moieties. Such attached moieties include polycations
such as polylysine that act as charge neutralizers of the phosphate
backbone, or hydrophobic moieties such as lipids (e.g.,
phospholipids, cholesterols, etc.) that enhance the interaction
with cell membranes or increase uptake of the nucleic acid. These
moieties may be attached to the nucleic acid at the 3' or 5' ends
and may also be attached through a base, sugar, or intramolecular
nucleoside linkage. Other moieties may be capping groups
specifically placed at the 3' or 5' ends of the nucleic acid to
prevent degradation by nucleases such as exonuclease, RNase, etc.
Such capping groups include hydroxyl protecting groups known in the
art, including glycols such as polyethylene glycol and
tetraethylene glycol. The inhibitory action of the polynucleotide
can be examined using a cell-line or animal based gene expression
system of the present invention in vivo and in vitro. In some
embodiments, the polynucleotide decreases the level and/or activity
or function of BRG1 and/or BRM. In embodiments, the polynucleotide
inhibits expression of BRG1 and/or BRM. In other embodiments, the
polynucleotide increases degradation of BRG1 and/or BRM and/or
decreases the stability (i.e., half-life) of BRG1 and/or BRM. The
polynucleotide can be chemically synthesized or transcribed in
vitro.
[0152] Inhibitory polynucleotides can be designed by methods well
known in the art. siRNA, miRNA, shRNA, and asRNA molecules with
homology sufficient to provide sequence specificity required to
uniquely degrade any RNA can be designed using programs known in
the art, including, but not limited to, those maintained on
websites for Thermo Fisher Scientific, the German Cancer Research
Center, and The Ohio State University Wexner Medical Center.
Systematic testing of several designed species for optimization of
the inhibitory polynucleotide sequence can be routinely performed
by those skilled in the art. Considerations when designing
interfering polynucleotides include, but are not limited to,
biophysical, thermodynamic, and structural considerations, base
preferences at specific positions in the sense strand, and
homology. The making and use of inhibitory therapeutic agents based
on non-coding RNA such as ribozymes, RNAse P, siRNAs, and miRNAs
are also known in the art, for example, as described in Sioud, RNA
Therapeutics: Function, Design, and Delivery (Methods in Molecular
Biology). Humana Press 2010. Exemplary inhibitory polynucleotides,
for use in the methods of the invention, are provided in Table 1,
below. In some embodiments, the inhibitory polynucleotides have a
nucleic acid sequence with at least 50% (e.g., at least 50%, at
least 60%, at least 70%, at least 80%, at least 85%, at least 90%,
at least 95%, at least 96%, at least 97%, at least 98%, at least
99%, or 100%) sequence identity to the nucleic acid sequence of an
inhibitory polynucleotide in Table 1. In some embodiments, the
inhibitory polynucleotides have a nucleic acid sequence with at
least 70% sequence identity (e.g., 70%, 75%, 80%, 85%, 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.9%
identity, or more) to the nucleic acid sequence of an inhibitory
polynucleotide in Table 1.
[0153] Construction of vectors for expression of polynucleotides
for use in the invention may be accomplished using conventional
techniques which do not require detailed explanation to one of
ordinary skill in the art. For generation of efficient expression
vectors, it is necessary to have regulatory sequences that control
the expression of the polynucleotide. These regulatory sequences
include promoter and enhancer sequences and are influenced by
specific cellular factors that interact with these sequences, and
are well known in the art.
[0154] Gene Editing
[0155] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM is a component of a gene editing
system. For example, the agent that reduces the level and/or
activity of BRG1 and/or BRM introduces an alteration (e.g.,
insertion, deletion (e.g., knockout), translocation, inversion,
single point mutation, or other mutation) in BRG1 and/or BRM. In
some embodiments, the agent that reduces the level and/or activity
of BRG1 and/or BRM is a nuclease. Exemplary gene editing systems
include the zinc finger nucleases (ZFNs), Transcription
Activator-Like Effector-based Nucleases (TALENs), and the clustered
regulatory interspaced short palindromic repeat (CRISPR) system.
ZFNs, TALENs, and CRISPR-based methods are described, e.g., in Gaj
et al., Trends Biotechnol. 31(7):397-405 (2013).
[0156] CRISPR refers to a set of (or system including a set of)
clustered regularly interspaced short palindromic repeats. A CRISPR
system refers to a system derived from CRISPR and Cas (a
CRISPR-associated protein) or other nuclease that can be used to
silence or mutate a gene described herein. The CRISPR system is a
naturally occurring system found in bacterial and archeal genomes.
The CRISPR locus is made up of alternating repeat and spacer
sequences. In naturally-occurring CRISPR systems, the spacers are
typically sequences that are foreign to the bacterium (e.g.,
plasmid or phage sequences). The CRISPR system has been modified
for use in gene editing (e.g., changing, silencing, and/or
enhancing certain genes) in eukaryotes. See, e.g., Wiedenheft et
al., Nature 482(7385):331-338 (2012). For example, such
modification of the system includes introducing into a eukaryotic
cell a plasmid containing a specifically-designed CRISPR and one or
more appropriate Cas proteins. The CRISPR locus is transcribed into
RNA and processed by Cas proteins into small RNAs that include a
repeat sequence flanked by a spacer. The RNAs serve as guides to
direct Cas proteins to silence specific DNA/RNA sequences,
depending on the spacer sequence. See, e.g., Horvath et al.,
Science 327(5962):167-170 (2010); Makarova et al., Biology Direct
1:7 (2006); Pennisi, Science 341(6148):833-836 (2013). In some
examples, the CRISPR system includes the Cas9 protein, a nuclease
that cuts on both strands of the DNA. See, e.g., Id.
[0157] In some embodiments, in a CRISPR system for use described
herein, e.g., in accordance with one or more methods described
herein, the spacers of the CRISPR are derived from a target gene
sequence, e.g., from a BRG1 and/or BRM sequence. In some
embodiments, in a CRISPR system for use described herein, e.g., in
accordance with one or more methods described herein, the spacers
of the CRISPR are derived from a target gene sequence, e.g., from a
BRG1 sequence. In some embodiments, in a CRISPR system for use
described herein, e.g., in accordance with one or more methods
described herein, the spacers of the CRISPR are derived from a
target gene sequence, e.g., from a BRM sequence.
[0158] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM includes a guide RNA (gRNA) for use in
a CRISPR system for gene editing. Exemplary gRNAs, for use in the
methods of the invention, are provided in Table 1, below. In
embodiments, the agent that reduces the level and/or activity of
BRG1 and/or BRM includes a ZFN, or an mRNA encoding a ZFN, that
targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA
sequence) of BRG1 and/or BRM. In embodiments, the agent that
reduces the level and/or activity of BRG1 and/or BRM includes a
TALEN, or an mRNA encoding a TALEN, that targets (e.g., cleaves) a
nucleic acid sequence (e.g., DNA sequence) of BRG1 and/or BRM. In
embodiments, the agent that reduces the level and/or activity of
BRG1 and/or BRM includes a TALEN, or an mRNA encoding a TALEN, that
targets (e.g., cleaves) a nucleic acid sequence (e.g., DNA
sequence) of BRG1. In embodiments, the agent that reduces the level
and/or activity of BRG1 and/or BRM includes a TALEN, or an mRNA
encoding a TALEN, that targets (e.g., cleaves) a nucleic acid
sequence (e.g., DNA sequence) of BRM.
[0159] For example, the gRNA can be used in a CRISPR system to
engineer an alteration in a gene (e.g., BRG1 and/or BRM). In other
examples, the ZFN and/or TALEN can be used to engineer an
alteration in a gene (e.g., BRG1 and/or BRM). Exemplary alterations
include insertions, deletions (e.g., knockouts), translocations,
inversions, single point mutations, or other mutations. The
alteration can be introduced in the gene in a cell, e.g., in vitro,
ex vivo, or in vivo. In some embodiments, the alteration decreases
the level and/or activity of (e.g., knocks down or knocks out) BRG1
and/or BRM, e.g., the alteration is a negative regulator of
function. In yet another example, the alteration corrects a defect
(e.g., a mutation causing a defect), in BRG1 and/or BRM. In yet
another example, the alteration corrects a defect (e.g., a mutation
causing a defect), in BRG1. In yet another example, the alteration
corrects a defect (e.g., a mutation causing a defect), in BRM.
[0160] In certain embodiments, the CRISPR system is used to edit
(e.g., to add or delete a base pair) a target gene, e.g., BRG1
and/or BRM. In other embodiments, the CRISPR system is used to
introduce a premature stop codon, e.g., thereby decreasing the
expression of a target gene. In yet other embodiments, the CRISPR
system is used to turn off a target gene in a reversible manner,
e.g., similarly to RNA interference. In embodiments, the CRISPR
system is used to direct Cas to a promoter of a target gene, e.g.,
BRG1 and/or BRM, thereby blocking an RNA polymerase sterically. In
embodiments, the CRISPR system is used to direct Cas to a promoter
of a target gene, e.g., BRG1, thereby blocking an RNA polymerase
sterically. In embodiments, the CRISPR system is used to direct Cas
to a promoter of a target gene, e.g., BRM, thereby blocking an RNA
polymerase sterically.
[0161] In some embodiments, a CRISPR system can be generated to
edit BRG1 and/or BRM using technology described in, e.g., U.S.
Publication No. 20140068797; Cong et al., Science 339(6121):819-823
(2013); Tsai, Nature Biotechnol., 32(6):569-576 (2014); and U.S.
Pat. Nos. 8,871,445; 8,865,406; 8,795,965; 8,771,945; and
8,697,359.
[0162] In some embodiments, the CRISPR interference (CRISPRi)
technique can be used for transcriptional repression of specific
genes, e.g., the gene encoding BRG1 and/or BRM. In CRISPRi, an
engineered Cas9 protein (e.g., nuclease-null dCas9, or dCas9 fusion
protein, e.g., dCas9-KRAB or dCas9-SID4.times. fusion) can pair
with a sequence specific guide RNA (sgRNA). The Cas9-gRNA complex
can block RNA polymerase, thereby interfering with transcription
elongation. The complex can also block transcription initiation by
interfering with transcription factor binding. The CRISPRi method
is specific with minimal off-target effects and is multiplexable,
e.g., can simultaneously repress more than one gene (e.g., using
multiple gRNAs). Also, the CRISPRi method permits reversible gene
repression. In some embodiments, CRISPR-mediated gene activation
(CRISPRa) can be used for transcriptional activation, e.g., of one
or more genes described herein, e.g., a gene that inhibits BRG1
and/or BRM. In the CRISPRa technique, dCas9 fusion proteins recruit
transcriptional activators. For example, dCas9 can be used to
recruit polypeptides (e.g., activation domains) such as VP64 or the
p65 activation domain (p65D) and used with sgRNA (e.g., a single
sgRNA or multiple sgRNAs), to activate a gene or genes, e.g.,
endogenous gene(s). Multiple activators can be recruited by using
multiple sgRNAs--this can increase activation efficiency. A variety
of activation domains and single or multiple activation domains can
be used. In addition to engineering dCas9 to recruit activators,
sgRNAs can also be engineered to recruit activators. For example,
RNA aptamers can be incorporated into a sgRNA to recruit proteins
(e.g., activation domains) such as VP64. In some examples, the
synergistic activation mediator (SAM) system can be used for
transcriptional activation. In SAM, MS2 aptamers are added to the
sgRNA. MS2 recruits the MS2 coat protein (MCP) fused to p65AD and
heat shock factor 1 (HSF1). The CRISPRi and CRISPRa techniques are
described in greater detail, e.g., in Dominguez et al., Nat. Rev.
Mol. Cell Biol. 17(1):5-15 (2016), incorporated herein by
reference.
[0163] Small Molecule Compounds
[0164] In some embodiments of the invention, the agent that reduces
the level and/or activity of BRG1 and/or BRM in a cell is a small
molecule compound. In some embodiments, the small molecule compound
is a structure of Formula I-III.
[0165] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula I:
##STR00038##
[0166] wherein m is 0, 1, 2, 3, or 4;
[0167] X.sup.1 is N or CH; and
[0168] each R.sup.1 is, independently, independently, halogen,
optionally substituted C.sub.1-C.sub.6 alkyl, optionally
substituted C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino.
[0169] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula II:
##STR00039##
[0170] wherein R.sup.2 is phenyl that is substituted with hydroxy
and that is optionally substituted with one or more groups
independently selected from the group consisting of halo, cyano,
trifluoromethyl, trifluoromethoxy, C.sub.1-3 alkyl, and C.sub.1-3
alkoxy;
[0171] R.sup.3 is selected from the group consisting of --R.sup.a,
--O--R.sup.a, --N(R.sup.a).sub.2, --S(O).sub.2R.sup.a, and
--C(O)--N(R.sup.a).sub.2;
[0172] each R.sup.a is, independently, selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15 membered
heterocyclyl, wherein each C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15 membered
heterocyclyl is optionally substituted with one or more groups
independently selected from the group consisting of R.sup.b, oxo,
halo, --NO.sub.2, --N(R.sup.b).sub.2, --CN,
--C(O)--N(R.sup.b).sub.2, --S(O)--N(R.sup.b).sub.2,
--S(O).sub.2--N(R.sup.b).sub.2, --O--R.sup.b, --S--R.sup.b,
--O--C(O)--R.sup.b, --C(O)-- R.sup.b, --C(O)--OR.sup.b,
--S(O)--R.sup.b, --S(O).sub.2--R.sup.b, --N(R.sup.b)--C(O)--
R.sup.b, --N(R.sup.b)--S(O)--R.sup.b,
--N(R.sup.b)--C(O)--N(R.sup.b).sub.2, and
--N(R.sup.b)--S(O).sub.2--R.sup.b;
[0173] each R.sup.b is independently selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, 3-15 membered carbocyclyl, and
3-15 membered heterocyclyl, wherein each C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.1-6 alkoxy, 3-15 membered
carbocyclyl, and 3-15 membered heterocyclyl is optionally
substituted with one or more groups independently selected from RC;
or two R.sup.b are taken together with the nitrogen to which they
are attached to form a heterocyclyl that is optionally substituted
with one or more groups independently selected from the group
consisting of oxo, halo and C.sub.1-3 alkyl that is optionally
substituted with one or more groups independently selected from the
group consisting of oxo and halo;
[0174] each RC is independently selected from the group consisting
of oxo, halo, --NO.sub.2, --N(R.sup.d).sub.2, --CN,
--C(O)--N(R.sup.d).sub.2, --S(O)--N(R.sup.d).sub.2,
--S(O).sub.2--N(R.sup.d).sub.2, --S--R.sup.d, --O--C(O)--R.sup.d,
--C(O)--R.sup.d, --C(O)--OR d, --S(O)-- R.sup.d,
--S(O).sub.2--R.sup.d, --N(R.sup.d)--C(O)--R.sup.d,
--N(R.sup.d)--S(O)-- R.sup.d, --N(R.sup.d)--C(O)--N(R.sup.d).sub.2,
--N(R.sup.d)--S(O).sub.2-- R.sup.d, C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl, wherein any C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, 3-15 membered carbocyclyl, and 3-15
membered heterocyclyl is optionally substituted with one or more
groups independently selected from the group consisting of R.sup.d,
oxo, halo, --NO.sub.2, --N(R.sup.d).sub.2, --CN,
--C(O)--N(R.sup.d).sub.2, --S(O)--N(R.sup.d).sub.2,
--S(O).sub.2--N(R.sup.d).sub.2, --O--R.sup.d, --S--R.sup.d,
--O--C(O)--R.sup.d, --C(O)-- R.sup.d, --C(O)-- R.sup.d, --S(O)--
R.sup.d, --S(O).sub.2--R.sup.d, --N(R.sup.d)--C(O)-- R.sup.d,
--N(R.sup.d)--S(O)-- R.sup.d, --N(R.sup.d)--C(O)--N(R.sup.d).sub.2,
and --N(R.sup.d)--S(O).sub.2--R.sup.d;
[0175] each R.sup.d is independently selected from the group
consisting of hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl,
C.sub.2-6 alkynyl, carbocyclyl, and carbocyclyl(C.sub.1-3
alkyl)-;
[0176] R.sup.4 is H, C.sub.1-6 alkyl, or --C(.dbd.O)--C.sub.1-6
alkyl; and
[0177] R.sup.5 is H or C.sub.1-6 alkyl.
[0178] Compounds of Formula II may be synthesized by methods known
in the art, e.g., those described in U.S. Patent Publication No.
2018/0086720, the synthetic methods of which are incorporated by
reference.
[0179] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula III:
##STR00040##
[0180] wherein R.sup.6 is halo, e.g., fluoro or chloro;
[0181] R.sup.7 is hydrogen, optionally substituted amino, or
optionally substituted C.sub.1--B alkyl; and
[0182] R.sup.8 is optionally substituted C.sub.6-10 aryl or
optionally substituted C.sub.2-9 heteroaryl.
[0183] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of any one of compounds 1-16:
##STR00041## ##STR00042## ##STR00043##
[0184] In some embodiments, the small molecule BRG1 and/or BRM
inhibitor is a compound, or pharmaceutically acceptable salt
thereof, having the structure of Formula IV:
##STR00044##
[0185] where R.sup.1 is absent, H, optionally substituted
C.sub.1-C.sub.6 acyl, optionally substituted C.sub.1-C.sub.6 alkyl,
optionally substituted C.sub.3-C.sub.8 cycloalkyl, optionally
substituted C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, or --SO.sub.2R.sup.6;
##STR00045##
is 5- or 6-membered heteroarylene;
[0186] each of R.sup.2 and R.sup.5 is, independently, H or
optionally substituted C.sub.1-C.sub.6 alkyl;
[0187] R.sup.3 is H or optionally substituted C.sub.1-C.sub.6
alkyl; and R.sup.4 is H, optionally substituted C.sub.1-C.sub.6
alkyl, or optionally substituted C.sub.1-C.sub.6 heteroalkyl; or
R.sup.3 and R.sup.4, together with the carbon atom to which each is
attached, form an optionally substituted C.sub.3-C.sub.6
cycloalkyl;
[0188] R.sup.6 is optionally substituted C.sub.1-C.sub.6 alkyl or
--NR.sup.7R.sup.8;
[0189] R.sup.7 and R.sup.8 are, independently, optionally
substituted C.sub.1-C.sub.6 alkyl;
[0190] Het is optionally substituted 5-membered heteroarylene,
optionally substituted 6-membered heteroarylene, or
##STR00046##
[0191] A is optionally substituted C.sub.6-C.sub.10 arylene,
optionally substituted C.sub.2-C.sub.9 heterocyclylene, or
optionally substituted C.sub.2-C.sub.9 heteroarylene;
[0192] L is absent, --O--, optionally substituted C.sub.1-C.sub.6
alkylene, optionally substituted C.sub.1-C.sub.6 heteroalkylene,
optionally substituted C.sub.2-C.sub.6 alkenylene, optionally
substituted C.sub.2-C.sub.6 heteroalkenylene, optionally
substituted C.sub.2-C.sub.6 alkynylene, optionally substituted
C.sub.2-C.sub.6 heteroalkynylene, optionally substituted
C.sub.2-C.sub.9 heterocyclylene, optionally substituted
C.sub.2-C.sub.9 heterocyclyl C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.2-C.sub.9 heteroarylene, or optionally
substituted C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene;
and
[0193] B is H, halogen, cyano, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.3-C.sub.10
cycloalkyl, optionally substituted C.sub.2-C.sub.9 heterocyclyl, or
optionally substituted C.sub.2-C.sub.9 heteroaryl, or a
pharmaceutically acceptable salt thereof.
[0194] In some embodiments,
##STR00047##
is 6-membered heteroarylene. In some embodiments,
##STR00048##
is 5-membered heteroarylene.
[0195] In some embodiments,
##STR00049##
where each of X, Y, and Z is, independently, N or CH.
[0196] In some embodiments, the compound of Formula IV has the
structure of Formula IVa:
##STR00050##
[0197] where each of X, Y, and Z is, independently, N or CH;
[0198] R.sup.1 is H, optionally substituted C.sub.1-C.sub.6 acyl,
optionally substituted C.sub.1-C.sub.6 alkyl, optionally
substituted C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.8 cycloalkyl, optionally substituted C.sub.2-C.sub.9
heterocyclyl, or --SO.sub.2R.sup.6;
[0199] each of R.sup.2, R.sup.3, and R.sup.5 is, independently, H
or optionally substituted C.sub.1-C.sub.6 alkyl;
[0200] R.sup.4 is H, optionally substituted C.sub.1-C.sub.6 alkyl,
or optionally substituted C.sub.1-C.sub.6 heteroalkyl;
[0201] R.sup.6 is optionally substituted C.sub.1-C.sub.6 alkyl or
--NR.sup.7R.sup.8;
[0202] each of R.sup.7 and R.sup.8 is, independently, optionally
substituted C.sub.1-C.sub.6 alkyl;
[0203] Het is optionally substituted 5-membered heteroarylene,
optionally substituted 6-membered heteroarylene, or
##STR00051##
[0204] A is optionally substituted C.sub.6-C.sub.10 arylene,
optionally substituted C.sub.2-C.sub.9 heterocyclylene, or
optionally substituted C.sub.2-C.sub.9 heteroarylene;
[0205] L is absent, --O--, optionally substituted C.sub.1-C.sub.6
alkylene, optionally substituted C.sub.1-C.sub.6 heteroalkylene,
optionally substituted C.sub.2-C.sub.6 alkenylene, optionally
substituted C.sub.2-C.sub.6 heteroalkenylene, optionally
substituted C.sub.2-C.sub.6 alkynylene, optionally substituted
C.sub.2-C.sub.6 heteroalkynylene, optionally substituted
C.sub.2-C.sub.9 heterocyclylene, optionally substituted
C.sub.2-C.sub.9 heterocyclyl C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.2-C.sub.9 heteroarylene, or optionally
substituted C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene;
and
[0206] B is H, halogen, cyano, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.3-C.sub.10
cycloalkyl, optionally substituted C.sub.2-C.sub.9 heterocyclyl, or
optionally substituted C.sub.2-C.sub.9 heteroaryl, or a
pharmaceutically acceptable salt thereof.
[0207] In some embodiments, X, Y, and Z are CH; X is N and Y and Z
are CH; Z is N and X and Y are CH; Y is N and X and Z are CH; X is
CH and Y and Z are N; Z is CH and X and y are N; Y is CH and X and
Z are N; or X, Y, and Z are N.
[0208] In some embodiments, the compound of Formula IV has the
structure of Formula IVb:
##STR00052##
or a pharmaceutically acceptable salt thereof.
[0209] In some embodiments, the compound of Formula IV has the
structure of Formula IVc:
##STR00053##
[0210] or a pharmaceutically acceptable salt thereof. In some
embodiments, the compound of Formula IV has the structure of
Formula Ic:
##STR00054##
[0211] or a pharmaceutically acceptable salt thereof.
[0212] In some embodiments, the compound of Formula IV has the
structure of Formula IVe:
##STR00055##
[0213] or a pharmaceutically acceptable salt thereof.
[0214] In some embodiments,
##STR00056##
where X' is O or S; Y' is N or CH; and Z' is N or CH.
[0215] In some embodiments, the compound of Formula IVa has the
structure of Formula V:
##STR00057##
[0216] where
[0217] W is C or N;
[0218] X' is O, S, or N--CH3;
[0219] Y' is N or CH;
[0220] Z' is N or CH;
[0221] R.sup.1 is absent, H, optionally substituted C.sub.1-C.sub.6
acyl, optionally substituted C.sub.1-C.sub.6 alkyl, optionally
substituted C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.8 cycloalkyl, optionally substituted C.sub.2-C.sub.9
heterocyclyl, or --SO.sub.2R.sup.6;
[0222] each of R.sup.2, R.sup.3, and R.sup.5 is, independently, H
or optionally substituted C.sub.1-C.sub.6 alkyl;
[0223] R.sup.4 is H, optionally substituted C.sub.1-C.sub.6 alkyl,
or optionally substituted C.sub.1-C.sub.6 heteroalkyl;
[0224] R.sup.6 is optionally substituted C.sub.1-C.sub.6 alkyl or
--NR.sup.7R.sup.8;
[0225] each of R.sup.7 and R.sup.8 is, independently, optionally
substituted C.sub.1-C.sub.6 alkyl;
[0226] Het is optionally substituted 5-membered heteroarylene,
optionally substituted 6-membered heteroarylene, or
##STR00058##
[0227] A is optionally substituted C.sub.6-C.sub.10 arylene,
optionally substituted C.sub.2-C.sub.9 heterocyclylene, or
optionally substituted C.sub.2-C.sub.9 heteroarylene;
[0228] L is absent, --O--, optionally substituted C.sub.1-C.sub.6
alkylene, optionally substituted C.sub.1-C.sub.6 heteroalkylene,
optionally substituted C.sub.1-C.sub.6 alkenylene, optionally
substituted C.sub.2-C.sub.6 heteroalkenylene, optionally
substituted C.sub.2-C.sub.6 alkynylene, optionally substituted
C.sub.2-C.sub.6 heteroalkynylene, optionally substituted
C.sub.2-C.sub.9 heterocyclylene, optionally substituted
C.sub.2-C.sub.9 heterocyclyl C.sub.1-C.sub.6 alkylene, optionally
substituted C.sub.2-C.sub.9 heteroarylene, or optionally
substituted C.sub.2-C.sub.9 heteroaryl C.sub.1-C.sub.6 alkylene;
and
[0229] B is H, halogen, cyano, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.3-C.sub.10
cycloalkyl, optionally substituted C.sub.2-C.sub.9 heterocyclyl, or
optionally substituted C.sub.2-C.sub.9 heteroaryl,
[0230] or a pharmaceutically acceptable salt thereof.
[0231] In some embodiments, X' is O, Y' is CH, and Z' is N; X' is
S, Y' is CH, and Z' is N; X' is O, Y' is N, and Z' is CH; X' is S,
Y' is N, and Z' is CH; X' is O, Y' is N, and Z' is N; or X' is S,
Y' is N, and Z' is N.
[0232] In some embodiments, the compound of Formula V has the
structure of Formula Va:
##STR00059##
[0233] or a pharmaceutically acceptable salt thereof.
[0234] In some embodiments, the compound of Formula II has the
structure of Formula Vb:
##STR00060##
[0235] or a pharmaceutically acceptable salt thereof.
[0236] In some embodiments, the small molecule compound, or
pharmaceutically acceptable salt thereof is any one of compounds
17-20 having the structure:
##STR00061##
[0237] In some embodiments, the small molecule compound, or a
pharmaceutically acceptable salt thereof is a degrader. In some
embodiments, the degrader has the structure of Formula VI:
C-L-D Formula VI
wherein C is a BRG1 and/or BRM binding moiety; L is a linker; and D
is a degradation moiety, or a pharmaceutically acceptable salt
thereof. In some embodiments, the degradation moiety is a ubiquitin
ligase moiety. In some embodiments, the ubiquitin ligase binding
moiety includes Cereblon ligands, IAP (Inhibitors of Apoptosis)
ligands, mouse double minute 2 homolog (MDM2), hydrophobic tag, or
von Hippel-Lindau ligands, or derivatives or analogs thereof.
[0238] In some embodiments, A includes the structure of any one of
Formula I-V, or any one of compounds 1-20.
[0239] In some embodiments, the hydrophobic tag includes a
diphenylmethane, adamantine, or tri-Boc arginine, i.e., the
hydrophobic tag includes the structure:
##STR00062##
[0240] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula A:
##STR00063##
wherein X.sup.1 is CH.sub.2, O, S, or NR.sup.1, wherein R.sup.1 is
H, optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; X.sup.2 is C.dbd.O,
CH.sub.2, or
##STR00064##
R.sup.3 and R.sup.4 are, independently, H, optionally substituted
C.sub.1-C.sub.6 alkyl, or optionally substituted C.sub.1-C.sub.6
heteroalkyl; m is 0, 1, 2, 3, or 4; and each R.sup.2 is,
independently, halogen, optionally substituted C.sub.1-C.sub.6
alkyl, optionally substituted C.sub.1-C.sub.6 heteroalkyl,
optionally substituted C.sub.3-C.sub.10 carbocyclyl, optionally
substituted C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino,
[0241] or a pharmaceutically acceptable salt thereof.
[0242] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00065##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0243] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula B:
##STR00066##
wherein each R.sup.4, R.sup.4', and R.sup.7 is, independently, H,
optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.5 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; R.sup.6 is H,
optionally substituted C.sub.1-C.sub.6 alkyl, optionally
substituted C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; n is 0, 1, 2, 3, or 4;
each R.sup.8 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; and each R.sup.9
and R.sup.10 is, independently, H, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, or optionally substituted C.sub.6-C.sub.10
aryl, wherein R.sup.4' or R.sup.5 includes a bond to the linker, or
a pharmaceutically acceptable salt thereof.
[0244] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00067##
or is a derivative or analog thereof, or a pharmaceutically
acceptable salt thereof.
[0245] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula C:
##STR00068##
wherein each R.sup.11, R.sup.13, and R.sup.15 is, independently, H,
optionally substituted C.sub.1-C.sub.6 alkyl, or optionally
substituted C.sub.1-C.sub.6 heteroalkyl; R.sup.12 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; R.sup.14 is optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; p is 0, 1, 2, 3, or 4;
each R.sup.16 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; q is 0, 1, 2, 3,
or 4; and each R.sup.17 is, independently, halogen, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino, or a pharmaceutically
acceptable salt thereof.
[0246] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00069##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0247] In some embodiments, the ubiquitin ligase binding moiety
includes the structure of Formula D:
##STR00070##
wherein each R.sup.18 and R.sup.19 is, independently, H, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.1-C.sub.6 alkyl
C.sub.3-C.sub.10 carbocyclyl, or optionally substituted
C.sub.1-C.sub.6 alkyl C.sub.6-C.sub.10 aryl; r1 is 0, 1, 2, 3, or
4; each R.sup.20 is, independently, halogen, optionally substituted
C.sub.1-C.sub.6 alkyl, optionally substituted C.sub.1-C.sub.6
heteroalkyl, optionally substituted C.sub.3-C.sub.10 carbocyclyl,
optionally substituted C.sub.2-C.sub.9 heterocyclyl, optionally
substituted C.sub.6-C.sub.10 aryl, optionally substituted
C.sub.2-C.sub.9 heteroaryl, optionally substituted C.sub.2-C.sub.6
alkenyl, optionally substituted C.sub.2-C.sub.6 heteroalkenyl,
hydroxy, thiol, or optionally substituted amino; r2 is 0, 1, 2, 3,
or 4; and each R.sup.21 is, independently, halogen, optionally
substituted C.sub.1-C.sub.6 alkyl, optionally substituted
C.sub.1-C.sub.6 heteroalkyl, optionally substituted
C.sub.3-C.sub.10 carbocyclyl, optionally substituted
C.sub.2-C.sub.9 heterocyclyl, optionally substituted
C.sub.6-C.sub.10 aryl, optionally substituted C.sub.2-C.sub.9
heteroaryl, optionally substituted C.sub.2-C.sub.6 alkenyl,
optionally substituted C.sub.2-C.sub.6 heteroalkenyl, hydroxy,
thiol, or optionally substituted amino, or a pharmaceutically
acceptable salt thereof.
[0248] In some embodiments, the ubiquitin ligase binding moiety
includes the structure:
##STR00071##
or is a derivative or an analog thereof, or a pharmaceutically
acceptable salt thereof.
[0249] In some embodiments, the linker has the structure of Formula
VII:
A.sup.1-(B.sup.1).sub.f--(C.sup.1).sub.g--(B.sup.2).sub.h-(D)-(B.sup.3).-
sub.i--(C.sup.2).sub.j--(B.sup.4).sub.k-A.sup.2 Formula VII
wherein A.sup.1 is a bond between the linker and A; A.sup.2 is a
bond between B and the linker; B.sup.1, B.sup.2, B.sup.3, and
B.sup.4 each, independently, is selected from optionally
substituted C.sub.1-C.sub.2 alkyl, optionally substituted
C.sub.1-C.sub.3 heteroalkyl, O, S, S(O).sub.2, and NR.sup.N;
R.sup.N is hydrogen, optionally substituted C.sub.1-4 alkyl,
optionally substituted C.sub.2-4 alkenyl, optionally substituted
C.sub.2-4 alkynyl, optionally substituted C.sub.2-6 heterocyclyl,
optionally substituted C.sub.6-12 aryl, or optionally substituted
C.sub.1-7 heteroalkyl; C.sup.1 and C.sup.2 are each, independently,
selected from carbonyl, thiocarbonyl, sulphonyl, or phosphoryl; f,
g, h, l, j, and k are each, independently, 0 or 1; and D is
optionally substituted C.sub.1-10 alkyl, optionally substituted
C.sub.2-10 alkenyl, optionally substituted C.sub.2-10 alkynyl,
optionally substituted C.sub.2-6 heterocyclyl, optionally
substituted C.sub.B-12 aryl, optionally substituted
C.sub.2-C.sub.10 polyethylene glycol, or optionally substituted
C.sub.1-10 heteroalkyl, or a chemical bond linking
A.sup.1-(B.sup.1).sub.f--(C.sup.1).sub.g--(B.sup.2).sub.h-- to
--(B.sup.3).sub.i--(C.sup.2).sub.j--(B.sup.4).sub.k-A.sup.2.
[0250] In some embodiments, D is optionally substituted
C.sub.2-C.sub.10 polyethylene glycol. In some embodiments, C.sup.1
and C.sup.2 are each, independently, a carbonyl or sulfonyl. In
some embodiments, B.sup.1, B.sup.2, B.sup.3, and B.sup.4 each,
independently, is selected from optionally substituted
C.sub.1-C.sub.2 alkyl, optionally substituted C.sub.1-C.sub.3
heteroalkyl, O, S, S(O).sub.2, and NR.sup.N; R.sup.N is hydrogen or
optionally substituted C.sub.1-4 alkyl. In some embodiments,
B.sup.1, B.sup.2, B.sup.3, and B.sup.4 each, independently, is
selected from optionally substituted C.sub.1-C.sub.2 alkyl or
optionally substituted C.sub.1-C.sub.3 heteroalkyl. In some
embodiments, j is 0. In some embodiments, k is 0.
[0251] In some embodiments, j and k are each, independently, 0. In
some embodiments, f, g, h, and i are each, independently, 1.
[0252] In some embodiments, the linker of Formula VII has the
structure of Formula Vila:
##STR00072##
wherein A.sup.1 is a bond between the linker and A, and A.sup.2 is
a bond between B and the linker.
[0253] In some embodiments, D is optionally substituted C.sub.1-10
alkyl. In some embodiments, C.sup.1 and C.sup.2 are each,
independently, a carbonyl. In some embodiments, B.sup.1, B.sup.2,
B.sup.3, and B.sup.4 each, independently, is selected from
optionally substituted C.sub.1-C.sub.2 alkyl, optionally
substituted C.sub.1-C.sub.3 heteroalkyl, O, S, S(O).sub.2, and
NR.sup.N, wherein R.sup.N is hydrogen or optionally substituted
C.sub.1-4 alkyl. In some embodiments, B.sup.1, B.sup.2, B.sup.3,
and B.sup.4 each, independently, is selected from optionally
substituted C.sub.1-C.sub.2 alkyl, O, S, S(O).sub.2, and NR.sup.N,
wherein R.sup.N is hydrogen or optionally substituted C.sub.1-4
alkyl. In some embodiments, B.sup.1 and B.sup.4 each,
independently, is optionally substituted C.sub.1-C.sub.2 alkyl. In
some embodiments, B.sup.1 and B.sup.4 each, independently, is
C.sub.1 alkyl. In some embodiments, B.sup.2 and B.sup.4 each,
independently, is NR.sup.N, wherein R.sup.N is hydrogen or
optionally substituted C.sub.1-4 alkyl. In some embodiments,
B.sup.2 and B.sup.4 each, independently, is NH. In some
embodiments, f, g, h, l, j, and k are each, independently, 1.
[0254] In some embodiments, the linker of Formula V has the
structure of Formula VIIb:
##STR00073##
wherein A.sup.1 is a bond between the linker and A, and A.sup.2 is
a bond between B and the linker.
Pharmaceutical Uses
[0255] The compounds described herein are useful in the methods of
the invention and, while not bound by theory, are believed to exert
their desirable effects through their ability to modulate the
level, status, and/or activity of a BAF complex, e.g., by
inhibiting the activity or level of the BRG1 and/or BRM proteins in
a cell within the BAF complex in a mammal.
[0256] An aspect of the present invention relates to methods of
treating disorders related to BRG1 and/or BRM proteins such as AML
in a subject in need thereof. In some embodiments, the compound is
administered in an amount and for a time effective to result in one
of (or more, e.g., two or more, three or more, four or more of):
(a) reduced tumor size, (b) reduced rate of tumor growth, (c)
increased tumor cell death (d) reduced tumor progression, (e)
reduced number of metastases, (f) reduced rate of metastasis, (g)
decreased tumor recurrence (h) increased survival of subject, and
(i) increased progression free survival of a subject.
[0257] Treating cancer can result in a reduction in size or volume
of a tumor. For example, after treatment, tumor size is reduced by
5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
or greater) relative to its size prior to treatment. Size of a
tumor may be measured by any reproducible means of measurement. For
example, the size of a tumor may be measured as a diameter of the
tumor.
[0258] Treating cancer may further result in a decrease in number
of tumors. For example, after treatment, tumor number is reduced by
5% or greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,
or greater) relative to number prior to treatment. Number of tumors
may be measured by any reproducible means of measurement, e.g., the
number of tumors may be measured by counting tumors visible to the
naked eye or at a specified magnification (e.g., 2.times.,
3.times., 4.times., 5.times., 10.times., or 50.times.).
[0259] Treating cancer can result in a decrease in number of
metastatic nodules in other tissues or organs distant from the
primary tumor site (e.g., in the liver). For example, after
treatment, the number of metastatic nodules is reduced by 5% or
greater (e.g., 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or
greater) relative to number prior to treatment. The number of
metastatic nodules may be measured by any reproducible means of
measurement. For example, the number of metastatic nodules may be
measured by counting metastatic nodules visible to the naked eye or
at a specified magnification (e.g., 2.times., 10.times., or
50.times.).
[0260] Treating cancer can result in inhibition or slowing of the
metastatic progression of the cancer. For example, a patient may be
administered an amount of an agent that reduces the activity or
level of the BRG1 and/or BRM that is effective to inhibit
metastasis of the cancer to other parts of the body (e.g., a
patient having uveal melanoma that has metastasized (e.g., to the
liver)). An agent may be administered in an adjuvant or
neo-adjuvant setting, such as prior to or subsequent to surgical
rescission of the cancer, and result in a decrease incidence of
metastasis of the cancer.
[0261] Treating cancer can result in an increase in average
survival time of a population of subjects treated according to the
present invention in comparison to a population of untreated
subjects. For example, the average survival time is increased by
more than 30 days (more than 60 days, 90 days, or 120 days). An
increase in average survival time of a population may be measured
by any reproducible means. An increase in average survival time of
a population may be measured, for example, by calculating for a
population the average length of survival following initiation of
treatment with the compound described herein. An increase in
average survival time of a population may also be measured, for
example, by calculating for a population the average length of
survival following completion of a first round of treatment with a
pharmaceutically acceptable salt of a compound described
herein.
[0262] Treating cancer can also result in a decrease in the
mortality rate of a population of treated subjects in comparison to
an untreated population. For example, the mortality rate is
decreased by more than 2% (e.g., more than 5%, 10%, or 25%). A
decrease in the mortality rate of a population of treated subjects
may be measured by any reproducible means, for example, by
calculating for a population the average number of disease-related
deaths per unit time following initiation of treatment with a
pharmaceutically acceptable salt of a compound described herein. A
decrease in the mortality rate of a population may also be
measured, for example, by calculating for a population the average
number of disease-related deaths per unit time following completion
of a first round of treatment with a pharmaceutically acceptable
salt of a compound described herein.
Combination Therapies
[0263] A method of the invention can be used alone or in
combination with an additional therapeutic agent, e.g., other
agents that treat cancer or symptoms associated therewith, or in
combination with other types of therapies to treat cancer. In
combination treatments, the dosages of one or more of the
therapeutic compounds may be reduced from standard dosages when
administered alone. For example, doses may be determined
empirically from drug combinations and permutations or may be
deduced by isobolographic analysis (e.g., Black et al., Neurology
65:S3-S6 (2005)). In this case, dosages of the compounds when
combined should provide a therapeutic effect.
[0264] In some embodiments, the second therapeutic agent is a
chemotherapeutic agent (e.g., a cytotoxic agent or other chemical
compound useful in the treatment of cancer). These include
alkylating agents, antimetabolites, folic acid analogs, pyrimidine
analogs, purine analogs and related inhibitors, vinca alkaloids,
epipodopyyllotoxins, antibiotics, L-Asparaginase, topoisomerase
inhibitors, interferons, platinum coordination complexes,
anthracenedione substituted urea, methyl hydrazine derivatives,
adrenocortical suppressant, adrenocorticosteroides, progestins,
estrogens, antiestrogen, androgens, antiandrogen, and
gonadotropin-releasing hormone analog. Also included is
5-fluorouracil (5-FU), leucovorin (LV), irenotecan, oxaliplatin,
capecitabine, paclitaxel, and doxetaxel. Non-limiting examples of
chemotherapeutic agents include alkylating agents such as thiotepa
and cyclosphosphamide; alkyl sulfonates such as busulfan,
improsulfan and piposulfan; aziridines such as benzodopa,
carboquone, meturedopa, and uredopa; ethylenimines and
methylamelamines including altretamine, triethylenemelamine,
trietylenephosphoramide, triethiylenethiophosphoramide and
trimethylolomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including the synthetic analogue
topotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogues);
cryptophycins (particularly cryptophycin 1 and cryptophycin 8);
dolastatin; duocarmycin (including the synthetic analogues, KW-2189
and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil
mustard; nitrosureas such as carmustine, chlorozotocin,
fotemustine, lomustine, nimustine, and ranimnustine; antibiotics
such as the enediyne antibiotics (e.g., calicheamicin, especially
calicheamicin gammall and calicheamicin omegall (see, e.g., Agnew,
Chem. Intl. Ed Engl. 33:183-186 (1994)); dynemicin, including
dynemicin A; bisphosphonates, such as clodronate; an esperamicin;
as well as neocarzinostatin chromophore and related chromoprotein
enediyne antiobiotic chromophores), aclacinomysins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin,
caminomycin, carzinophilin, chromomycinis, dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine,
ADRIAMYCIN.RTM. (doxorubicin, including morpholino-doxorubicin,
cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and
deoxydoxorubicin), epirubicin, esorubicin, idarubicin,
marcellomycin, mitomycins such as mitomycin C, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin,
quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,
ubenimex, zinostatin, zorubicin; anti-metabolites such as
methotrexate and 5-fluorouracil (5-FU); folic acid analogues such
as denopterin, methotrexate, pteropterin, trimetrexate; purine
analogs such as fludarabine, 6-mercaptopurine, thiamiprine,
thioguanine; pyrimidine analogs such as ancitabine, azacitidine,
6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine,
enocitabine, floxuridine; androgens such as calusterone,
dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replenisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate;
defofamine; demecolcine; diaziquone; elfomithine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea;
lentinan; lonidainine; maytansinoids such as maytansine and
ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine;
pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic
acid; 2-ethylhydrazide; procarbazine; PSK.RTM. polysaccharide
complex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;
sizofuran; spirogermanium; tenuazonic acid; triaziquone;
2,2',2''-trichlorotriethylamine; trichothecenes (especially T-2
toxin, verracurin A, roridin A and anguidine); urethan; vindesine;
dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman;
gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa;
taxoids, e.g., TAXOL.RTM. (paclitaxel; Bristol-Myers Squibb
Oncology, Princeton, N.J.), ABRAXANE.RTM., cremophor-free,
albumin-engineered nanoparticle formulation of paclitaxel (American
Pharmaceutical Partners, Schaumberg, Ill.), and TAXOTERE.RTM.
doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil;
GEMZAR.RTM. gemcitabine; 6-thioguanine; mercaptopurine;
methotrexate; platinum coordination complexes such as cisplatin,
oxaliplatin and carboplatin; vinblastine; platinum; etoposide
(VP-16); ifosfamide; mitoxantrone; vincristine; NAVELBINE.RTM.
vinorelbine; novantrone; teniposide; edatrexate; daunomycin;
aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-11);
topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO);
retinoids such as retinoic acid; capecitabine; and pharmaceutically
acceptable salts, acids or derivatives of any of the above. Two or
more chemotherapeutic agents can be used in a cocktail to be
administered in combination with the first therapeutic agent
described herein. Suitable dosing regimens of combination
chemotherapies are known in the art and described in, for example,
Saltz et al., Proc. Am. Soc. Clin. Oncol. 18:233a (1999), and
Douillard et al., Lancet 355(9209):1041-1047 (2000).
[0265] In some embodiments, the second therapeutic agent is a
therapeutic agent which is a biologic such a cytokine (e.g.,
interferon or an interleukin (e.g., IL-2)) used in cancer
treatment. In some embodiments the biologic is an anti-angiogenic
agent, such as an anti-VEGF agent, e.g., bevacizumab
(AVASTIN.RTM.). In some embodiments the biologic is an
immunoglobulin-based biologic, e.g., a monoclonal antibody (e.g., a
humanized antibody, a fully human antibody, an Fc fusion protein or
a functional fragment thereof) that agonizes a target to stimulate
an anti-cancer response, or antagonizes an antigen important for
cancer. Such agents include RITUXAN.RTM. (rituximab); ZENAPAX.RTM.
(daclizumab); SIMULECT.RTM. (basiliximab); SYNAGIS.RTM.
(palivizumab); REMICADE.RTM. (infliximab); HERCEPTIN.RTM.
(trastuzumab); MYLOTARG.RTM. (gemtuzumab ozogamicin); CAMPATH.RTM.
(alemtuzumab); ZEVALIN.RTM. (ibritumomab tiuxetan); HUMIRA.RTM.
(adalimumab); XOLAIR.RTM. (omalizumab); BEXXAR.RTM.
(tositumomab-1-131); RAPTIVA.RTM. (efalizumab); ERBITUX.RTM.
(cetuximab); AVASTIN.RTM. (bevacizumab); TYSABRI.RTM.
(natalizumab); ACTEMRA.RTM. (tocilizumab); VECTIBIX.RTM.
(panitumumab); LUCENTIS.RTM. (ranibizumab); SOLIRIS.RTM.
(eculizumab); CIMZIA.RTM. (certolizumab pegol); SIMPONI.RTM.
(golimumab); ILARIS.RTM. (canakinumab); STELARA.RTM. (ustekinumab);
ARZERRA.RTM. (ofatumumab); PROLIA.RTM. (denosumab); NUMAX.RTM.
(motavizumab); ABTHRAX.RTM. (raxibacumab); BENLYSTA.RTM.
(belimumab); YERVOY.RTM. (ipilimumab); ADCETRIS.RTM. (brentuximab
vedotin); PERJETA.RTM. (pertuzumab); KADCYLA.RTM. (ado-trastuzumab
emtansine); and GAZYVA.RTM. (obinutuzumab). Also included are
antibody-drug conjugates.
[0266] In some embodiments, the second agent is dacarbazine,
temozolomide, cisplatin, treosulfan, fotemustine, IMCgp100, a
CTLA-4 inhibitor (e.g., ipilimumab), a PD-1 inhibitor (e.g.,
Nivolumab or pembrolizumab), a PD-L1 inhibitor (e.g., atezolizumab,
avelumab, or durvalumab), a mitogen-activated protein kinase (MEK)
inhibitor (e.g., selumetinib, binimetinib, or tametinib), and/or a
protein kinase C (PKC) inhibitor (e.g., sotrastaurin or
LXS196).
[0267] In some embodiments, the second agent is a mitogen-activated
protein kinase (MEK) inhibitor (e.g., selumetinib, binimetinib, or
tametinib) and/or a protein kinase C (PKC) inhibitor (e.g.,
sotrastaurin or LXS196).
[0268] In some embodiments, the second agent is cytarabine, an
anthracycline such as daunorubicin, arsenic trioxide,
all-trans-retinoic acid, or a combination thereof. In some
embodiments, the second agent is an immunotherapy such as histamine
dihydrochloride and interleukin 2. In some embodiments, the second
agent is gemtuzumab ozogamicin.
[0269] The second agent may be a therapeutic agent which is a
non-drug treatment. For example, the second therapeutic agent is
radiation therapy, thermotherapy, photocoagulation, cryotherapy,
hyperthermia, surgical excision of tumor, and/or a stem cell
transplant (e.g., an allogenic stem cell transplant or hemapoietic
stem cell transplant).
[0270] The second agent may be a checkpoint inhibitor. In one
embodiment, the inhibitor of checkpoint is an inhibitory antibody
(e.g., a monospecific antibody such as a monoclonal antibody). The
antibody may be, e.g., humanized or fully human. In some
embodiments, the inhibitor of checkpoint is a fusion protein, e.g.,
an Fc-receptor fusion protein. In some embodiments, the inhibitor
of checkpoint is an agent, such as an antibody, that interacts with
a checkpoint protein. In some embodiments, the inhibitor of
checkpoint is an agent, such as an antibody, that interacts with
the ligand of a checkpoint protein. In some embodiments, the
inhibitor of checkpoint is an inhibitor (e.g., an inhibitory
antibody or small molecule inhibitor) of CTLA-4 (e.g., an
anti-CTLA4 antibody or fusion a protein such as
ipilimumab/YERVOY.RTM. or tremelimumab). In some embodiments, the
inhibitor of checkpoint is an inhibitor (e.g., an inhibitory
antibody or small molecule inhibitor) of PD-1 (e.g.,
nivolumab/OPDIVO.RTM.; pembrolizumab/KEYTRUDA.RTM.;
pidilizumab/CT-011). In some embodiments, the inhibitor of
checkpoint is an inhibitor (e.g., an inhibitory antibody or small
molecule inhibitor) of PDL1 (e.g., atezolizumab, avelumab,
durvalumab, MPDL3280A/RG7446; MEDI4736; MSB0010718C; BMS 936559).
In some embodiments, the inhibitor of checkpoint is an inhibitor
(e.g., an inhibitory antibody or Fc fusion or small molecule
inhibitor) of PDL2 (e.g., a PDL2/Ig fusion protein such as AMP
224). In some embodiments, the inhibitor of checkpoint is an
inhibitor (e.g., an inhibitory antibody or small molecule
inhibitor) of B7-H3 (e.g., MGA271), B7-H4, BTLA, HVEM, TIM3, GAL9,
LAG3, VISTA, KIR, 2B4, CD160, CGEN-15049, CHK 1, CHK2, A2aR, B-7
family ligands, or a combination thereof.
[0271] In some embodiments, the anti-cancer therapy is a T cell
adoptive transfer (ACT) therapy. In some embodiments, the T cell is
an activated T cell. The T cell may be modified to express a
chimeric antigen receptor (CAR). CAR modified T (CAR-T) cells can
be generated by any method known in the art. For example, the CAR-T
cells can be generated by introducing a suitable expression vector
encoding the CAR to a T cell. Prior to expansion and genetic
modification of the T cells, a source of T cells is obtained from a
subject. T cells can be obtained from a number of sources,
including peripheral blood mononuclear cells, bone marrow, lymph
node tissue, cord blood, thymus tissue, tissue from a site of
infection, ascites, pleural effusion, spleen tissue, and tumors. In
certain embodiments of the present invention, any number of T cell
lines available in the art, may be used. In some embodiments, the T
cell is an autologous T cell. Whether prior to or after genetic
modification of the T cells to express a desirable protein (e.g., a
CAR), the T cells can be activated and expanded generally using
methods as described, for example, in U.S. Pat. Nos. 6,352,694;
6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681;
7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223;
6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application
Publication No. 20060121005.
[0272] In any of the combination embodiments described herein, the
first and second therapeutic agents are administered simultaneously
or sequentially, in either order. The first therapeutic agent may
be administered immediately, up to 1 hour, up to 2 hours, up to 3
hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours,
up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up
to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17
hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours,
up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14,
1-21 or 1-30 days before or after the second therapeutic agent.
[0273] Delivery of Anti-BRG1 and/or BRM Agents
[0274] A variety of methods are available for the delivery of
anti-BRG1 and/or BRM agents to a subject including viral and
non-viral methods.
[0275] Viral Delivery Methods
[0276] In some embodiments, the agent that reduces the level and/or
activity of BRG1 and/or BRM is delivered by a viral vector (e.g., a
viral vector expressing an anti-BRG1 and/or BRM agent). Viral
genomes provide a rich source of vectors that can be used for the
efficient delivery of exogenous genes into a mammalian cell. Viral
genomes are particularly useful vectors for gene delivery because
the polynucleotides contained within such genomes are typically
incorporated into the nuclear genome of a mammalian cell by
generalized or specialized transduction. These processes occur as
part of the natural viral replication cycle, and do not require
added proteins or reagents in order to induce gene integration.
Examples of viral vectors include a retrovirus (e.g., Retroviridae
family viral vector), adenovirus (e.g., Ad5, Ad26, Ad34, Ad35, and
Ad48), parvovirus (e.g., adeno-associated viruses), coronavirus,
negative strand RNA viruses such as orthomyxovirus (e.g., influenza
virus), rhabdovirus (e.g., rabies and vesicular stomatitis virus),
paramyxovirus (e.g., measles and Sendai), positive strand RNA
viruses, such as picornavirus and alphavirus, and double-stranded
DNA viruses including adenovirus, herpesvirus (e.g., Herpes Simplex
virus types 1 and 2, Epstein-Barr virus, cytomegalovirus,
replication deficient herpes virus), and poxvirus (e.g., vaccinia,
modified vaccinia Ankara (MVA), fowlpox and canarypox). Other
viruses include Norwalk virus, togavirus, flavivirus, reoviruses,
papovavirus, hepadnavirus, human papilloma virus, human foamy
virus, and hepatitis virus, for example. Examples of retroviruses
include: avian leukosis-sarcoma, avian C-type viruses, mammalian
C-type, B-type viruses, D-type viruses, oncoretroviruses, HTLV-BLV
group, lentivirus, alpharetrovirus, gammaretrovirus, spumavirus
(Coffin, J. M., Retroviridae: The viruses and their replication,
Virology (Third Edition) Lippincott-Raven, Philadelphia, 1996).
Other examples include murine leukemia viruses, murine sarcoma
viruses, mouse mammary tumor virus, bovine leukemia virus, feline
leukemia virus, feline sarcoma virus, avian leukemia virus, human T
cell leukemia virus, baboon endogenous virus, Gibbon ape leukemia
virus, Mason Pfizer monkey virus, simian immunodeficiency virus,
simian sarcoma virus, Rous sarcoma virus and lentiviruses. Other
examples of vectors are described, for example, in U.S. Pat. No.
5,801,030, the teachings of which are incorporated herein by
reference.
[0277] Exemplary viral vectors include lentiviral vectors, AAVs,
and retroviral vectors. Lentiviral vectors and AAVs can integrate
into the genome without cell divisions, and both types have been
tested in pre-clinical animal studies. Methods for preparation of
AAVs are described in the art e.g., in U.S. Pat. Nos. 5,677,158,
6,309,634, and 6,683,058, each of which is incorporated herein by
reference. Methods for preparation and in vivo administration of
lentiviruses are described in US 20020037281 (incorporated herein
by reference). Preferably, a lentiviral vector is a
replication-defective lentivirus particle. Such a lentivirus
particle can be produced from a lentiviral vector comprising a 5'
lentiviral LTR, a tRNA binding site, a packaging signal, a promoter
operably linked to a polynucleotide signal encoding the fusion
protein, an origin of second strand DNA synthesis and a 3'
lentiviral LTR.
[0278] Retroviruses are most commonly used in human clinical
trials, as they carry 7-8 kb, and have the ability to infect cells
and have their genetic material stably integrated into the host
cell with high efficiency (see, e.g., WO 95/30761; WO 95/24929,
each of which is incorporated herein by reference). Preferably, a
retroviral vector is replication defective. This prevents further
generation of infectious retroviral particles in the target tissue.
Thus, the replication defective virus becomes a "captive" transgene
stable incorporated into the target cell genome. This is typically
accomplished by deleting the gag, env, and pol genes (along with
most of the rest of the viral genome). Heterologous nucleic acids
are inserted in place of the deleted viral genes. The heterologous
genes may be under the control of the endogenous heterologous
promoter, another heterologous promoter active in the target cell,
or the retroviral 5' LTR (the viral LTR is active in diverse
tissues).
[0279] These delivery vectors described herein can be made
target-specific by attaching, for example, a sugar, a glycolipid,
or a protein (e.g., an antibody to a target cell receptor).
[0280] Reversible delivery expression systems may also be used. The
Cre-loxP or FLP/FRT system and other similar systems can be used
for reversible delivery-expression of one or more of the
above-described nucleic acids. See WO2005/112620, WO2005/039643,
US20050130919, US20030022375, US20020022018, US20030027335, and
US20040216178. In particular, the reversible delivery-expression
system described in US20100284990 can be used to provide a
selective or emergency shut-off.
[0281] Non-Viral Delivery Methods
[0282] Several non-viral methods exist for delivery of anti-BRG1
and/or BRM agents including polymeric, biodegradable microparticle,
or microcapsule delivery devices known in the art. For example, a
colloidal dispersion system may be used for targeted delivery an
anti-BRG1 and/or BRM agent described herein. Colloidal dispersion
systems include macromolecule complexes, nanocapsules,
microspheres, beads, and lipid-based systems including oil-in-water
emulsions, micelles, mixed micelles, and liposomes. Liposomes are
artificial membrane vesicles that are useful as delivery vehicles
in vitro and in vivo. It has been shown that large unilamellar
vesicles (LUV), which range in size from 0.2-4.0 .mu.m can
encapsulate a substantial percentage of an aqueous buffer
containing large macromolecules.
[0283] The composition of the liposome is usually a combination of
phospholipids, usually in combination with steroids, especially
cholesterol. Other phospholipids or other lipids may also be used.
The physical characteristics of liposomes depend on pH, ionic
strength, and the presence of divalent cations.
[0284] Lipids useful in liposome production include phosphatidyl
compounds, such as phosphatidylglycerol, phosphatidylcholine,
phosphatidylserine, phosphatidyl-ethanolamine, sphingolipids,
cerebrosides, and gangliosides. Exemplary phospholipids include egg
phosphatidylcholine, dipalmitoylphosphatidylcholine, and
distearoyl-phosphatidylcholine. The targeting of liposomes is also
possible based on, for example, organ-specificity,
cell-specificity, and organelle-specificity and is known in the
art. In the case of a liposomal targeted delivery system, lipid
groups can be incorporated into the lipid bilayer of the liposome
in order to maintain the targeting ligand in stable association
with the liposomal bilayer. Various linking groups can be used for
joining the lipid chains to the targeting ligand. Additional
methods are known in the art and are described, for example in U.S.
Patent Application Publication No. 20060058255.
Pharmaceutical Compositions
[0285] The pharmaceutical compositions described herein are
preferably formulated into pharmaceutical compositions for
administration to human subjects in a biologically compatible form
suitable for administration in vivo.
[0286] The compounds described herein may be used in the form of
the free base, in the form of salts, solvates, and as prodrugs. All
forms are within the methods described herein. In accordance with
the methods of the invention, the described compounds or salts,
solvates, or prodrugs thereof may be administered to a patient in a
variety of forms depending on the selected route of administration,
as will be understood by those skilled in the art. The compounds
described herein may be administered, for example, by oral,
parenteral, buccal, sublingual, nasal, rectal, patch, pump,
intratumoral, or transdermal administration and the pharmaceutical
compositions formulated accordingly. Parenteral administration
includes intravenous, intraperitoneal, subcutaneous, intramuscular,
transepithelial, nasal, intrapulmonary, intrathecal, rectal, and
topical modes of administration. Parenteral administration may be
by continuous infusion over a selected period of time.
[0287] A compound described herein may be orally administered, for
example, with an inert diluent or with an assimilable edible
carrier, or it may be enclosed in hard or soft shell gelatin
capsules, or it may be compressed into tablets, or it may be
incorporated directly with the food of the diet. For oral
therapeutic administration, a compound described herein may be
incorporated with an excipient and used in the form of ingestible
tablets, buccal tablets, troches, capsules, elixirs, suspensions,
syrups, and wafers. A compound described herein may also be
administered parenterally. Solutions of a compound described herein
can be prepared in water suitably mixed with a surfactant, such as
hydroxypropylcellulose. Dispersions can also be prepared in
glycerol, liquid polyethylene glycols, DMSO, and mixtures thereof
with or without alcohol, and in oils. Under ordinary conditions of
storage and use, these preparations may contain a preservative to
prevent the growth of microorganisms. Conventional procedures and
ingredients for the selection and preparation of suitable
formulations are described, for example, in Remington's
Pharmaceutical Sciences (2012, 22nd ed.) and in The United States
Pharmacopeia: The National Formulary (USP 41 NF36), published in
2018. The pharmaceutical forms suitable for injectable use include
sterile aqueous solutions or dispersions and sterile powders for
the extemporaneous preparation of sterile injectable solutions or
dispersions. In all cases the form must be sterile and must be
fluid to the extent that may be easily administered via syringe.
Compositions for nasal administration may conveniently be
formulated as aerosols, drops, gels, and powders. Aerosol
formulations typically include a solution or fine suspension of the
active substance in a physiologically acceptable aqueous or
non-aqueous solvent and are usually presented in single or
multidose quantities in sterile form in a sealed container, which
can take the form of a cartridge or refill for use with an
atomizing device. Alternatively, the sealed container may be a
unitary dispensing device, such as a single dose nasal inhaler or
an aerosol dispenser fitted with a metering valve which is intended
for disposal after use. Where the dosage form includes an aerosol
dispenser, it will contain a propellant, which can be a compressed
gas, such as compressed air or an organic propellant, such as
fluorochlorohydrocarbon. The aerosol dosage forms can also take the
form of a pump-atomizer. Compositions suitable for buccal or
sublingual administration include tablets, lozenges, and pastilles,
where the active ingredient is formulated with a carrier, such as
sugar, acacia, tragacanth, gelatin, and glycerine. Compositions for
rectal administration are conveniently in the form of suppositories
containing a conventional suppository base, such as cocoa butter. A
compound described herein may be administered intratumorally, for
example, as an intratumoral injection. Intratumoral injection is
injection directly into the tumor vasculature and is specifically
contemplated for discrete, solid, accessible tumors. Local,
regional, or systemic administration also may be appropriate. A
compound described herein may advantageously be contacted by
administering an injection or multiple injections to the tumor,
spaced for example, at approximately, 1 cm intervals. In the case
of surgical intervention, the present invention may be used
preoperatively, such as to render an inoperable tumor subject to
resection. Continuous administration also may be applied where
appropriate, for example, by implanting a catheter into a tumor or
into tumor vasculature.
[0288] The compounds described herein may be administered to an
animal, e.g., a human, alone or in combination with
pharmaceutically acceptable carriers, as noted herein, the
proportion of which is determined by the solubility and chemical
nature of the compound, chosen route of administration, and
standard pharmaceutical practice.
Dosages
[0289] The dosage of the compounds described herein, and/or
compositions including a compound described herein, can vary
depending on many factors, such as the pharmacodynamic properties
of the compound; the mode of administration; the age, health, and
weight of the recipient; the nature and extent of the symptoms; the
frequency of the treatment, and the type of concurrent treatment,
if any; and the clearance rate of the compound in the animal to be
treated. One of skill in the art can determine the appropriate
dosage based on the above factors. The compounds described herein
may be administered initially in a suitable dosage that may be
adjusted as required, depending on the clinical response. In
general, satisfactory results may be obtained when the compounds
described herein are administered to a human at a daily dosage of,
for example, between 0.05 mg and 3000 mg (measured as the solid
form).
[0290] Alternatively, the dosage amount can be calculated using the
body weight of the patient. For example, the dose of a compound, or
pharmaceutical composition thereof, administered to a patient may
range from 0.1-50 mg/kg.
Kits
[0291] The invention also features kits including (a) a
pharmaceutical composition including an agent that reduces the
level and/or activity of BRG1 and/or BRM in a cell or subject
described herein, and (b) a package insert with instructions to
perform any of the methods described herein. In some embodiments,
the kit includes (a) a pharmaceutical composition including an
agent that reduces the level and/or activity of BRG1 and/or BRM in
a cell or subject described herein, (b) an additional therapeutic
agent (e.g., an anti-cancer agent), and (c) a package insert with
instructions to perform any of the methods described herein.
EXAMPLES
Example 1. Compound 17
Synthesis of Compound 17: BRG1/BRM Inhibitor Compound 17 has the
Structure
##STR00074##
[0292] Compound 17 was synthesized as shown in Scheme 1 below.
##STR00075##
Step 1: Preparation of 2-bromo-1-(3-bromophenyl)ethenone
(Intermediate B)
##STR00076##
[0294] To a solution of 1-(3-bromophenyl)ethanone (132.45 mL, 1.00
mol) in CHCl.sub.3 (250 mL) was added Br.sub.2 (77.70 mL, 1.51 mol)
in a dropwise manner at 20.degree. C. under N.sub.2 (g). The
reaction mixture was subsequently stirred at 80.degree. C. After 1
h, the mixture was cooled to room temperature and concentrated to
give intermediate B (279.27 g) as yellow oil, which was used for
next step directly.
Step 2: Preparation of 4-(3-bromophenyl)thiazol-2-amine
(Intermediate C)
##STR00077##
[0296] To a solution of thiourea (229.23 g, 3.01 mol) in EtOH (1.5
L) was added intermediate B (279 g, 1.00 mol). The reaction mixture
was stirred at 85.degree. C. After 2 h, the mixture was cooled to
room temperature and concentrated in vacuum to give an oil. The oil
was carefully poured into saturated aqueous NaHCO.sub.3 (2 L). The
resulting basic (pH .about.8) solution was extracted with ethyl
acetate (3.times.2 L). The combined organic layers were washed with
brine (4 L), dried over Na.sub.2SO.sub.4, filtered, and
concentrated to give an oil. The oil was purified by column
chromatography (SiO.sub.2. PE:EA=5:1) to give intermediate C
(130.00 g, 494.40 mmol, 49.25% yield) as a yellow solid. LCMS (ESI)
m/z: [M+H].sup.+=257.0. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.98
(m, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.44-7.42 (m, 1H), 7.33-7.29 (m,
1H), 7.14 (s, 1H), 7.09 (s, 2H).
Step 3: Preparation of 4-[3-(4-pyridyl)phenyl]thiazol-2-amine
(Intermediate E)
##STR00078##
[0298] Intermediate C (20.00 g, 78.40 mmol), 4-pyridylboronic acid
(28.9 g, 239.18 mmol),
dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) (2.56
g, 3.92 mmol) and K.sub.3PO.sub.4 (66.56 g, 313.56 mmol) were
diluted in 1,4-dioxane (240 mL) and water (24 mL). The mixture was
purged with N.sub.2 (g) three times and then stirred at 80.degree.
C. After 7 h, the reaction mixture was cooled to room temperature
and water (800 mL) was added. The mixture was extracted with EtOAc
(3.times.800 mL). The combined organic layers were washed with
brine, dried over anhydrous Na.sub.2SO.sub.4, filtered, and
concentrated in vacuo. The resulting oil was stirred over a mixture
of dichoromethane (30 mL) and MTBE (100 mL). After stirring for 5
min, the precipitate was filtered and washed with MTBE (10 mL) to
give intermediate E (16.20 g, 61.17 mmol, 78.03% yield) as a yellow
solid. LCMS (ESI) m/z: [M+H].sup.+=254.0.
Step 4: Preparation
(S)-4-(methylthio)-1-oxo-1-((4-(3-(pyridin-4-yl)phenyl)thiazol-2-yl)amino-
)butan-2-aminium chloride (Intermediate G)
##STR00079##
[0300] To a mixture of intermediate E (12.60 g, 49.74 mmol) and
(2S)-2-(tert-butoxycarbonylamino)-4-methylsulfanyl-butanoic acid
(18.60 g, 74.61 mmol) in dicholromethane (900 mL) was added EEDQ
(24.60 g, 99.48 mmol). After stirring for 2 h at room temperature,
the reaction mixture was concentrated in vacuo. The residue was
triturated with dichloromethane (100 mL) followed by MeOH (200 mL)
to give the intermediate G (11.70 g, 23.73 mmol, 47.71% yield, ee
%=99.44%) as white solids. LCMS (ESI) m/z: [M+H].sup.+=485.1.
.sup.1H NMR (400 MHz, DMSO) .delta. 12.39 (s, 1H), 8.68-8.66 (m,
2H), 8.30 (s, 1H), 8.02-7.99 (m, 1H), 7.83 (s, 1H), 7.76-7.74 (m,
3H), 7.61-7.57 (m, 1H), 7.28 (d, J=7.6 Hz, 1H), 4.31-4.30 (m, 1H),
2.65-2.44 (m, 2H), 2.06 (s, 3H) 2.01-1.85 (m, 2H), 1.38 (s,
9H).
Step 5: Preparation of
(S)-4-(methylthio)-1-oxo-1-((4-(3-(pyridin-4-yl)phenyl)thiazol-2-yl)amino-
)butan-2-aminium chloride (Intermediate H)
##STR00080##
[0302] A mixture of intermediate G (11.50 g, 23.73 mmol) in MeOH
(50 mL) was added a solution of 4 M HCl in 1,4-dioxane (100 mL).
After stirring for 1 h at room temperature, the mixture was poured
into MTBE (1000 mL). The resulting precipitates were filtered to
give the intermediate H (9.99 g, 23.73 mmol, 100.00% yield, HCl
salt) as a yellow solid. LCMS (ESI) m/z: [M+H].sup.+=385.0
Step 6: Preparation of
4-amino-N-[(1S)-3-methylsulfanyl-1-[[4-[3-(4-pyridyl)phenyl]thiazol-2-yl]-
carbamoyl]propyl]benzamide (compound 17)
##STR00081##
[0304] To a mixture of intermediate H (4.00 g, 9.50 mmol) and
4-aminobenzoic acid (1.30 g, 9.50 mmol) in DMF (40 mL) was
sequentially added N,N-diisopropylethylamine (6.62 mL, 38.01 mmol),
EDCl (2.73 g, 14.25 mmol) and HOBt (1.93 g, 14.25 mmol). The
solution was stirred at 25.degree. C. for 14 h and subsequently
poured into water (200 mL). The resulting precipitates were
collected by filtration. The solids were triturated in MeOH (200
mL) and filtered The solids were further purified by column
chromatography (SiO.sub.2, DCM:MeOH=80:1-20:1) to give compound 17
(2.13 g, 4.19 mmol, 44.11% yield, ee %=99.28%) as white solids.
LCMS (ESI) m/z: [M+H].sup.+=504.0. .sup.1H NMR (400 MHz, DMSO)
.delta. 12.40 (s, 1H), 8.68-8.66 (m, 2H), 8.31-8.30 (m, 1H), 8.22
(d, J=7.2 Hz, 1H), 8.02-7.99 (m, 1H), 7.82 (s, 1H), 7.76-7.74 (m,
3H), 7.67-7.63 (m, 2H), 7.61-7.57 (m, 1H), 6.58-6.54 (m, 2H), 5.67
(s, 2H), 4.72-4.67 (m, 1H), 2.65-2.54 (m, 2H), 2.12-2.06 (m,
5H).
[0305] ATPase Activity of Compound 17
[0306] The ATPase catalytic activity of BRM or BRG-1 in the
presence of compound 17 was measured by the in vitro biochemical
assay using ADP-Glo.TM. (Promega, V9102). The ADP-Glo.TM. kinase
assay is performed in two steps once the reaction is complete. The
first step is to deplete any unconsumed ATP in the reaction. The
second step is to convert the reaction product ADP to ATP, which
will be utilized by the luciferase to generate luminesce and be
detected by a luminescence reader, such as Envision.
[0307] The assay reaction mixture (10 .mu.L) contains 30 nM of BRM
or BRG1, 20 nM salmon sperm DNA (from Invitrogen, UltraPure.TM.
Salmon Sperm DNA Solution, cat #15632011), and 400 .mu.M of ATP in
the ATPase assay buffer, which comprises of 20 mM Tris, pH 8, 20 mM
MgCl.sub.2, 50 mM NaCl, 0.1% Tween-20, and 1 mM fresh DTT
(Pierce.TM. DTT (Dithiothreitol), cat #20290). The reaction is
initiated by the addition of the 2.5 .mu.L ATPase solution to 2.5
.mu.L ATP/DNA solution on low volume white Proxiplate-384 plus
plate (PerkinElmer, cat #6008280) and incubates at room temperature
for 1 hour. Then following addition of 5 .mu.L of ADP-Glo.TM.
Reagent provided in the kit, the reaction incubates at room
temperature for 40 minutes. Then 10 .mu.L of Kinase Detection
Reagent provided in the kit is added to convert ADP to ATP, and the
reaction incubates at room temperature for 60 minutes. Finally,
luminescence measurement is collected with a plate-reading
luminometer, such as Envision.
[0308] BRM and BRG1 were synthesized from high five insect cell
lines with a purity of greater than 90%. Compound 17 was found to
have an IP.sub.50 of 10.4 nM against BRM and 19.3 nM against BRG1
in the assay.
Example 2. Effects of BRG1/BRM ATPase Inhibition on the Growth of
Cancer Cell Lines
[0309] Procedure: Uveal melanoma cell lines (92-1, MP41, MP38,
MP46), prostate cancer cell lines (LNCAP), lung cancer cell lines
(NCIH1299), and immortalized embryonic kidney lines (HEK293T) were
plated into 96 well plates with growth media (see Table 1).
BRG1/BRM ATPase inhibitor, compound 17, was dissolved in DMSO and
added to the cells in a concentration gradient from 0 to 10
micromolar at the time of plating. Cells were incubated at
37.degree. C. for 3 days. After 3 days of treatment, the media was
removed from the cells, and 30 microliters of TrypLE (Gibco) was
added to cells for 10 minutes. Cells were detached from the plates
and resuspended with the addition of 170 microliters of growth
media. Cells from two DMSO-treated control wells were counted, and
the initial number of cells plated at the start of the experiment,
were re-plated into fresh-compound containing plates for an
additional four days at 37.degree. C. At day 7, cells were
harvested as described above.
[0310] On day 3 and day 7, relative cell growth was measured by the
addition of Cell-titer glo (Promega), and luminescence was measured
on an Envision plate reader (Perkin Elmer). The concentration of
compound 17 at which each cell line's growth was inhibited by 50%
(GI.sub.50) was calculated using Graphpad Prism and is plotted in
FIG. 1.
[0311] For multiple myeloma cell lines (OPM2, MM1S, LP1), ALL cell
lines (TALL1, JURKAT, RS411), DLBCL cell lines (SUDHL6, SUDHL4, DB,
WSUDLCL2, PFEIFFER), AML cell lines (OCIAML5), MDS cell lines
(SKM1), ovarian cancer cell lines (OV7, TYKNU), esophageal cancer
cell lines (KYSE150), rhabdoid tumor lines (RD, G402, G401, HS729,
A204), liver cancer cell lines (HLF, HLE, PLCRPF5), and lung cancer
cell lines (SW1573, NCIH2444), the above methods were performed
with the following modifications: Cells were plated in 96 well
plates, and the next day, BRG1/BRM ATPase inhibitor, compound 17,
was dissolved in DMSO and added to the cells in a concentration
gradient from 0 to 10 micromolar. At the time of cell splitting on
days 3 and 7, cells were split into new 96 well plates, and fresh
compound was added four hours after re-plating.
[0312] Table 1 lists the tested cell lines and growth media
used.
TABLE-US-00005 TABLE 1 Cell Lines and Growth Media Cell Line Source
Growth Media 92-1 SIGMA RPMI1640 + 20% FBS A204 ATCC McCoy's 5A +
10% FBS DB ATCC RPMI1640 + 10% FBS G401 ATCC McCoy's 5A + 10% FBS
G402 ATCC McCoy's 5A + 10% FBS HEK293T ATCC DMEM + 10% FBS HLE JCRB
DMEM + 10% FBS HLF JCRB DMEM + 10% FBS HS729 ATCC DMEM + 10% FBS
JURKAT ATCC RPMI1640 + 10% FBS KYSE150 DSMZ RPMI1640/Ham's F12 +
10% FBS LNCAP ATCC RPMI1640 + 10% FBS LP1 DSMZ IMDM + 20% FBS MM1S
ATCC RPMI1640 + 10% FBS MP38 ATCC RPMI1640 + 20% FBS MP41 ATCC
RPMI1640 + 20% FBS MP46 ATCC RPMI1640 + 20% FBS NCIH1299 ATCC
RPMI1640 + 10% FBS NCIH2444 ATCC RPMI1640 + 20% FBS OCIAML5 DSMZ
alpha-MEM + 20% FBS + 10 ng/ml GM-CSF OPM2 DSMZ RPMI1640 + 10% FBS
OV7 ECACC DMEM/Ham's F12 (1:1) + 2 mM Glutamine + 10% FBS + 0.5
ug/ml hydrocortisone + 10 ug/ml insulin PFEIFFER ATCC RPMI1640 +
10% FBS PLCPRF5 ATCC EMEM + 10% FBS RD ATCC DMEM + 10% FBS RS411
ATCC RPMI1640 + 10% FBS SKM1 JCRB RPMI1640 + 10% FBS SUDHL4 DSMZ
RPMI1640 + 10% FBS SUDHL6 ATCC RPMI1640 + 20% FBS SW1573 ATCC DMEM
+ 10% FBS TALL1 JCRB RPMI1640 + 10% FBS TYKNU JCRB EMEM + 20% FBS
WSUDLCL2 DSMZ RPMI1640 + 10% FBS
[0313] Results: As shown in FIG. 1, the AML cell line was more
sensitive to BRG1/BRM inhibition than the other tested cell lines.
Inhibition of the AML cell lines was maintained through day 7.
Example 3. Synthesis of Compound 18
[0314] BRG1/BRM Inhibitor compound 18 has the structure:
##STR00082##
Compound 18 was synthesized as shown in Scheme 2 below.
##STR00083##
Step 1: Preparation of
(S)-1-(methylsulfonyl)-N-(4-(methylthio)-1-oxo-1-((4-(3-(pyridin-4-yl)phe-
nyl)thiazol-2-yl)amino)butan-2-yl)-1H-pyrrole-3-carboxamide
(compound 18)
##STR00084##
[0316] To a mixture of
(S)-4-(methylthio)-1-oxo-1-((4-(3-(pyridin-4-yl)phenyl)thiazol-2-yl)amino-
)butan-2-aminium chloride (2.00 g, 4.75 mmol) and
1-methylsulfonylpyrrole-3-carboxylic acid (0.899 g, 4.75 mmol) in
DMF (20 mL) was added EDCl (1.37 g, 7.13 mmol), HOBt (0.963 g, 7.13
mmol), and N,N-diisopropylethylamine (3.31 mL, 19.00 mmol). After
stirring for 3 h, the mixture was poured into water (100 mL) and
the resulting precipitates were filtered. The solids were
triturated in MeOH (20 mL) and the precipitate was collected by
filtration. The solids were re-dissolved in DMSO (10 mL) and poured
into MeOH (50 mL). The precipitates were filtered and lyophilized
to give Compound 18 (2.05 g, 3.66 mmol, 77.01% yield) as white
solids. LCMS (ESI) m/z [M+H].sup.+=555.9. .sup.1H NMR (400 MHz,
DMSO) .delta. 12.49 (s, 1H), 8.68-8.66 (m, 2H), 8.46 (d, J=7.2 Hz,
1H), 8.31-8.30 (m, 1H), 8.02-8.00 (m, 1H), 7.94-7.96 (m, 1H), 7.83
(s, 1H), 7.73-7.74 (m, 3H), 7.61-7.57 (m, 1H), 7.31-7.29 (m, 1H),
6.79-6.77 (m, 1H), 4.74-4.69 (m, 1H), 3.57 (s, 3H), 2.67-2.53 (m,
2H), 2.13-2.01 (m, 5H). SFC: AS-3-MeOH (DEA)-40-3 mL-35Tlcm,
t=0.932 min, ee %=100%.
Example 4. Effects of BRG1/BRM ATPase Inhibition on the Growth of
Cancer Cell Lines
[0317] Procedure: All cell lines described above in Example 2 were
also tested as described above with compound 18. In addition, the
following cell lines were also tested as follows. Briefly, for
Ewing's sarcoma cell lines (CADOES1, RDES, SKES1), retinoblastoma
cell lines (WERIRB1), ALL cell lines (REH), AML cell lines
(KASUMI1), prostate cancer cell lines (PC3, DU145, 22RV1), melanoma
cell lines (SH4, SKMEL28, WM115, COLO829, SKMEL3, A375), breast
cancer cell lines (MDAMB415, CAMA1, MCF7, BT474, HCC1419, DU4475,
BT549), B-ALL cell lines (SUPB15), CML cell lines (K562, MEG01),
Burkitt's lymphoma cell lines (RAMOS2G64C10, DAUDI), mantle cell
lymphoma cell lines (JEK01, REC1), bladder cancer cell lines
(HT1197), and lung cancer cell lines (SBC5), the above methods were
performed with the following modifications: Cells were plated in 96
well plates, and the next day, BRG1/BRM ATPase inhibitor, compound
18, was dissolved in DMSO and added to the cells in a concentration
gradient from 0 to 10 micromolar. At the time of cell splitting on
days 3 and 7, cells were split into new 96 well plates, and fresh
compound was added four hours after re-plating.
[0318] Table 2 lists the tested cell lines and growth media
used.
TABLE-US-00006 TABLE 2 Cell Lines and Growth Media Cell Line Source
Growth Media 22RV1 ATCC RPMI1640 + 10% FBS A375 ATCC DMEM + 10% FBS
BT474 ATCC Hybricare medium + 1.5 g/L sodium bicarbonate + 10% FBS
BT549 ATCC RPMI1640 + 0.023 IU/ml insulin + 10% FBS CADOES1 DSMZ
RPMI1640 + 10% FBS CAMA1 ATCC EMEM + 10% FBS COLO829 ATCC RPMI1640
+ 10% FBS DAUDI ATCC RPMI1640 + 10% FBS DU145 ATCC EMEM + 10% FBS
DU4475 ATCC RPMI1640 + 10% FBS HCC1419 ATCC RPMI1640 + 10% FBS
HT1197 ATCC EMEM + 10% FBS JEKO1 ATCC RPMI1640 + 20% FBS K562 ATCC
IMDM + 10% FBS KASUMI1 ATCC RPMI1640 + 10% FBS MCF7 ATCC EMEM +
0.01 mg/ml bovine insulin + 10% FBS MDAMB415 ATCC Leibovitz's L-15
+ 2 mM L-glutamine + 10 mcg/ml insulin + 10 mcg/ml glutathione +
15% FBS MEG01 ATCC RPMI1640 + 10% FBS PC3 ATCC F-12K + 10% FBS
RAMOS2G64C10 ATCC RPMI1640 + 10% FBS RDES ATCC RPMI1640 + 15% FBS
REC1 ATCC RPMI1640 + 10% FBS REH ATCC RPMI1640 + 10% FBS SBC5 JCRB
EMEM + 10% FBS SH4 ATCC DMEM + 10% FBS SKES1 ATCC McCoy's 5A + 15%
FBS SKMEL28 ATCC EMEM + 10% FBS SKMEL3 ATCC McCoy's 5A + 15% FBS
SUPB15 ATCC IMDM + 4 mM L- glutamine + 1.5 g/L sodium bicarbonate +
0.05 mM 2-mercaptoethanol + 20% FBS WERIRB1 ATCC RPMI1640 + 10% FBS
WM115 ATCC EMEM + 10% FBS
[0319] Results: As shown in FIG. 2, the AML cell lines were more
sensitive to BRG1/BRM inhibition than the other tested cell lines.
Inhibition of the AML cell lines was maintained through day 7.
Example 5. Effects of BRG1/BRM ATPase Inhibition on the Growth of
Cancer Cell Lines
[0320] Procedure: A pooled cell viability assay was performed using
PRISM (Profiling Relative Inhibition Simultaneously in Mixtures) as
previously described ("High-throughput identification of
genotype-specific cancer vulnerabilities in mixtures of barcoded
tumor cell lines", Yu et al, Nature Biotechnology 34, 419-423,
2016), with the following modifications. Cell lines were obtained
from the Cancer Cell Line Encyclopedia (CCLE) collection and
adapted to RPMI-1640 medium without phenol red, supplemented with
10% heat-inactivated fetal bovine serum (FBS), in order to apply a
unique infection and pooling protocol to such a big compendium of
cell lines. A lentiviral spin-infection protocol was executed to
introduce a 24 nucleotide-barcode in each cell line, with an
estimated multiplicity of infection (MOI) of 1 for all cell lines,
using blasticidin as selection marker. Over 750 PRISM cancer cell
lines stably barcoded were then pooled together according to
doubling time in pools of 25. For the screen execution, instead of
plating a pool of 25 cell lines in each well as previously
described (Yu et al.), all the adherent or all the suspension cell
line pools were plated together using T25 flasks (100,000
cells/flask) or 6-well plates (50,000 cells/well), respectively.
Cells were treated with either DMSO or compound in a 8-point 3-fold
dose response in triplicate, starting from a top concentration of
10 .mu.M. As control for assay robustness, cells were treated in
parallel with two previously validated compounds, the pan-Raf
inhibitor AZ-628, and the proteasome inhibitor bortezomib, using a
top concentration of 2.5 .mu.M and 0.039 .mu.M, respectively.
[0321] Following 3 days of treatment with compounds, cells were
lysed, genomic DNA was extracted, barcodes were amplified by PCR
and detected with Next-Generation Sequencing. Cell viability was
determined by comparing the counts of cell-line specific barcodes
in treated samples to those in the DMSO-control and Day 0 control.
Dose-response curves were fit for each cell line and corresponding
area under the curves (AUCs) were calculated and compared to the
median AUC of all cell lines (FIG. 3). Cell lines with AUCs less
than the median were considered most sensitive.
Example 6. Synthesis of Compound 19
[0322] BRG1/BRM inhibitor compound 19 has the structure:
##STR00085##
[0323] Compound 19 was synthesized as shown in Scheme 3 below.
##STR00086##
Step 1: Preparation of 6-fluoropyridine-2-carbonyl chloride
(Intermediate L)
##STR00087##
[0325] To a cooled (0.degree. C.) solution of
6-fluoropyridine-2-carboxylic acid (50.00 g, 354.36 mmol) in
dichloromethane (500 mL) and N,N-dimethylformamide (0.26 mL, 3.54
mmol) was added oxalyl chloride (155.10 mL, 1.77 mol). After
complete addition of oxalyl chloride, the reaction mixture was
warmed to room temperature and stirred for an additional 0.5 h. The
mixture was subsequently concentrated in vacuo to give intermediate
L (56.50 g) as white solids, which were used to next step without
further purification.
Step 2: Preparation of 2-chloro-1-(6-fluoro-2-pyridyl)ethenone
(Intermediate M)
##STR00088##
[0327] To a cooled (0.degree. C.) mixture of intermediate L (56.00
g, 351.00 mmol) in 1,4-dioxane (800 mL) was added in a dropwise
manner a solution of 2 M trimethylsilyl diazomethane in hexanes
(351 mL). The resulting reaction mixture was stirred at 25.degree.
C. for 10 h. The reaction mixture was subsequently quenched with a
solution of 4 M HCl in 1,4-dioxane (500 mL). After stirring for 2
h, the reaction solution was concentrated in vacuo to give an oil.
The residue was diluted with saturated aqueous NaHCO.sub.3 (500 mL)
and extracted with EtOAc (3.times.200 mL). The combined organic
layers were washed with brine (2.times.300 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give intermediate M (35.50 g) as white solids, which was used to
next step directly. LCMS (ESI) m/z: [M+H].sup.+=173.8.
Step 3: Preparation of 4-(6-fluoro-2-pyridyl)thiazol-2-amine
(Intermediate O)
##STR00089##
[0329] To a solution of intermediate M (35.50 g, 204.53 mmol) and
thiourea (14.01 g, 184.07 mmol) in a mixture of MeOH (250 mL) and
water (250 mL) at room temperature was added NaF (3.56 g, 84.82
mmol). After stirring for 30 min, the reaction mixture was
partially concentrated in vacuo to remove MeOH. The resulting
solution was acidified to pH .about.3 with 2 M aqueous HCl and
extracted with EtOAc (3.times.200 mL). The combined organic layers
were discarded, and the aqueous phase was basified with saturated
aqueous NaHCO.sub.3 (500 mL). After stirring for 30 min, the
aqueous phase was extracted with EtOAc (3.times.325 mL). The
combined organic layers were washed with brine (3.times.225 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The solids were triturated with petroleum ether
(300 mL), stirred at 25.degree. C. for 10 min, and filtered. The
solids were dried under vacuum to give intermediate O (28.00 g,
143.43 mmol, 70.13% yield, 100% purity) as white solids. LCMS (ESI)
m/z: [M+H].sup.+=195.8.; .sup.1H NMR (400 MHz, DMSO-d6) .delta.
8.00-7.96 (m, 1H), 7.72 (d, J=7.2 Hz, 1H), 7.24 (s, 1H), 7.16 (s,
2H), 7.02 (d, J=8.0 Hz, 1H).
Step 4: Preparation of tert-butyl
N-[2-[[4-(6-fluoro-2-pyridyl)thiazol-2-yl]amino]-2-oxo-ethyl]carbamate
(Intermediate P)
##STR00090##
[0331] To a solution of N-Boc-glycine (5.92 g, 33.81 mmol), HATU
(12.86 g, 33.81 mmol), and N,N-diisopropylethylamine (21.41 mL,
122.94 mmol) in dichloromethane (100 mL) was added intermediate O
(6.00 g, 30.74 mmol). After stirring for 2 h, the reaction mixture
was concentrated. The resulting oil was diluted with water (100 mL)
and subsequently extracted with EtOAc (4.times.60 mL). The combined
organic layers were washed with brine (2.times.100 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give solids. The solids were triturated with a 1:1 mixture of
petroleum ether and MeOH (40 mL). After stirring at 25.degree. C.
for 20 minutes, the suspension was filtered, and the filter cake
was washed with MTBE (20 mL). The solids were dried in vacuo to
give intermediate P (7.70 g, 21.63 mmol, 70.4% yield, 99.0% purity)
as white solids. LCMS (ESI) m/z: [M+H].sup.+=353.1.
Step 5: Preparation of
2-((4-(6-fluoropyridin-2-yl)thiazol-2-yl)amino)-2-oxoethan-1-aminium
chloride (Intermediate Q)
##STR00091##
[0333] A solution of intermediate P (5.40 g, 15.32 mmol) in 4 M HCl
in 1,4-dioxane (35 mL) was stirred at 25.degree. C. for 1.5 h. The
reaction mixture was subsequently concentrated under vacuum to give
intermediate Q (4.42 g) as white solids, which were used to next
step directly without further purification. LCMS (ESI) m/z:
[M+H].sup.+=252.9.
Step 6: Preparation of
1-tert-butyl-N-[2-[[4-(6-fluoro-2-pyridyl)thiazo]-2-yl]amino]-2-oxo-ethyl-
]pyrrole-3-carboxamide (Intermediate S)
##STR00092##
[0335] To a solution of intermediate Q (3.00 g, 10.39 mmol),
1-tert-butylpyrrole-3-carboxylic acid (1.74 g, 10.39 mmol) and
N,N-diisopropylethylamine (9.05 mL, 51.95 mmol) in dichloromethane
(40 mL) was sequentially added HOBt (1.68 g, 12.47 mmol) and EDCl
(2.39 g, 12.47 mmol). After stirring for 4 h, the mixture was
concentrated in vacuo. The residue was diluted with water (250 mL)
and extracted with EtOAc (3.times.200 mL). The combined organic
layers were washed with brine (3.times.300 mL), dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The resulting solids were triturated with a 1:1 mixture
of MTBE/EtOAc (400 mL) and after stirring for 30 min, the
suspension was filtered. The solids were washed with MTBE
(3.times.85 mL) and dried under vacuum to give intermediate S (3.10
g, 7.64 mmol, 73.6% yield, 99.0% purity) as white solids. LCMS
(ESI) m/z: [M+H].sup.+=402.3.; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 12.40 (s, 1H), 8.18-8.15 (m, 1H), 8.09-8.08 (m, 1H),
7.87-7.83 (m, 2H), 7.52 (s, 1H), 7.11 (d, J=8.0 Hz, 1H), 6.97 (m,
1H), 6.47 (s, 1H), 4.10 (d, J=5.6 Hz, 2H), 1.49 (s, 9H).
Step 7: Preparation of
1-(tert-butyl)-N-(2-((4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiaz-
ol-2-yl)amino)-2-oxoethyl)-1H-pyrrole-3-carboxamide (compound
19)
##STR00093##
[0337] To a solution of intermediate S (0.100 g, 0.249 mmol) in
DMSO (1 mL) was added N,N-diisopropylethylamine (0.130 mL, 0.747
mmol) and cis-2,6-dimethylmorpholine (0.057 g, 0.498 mmol). The
resulting reaction mixture was stirred at 120.degree. C. After 12
h, the solution was cooled to room temperature, diluted with MeOH
(3 mL), and subsequently concentrated in vacuo. The resulting oil
was purified by prep-HPLC (0.1% TFA; column: Luna C18 150*25 5u;
mobile phase: [water (0.075% TFA)-ACN]; B %: 30%-60%, 2 min). The
appropriate fractions were collected and lyophilized to give
Compound 19 (0.079 g, 0.129 mmol, 51.94% yield, 100% purity) as
white solids. LCMS (ESI) m/z: [M+H].sup.+=497.5.; .sup.1H NMR (400
MHz, DMSO-d6) .delta. 12.27 (s, 1H), 8.17-8.14 (m, 1H), 7.75 (s,
1H), 7.63-7.59 (m, 1H), 7.51 (s, 1H), 7.25 (d, J=7.2 Hz, 1H), 6.96
(s, 1H), 6.79 (d, J=8.8 Hz, 1H), 6.47 (s, 1H), 4.24 (d, J=12.4 Hz,
2H), 4.08 (d, J=5.6 Hz, 2H), 3.64-3.61 (m, 2H), 2.44-2.38 (m, 2H),
1.49 (s, 9H), 1.18 (d, J=5.6 Hz, 6H).
Example 7. BRM/BRG1 Inhibition Causes Tumor Growth Delay and Stasis
in MV4;11 and EOL-1 Human AML Tumors In Vivo
[0338] Method: BALB/c Nude mice (Beijing Anikeeper Biotech,
Beijing) were inoculated subcutaneously on the right flank with the
single cell suspension of EOL-1 or MV4;11 human AML tumor cells
(1.times.10.sup.7) in 100 .mu.L IDMD in 10% Fetal Bovine Serum
(FBS). When tumor size reach .about.100 mm3, the mice were
randomized into either Vehicle group [20% HP-.beta.-CD) or
Treatment group: Compound 19 at 50 mg/kg daily for 21 days per oral
route. All dose volumes were adjusted by body weights in terms of
mg/kg.
[0339] Results: As shown in FIG. 4 treatment with 50 mg/kg of
Compound 19 led to tumor stasis in MV4;11. As shown in FIG. 5,
treatment with 50 mg/kg of Compound 19 delayed the growth of EOL-1
tumor. All treatments were well tolerated based on % body weight
change observed.
Example 8. Synthesis of Compound 20
[0340]
N--((S)-1-((4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-
-yl)amino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-car-
boxamide (Compound 20) was synthesized as shown in Scheme 4
below.
##STR00094##
Step 1: Preparation of 6-fluoropyridine-2-carbonyl chloride
(Intermediate B)
##STR00095##
[0342] To a cooled (0.degree. C.) solution of
6-fluoropyridine-2-carboxylic acid (50.0 g, 354 mmol) in
dichloromethane (500 mL) and N,N-dimethylformamide (0.26 mL, 3.54
mmol) was added oxalyl chloride (155 mL, 1.77 mol). After complete
addition of oxalyl chloride, the reaction mixture was warmed to
room temperature. After 0.5 hours, the mixture was concentrated
under vacuum to give Intermediate B (56.50 g) as a white solid,
which was used in the next step without further purification.
Step 2: Preparation of 2-chloro-1-(6-fluoro-2-pyridyl)ethenone
(Intermediate C)
##STR00096##
[0344] To a cooled (0.degree. C.) mixture of Intermediate B (56.0
g, 351 mmol) in 1,4-dioxane (800 mL) was added in a dropwise manner
a solution of 2M trimethylsilyl diazomethane in hexanes (351 mL,
702 mmol). The resulting reaction mixture was stirred at 25.degree.
C. for 10 h. The reaction mixture was subsequently quenched with a
solution of 4M HCl in 1,4-dioxane (500 mL, 2.0 mol). After stirring
for 2 h, the reaction solution was concentrated under vacuum to
give an oil. The residue was diluted with saturated aqueous
NaHCO.sub.3 and extracted three times with ethyl acetate. The
combined organic layers were washed twice with brine, dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to give Intermediate C (35.5 g) as a white solid, which was used to
next step directly. LCMS (ESI) m/z: [M+H].sup.+=173.8.
Step 3: Preparation of 4-(6-fluoro-2-pyridyl)thiazol-2-amine
(Intermediate E)
##STR00097##
[0346] To a solution of Intermediate C (35.5 g, 205 mmol) and
thiourea (14.0 g, 184 mmol) in a mixture of methanol (250 mL) and
water (250 mL) at room temperature was added NaF (3.56 g, 84.8
mmol).
[0347] After stirring for 0.5 h, the reaction mixture was partially
concentrated under vacuum to remove MeOH, and the resulting
solution was acidified to pH .about.3 with aqueous 2M HCl. After 15
minutes, the solution was extracted three times with ethyl acetate.
The organic layers were discarded and the aqueous phase was
alkalized with saturated aqueous NaHCO.sub.3 and stirred for 30
minutes, and extracted three times with ethyl acetate. The combined
organic layers were washed three times with brine, dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced
pressure. The residue was triturated with petroleum ether and
stirred at 25.degree. C. for 10 minutes and filtered. The resultant
solids were dried under vacuum to give Intermediate E (28.0 g, 143
mmol, 70.1% yield, 100% purity) as a white solid.
[0348] LCMS (ESI) m/z: [M+H].sup.+=195.8.
[0349] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 8.00-7.96 (m, 1H),
7.72 (d, J=7.2 Hz, 1H), 7.24 (s, 1H), 7.16 (s, 2H), 7.02 (d, J=8.0
Hz, 1H).
Step 4: Preparation of
4-[6-[cis-2,6-dimethylmorpholin-4-yl]-2-pyridyl]thiazol-2-amine
(Intermediate G)
##STR00098##
[0351] Ten separate mixtures of Intermediate E (2.00 g, 10.3 mmol),
cis-2,6-dimethylmorpholine (3.54 g, 30.7 mmol), and DIPEA (5.35 mL,
30.7 mmol) in dimethyl sulfoxide (10 mL) were stirred in parallel
at 120.degree. C. under N2 atmosphere. After 36 h, the reaction
mixtures were combined and added dropwise to water. The resulting
suspension was filtered and the filter cake was washed three times
with water and once with petroleum ether, then dried over under
reduced pressure to give Intermediate G (25.5 g, 87.8 mmol, 95.2%
yield) as a yellow solid.
[0352] LCMS (ESI) m/z: [M+H].sup.+=291.2.
[0353] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.56-7.54 (m, 1H),
7.17 (s, 1H), 7.13 (d, J=7.6 Hz, 1H), 7.01 (s, 2H), 6.72 (d, J=8.8
Hz, 1H), 4.26-4.15 (m, 2H), 3.67-3.55 (m, 2H), 2.38-2.34 (m, 2H),
1.17 (d, J=6.4 Hz, 6H).
Step 5: Preparation of tert-butyl
N-[(1S)-2-[[4-[6-[cis-2,6-dimethylmorpholin-4-yl]-2-pyridyl]thiazol-2-yl]-
amino]-1-(methoxymethyl)-2-oxo-ethyl]carbamate (Intermediate I)
##STR00099##
[0355] To a solution of Intermediate G (12.0 g, 41.3 mmol) and
(2S)-2-(tertbutoxycarbonylamino)-3-methoxy-propanoic acid (10.9 g,
49.6 mmol) in dichloromethane (60 mL) was added EEDQ (12.3 g, 49.6
mmol). After stirring at room temperature for 16 h, the reaction
mixture was concentrated under reduced pressure to give a residue.
The residue was purified by silica gel column chromatography
(petroleum ether:ethyl acetate=2:1 to 3:2) to give Intermediate I
(20.0 g, 40.7 mmol, 98.5% yield) as a yellow gum.
[0356] LCMS (ESI) m/z: [M+H].sup.+=492.2.
[0357] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 12.37 (s, 1H), 7.78
(s, 1H), 7.64-7.60 (m, 1H), 7.25 (d, J=7.2 Hz, 1H), 7.16 (d, J=7.2
Hz, 1H), 6.79 (d, J=8.4 Hz, 1H), 4.50-4.48 (m, 1H), 4.25 (d, J=11.6
Hz, 2H), 3.70-3.51 (m, 4H), 3.26 (s, 3H), 2.44-2.40 (m, 2H), 1.39
(s, 9H), 1.18 (d, J=6.4 Hz, 6H).
Step 6: Preparation
of(S)-4-(4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)-1-me-
thoxy-3-oxobutan-2-aminium chloride (Intermediate J)
##STR00100##
[0359] To a solution of 4M HCl in 1,4-dioxane (200 mL, 800 mmol)
was added a solution of Intermediate I (20.0 g, 40.7 mmol) in
dichloromethane (50 mL). After stirring at room temperature for 2
h, the mixture was diluted with methyl tert-butyl ether resulting
in a suspension. The solid was collected by filtration, washed
twice with methyl tert-butyl ether, and dried in vacuo to give
Intermediate J (19.0 g) as a yellow solid, which was used in the
next step without further purification.
[0360] LCMS (ESI) m/z: [M+H].sup.+=392.3.
[0361] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 13.44-12.30 (m, 1H),
8.65 (d, J=4.4 Hz, 3H), 7.87 (s, 1H), 7.66-7.64 (m, 1H), 7.25 (d,
J=7.2 Hz, 1H), 6.83 (d, J=8.8 Hz, 1H), 4.39-4.30 (m, 1H), 4.25 (d,
J=11.6 Hz, 2H), 3.94-3.86 (m, 1H), 3.85-3.77 (m, 1H), 3.69-3.57 (m,
2H), 3.31 (s, 3H), 2.43 (m, 2H), 1.18 (d, J=6.4 Hz, 6H).
Preparation of 1-(methylsulfonyl)-1H-pyrrole-3-carboxylic acid
(Intermediate K)
[0362] 1-(methylsulfonyl)-1H-pyrrole-3-carboxylic acid was
synthesized as shown in Scheme 5 below.
##STR00101##
Step A: Preparation of tert-butyl 1H-pyrrole-3-carboxylate
(Intermediate N)
##STR00102##
[0364] To a mixture of tert-butyl-prop-2-enoate (78.6 mL, 542 mmol)
and 1-(isocyanomethylsulfonyl)-4-methylbenzene (106 g, 542 mmol) in
THE (1300 mL) was added 60% NaH in mineral oil (25.97 g, 649 mmol)
slowly at 30.degree. C. over 1 hour and then heated to 70.degree.
C. After 2 h, the reaction mixture was poured into saturated
aqueous NH.sub.4Cl solution and extracted three times with ethyl
acetate. The combined organic phase was washed twice with brine,
dried over anhydrous Na.sub.2SO.sub.4, filtered, and concentrated
under reduced pressure to afford a residue. The residue was
purified by silica gel column chromatography (petroleum ether:ethyl
acetate=20:1 to 3:1) to afford Intermediate N (41.5 g, 236 mmol,
43% yield) as a yellow solid.
[0365] LCMS (ESI) m/z [M+Na].sup.+=180.4.
[0366] .sup.1H NMR (400 MHz, CDCl3) .delta. 8.36 (br s, 1H),
7.35-7.25 (m, 1H), 6.71-6.62 (m, 1H), 6.59-6.49 (m, 1H), 1.48 (s,
9H).
Step B: Preparation of tert-butyl
1-methylsulfonylpyrrole-3-carboxylate (Intermediate O)
##STR00103##
[0368] To a cooled solution (0.degree. C.) of Intermediate N (40.5
g, 242 mmol) in THE (1500 mL) was added a 1 M solution of NaHMDS
(484 mL, 484 mmol). After stirring at 0.degree. C. for 30 min,
methanesulfonyl chloride (28.1 mL, 363 mmol) was slowly added and
the mixture was warmed to 30.degree. C. After 16 h, the reaction
mixture was slowly poured into saturated aqueous NH.sub.4Cl
solution and extracted three times with ethyl acetate. The combined
organic layers were washed twice with brine, dried over anhydrous
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to afford a residue. The residue was purified by silica gel
chromatography (petroleum ether:ethyl acetate=10:1) to afford a
yellow solid. The yellow solid was triturated with methyl
tert-butyl ether at room temperature, stirred for 20 minutes,
filtered, and dried in vacuum to afford Intermediate O (25.7 g, 105
mmol, 43% yield) as a white solid.
[0369] .sup.1H NMR (400 MHz, CDCl3) .delta. 7.66-7.64 (m, 1H),
7.10-7.08 (m, 1H), 6.73-6.71 (m, 1H), 3.21 (s, 3H), 1.56 (s,
9H).
Step C: Preparation of 1-methylsulfonylpyrrole-3-carboxylic acid
(Intermediate K)
##STR00104##
[0371] To a mixture of Intermediate O (25.7 g, 105 mmol) in
1,4-dioxane (100 mL) was added a 4M solution of HCl in 1,4-dioxane
(400 mL, 1.6 mol) at 15.degree. C. After stirring at at 15.degree.
C. for 14 h, the reaction mixture was concentrated under reduced
pressure to afford a residue. The residue was triturated with
methyl tert-butyl ether at 15.degree. C. for 16 h. The mixture was
filtered and dried in vacuum to afford Intermediate K (18.7 g, 98.8
mmol, 94% yield) as a white solid.
[0372] LCMS (ESI) m/z [M+H].sup.+=189.8.
[0373] .sup.1H NMR (400 MHz, methanol-d4) .delta. 7.78-7.77 (m,
1H), 7.25-7.23 (m, 1H), 6.72-6.70 (m, 1H), 3.37 (s, 3H).
Step 7: Preparation of
N--((S)-1-((4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)am-
ino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxami-
de
##STR00105##
[0375] To a solution of 1-methylsulfonylpyrrole-3-carboxylic acid
(Intermediate K) (2.43 g, 12.9 mmol), EDCl (2.69 g, 14.0 mmol),
HOBt (1.89 g, 14.0 mmol), and DIPEA (10.2 mL, 58.4 mmol) in
dichloromethane (50 mL) was added Intermediate J (5.00 g, 11.7
mmol). After stirring at room temperature for 4 h, the reaction
mixture was concentrated under reduced pressure. The residue was
diluted with water and extracted three times with ethyl acetate.
The combined organic layers were washed three times with saturated
aqueous NH4Cl, once with brine, dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure to give a
residue. The residue was purified by silica gel column
chromatography (petroleum ether:ethyl acetate=1:1 to 1:2). The
residue was triturated with methyl tert-butyl ether. After 0.5 h,
the suspension was filtered, the filter cake was washed with methyl
tert-butyl ether, and dried in vacuo. The solid was dissolved in
dimethyl sulfoxide (12 mL) and added dropwise to water (800 mL).
The suspension was filtered to give wet filter cake. The filter
cake was suspended in water and stirred at room temperature. After
1 hour, the solid was collected by filtration, washed three times
with water and dried in vacuo to give
N--((S)-1-((4-(6-(cis-2,6-dimethylmorpholino)pyridin-2-yl)thiazol-2-yl)am-
ino)-3-methoxy-1-oxopropan-2-yl)-1-(methylsulfonyl)-1H-pyrrole-3-carboxami-
de (3.9 g, 6.93 mmol, 59.3% yield) as a white solid.
[0376] LCMS (ESI) m/z: [M+H].sup.+=563.1.
[0377] .sup.1H NMR (400 MHz, DMSO-d6) .delta. 12.49 (br s, 1H),
8.51 (d, J=7.2 Hz, 1H), 7.98-7.97 (m, 1H), 7.78 (s, 1H), 7.67-7.57
(m, 1H), 7.29-7.27 (m, 1H), 7.26 (d, J=7.2 Hz, 1H), 6.88-6.74 (m,
2H), 4.94-4.91 (m, 1H), 4.25 (d, J=11.6 Hz, 2H), 3.77-3.67 (m, 2H),
3.63-3.62 (m, 2H), 3.57 (s, 3H), 3.31 (s, 3H), 2.44-2.38 (m, 2H),
1.18 (d, J=6.0 Hz, 6H).
Example 9. BRM/BRG1 Inhibition Causes Tumor Growth Delay in an
OCI-AML2 Tumor that Carries a DNMT3A Mutation
[0378] Method: SCID mice (Charles River, Wilmington) were
inoculated subcutaneously on the right flank with the single cell
suspension of OCI-AML2 human AML tumor cells (1.times.10.sup.7) in
100 .mu.L in RPMI-1640 media. When tumor size reach .about.100
mm.sup.3, the mice were randomized into either Vehicle group (20%
HP-.beta.-CD) or Treatment group (Compound 20 at 1.5 mg/kg daily
for 21 days per oral route). All dose volumes were adjusted by body
weights in terms of mg/kg.
[0379] Results: As shown in FIG. 6, treatment with Compound 20 at
1.5 mg/kg inhibited the growth of OCI-AML2 tumor. All treatments
were well tolerated based on % body weight change observed.
OTHER EMBODIMENTS
[0380] All publications, patents, and patent applications mentioned
in this specification are incorporated herein by reference in their
entirety to the same extent as if each individual publication,
patent, or patent application was specifically and individually
indicated to be incorporated by reference in its entirety. Where a
term in the present application is found to be defined differently
in a document incorporated herein by reference, the definition
provided herein is to serve as the definition for the term.
[0381] While the invention has been described in connection with
specific embodiments thereof, it will be understood that invention
is capable of further modifications and this application is
intended to cover any variations, uses, or adaptations of the
invention following, in general, the principles of the invention
and including such departures from the present disclosure that come
within known or customary practice within the art to which the
invention pertains and may be applied to the essential features
hereinbefore set forth, and follows in the scope of the claims.
[0382] Other embodiments are in the claims.
Sequence CWU 1
1
415589RNAHomo sapiens 1ggcgggggag gcgccgggaa gtcgacggcg ccggcggctc
ctgcaggagg ccactgtctg 60cagctcccgt gaagatgtcc actccagacc cacccctggg
cggaactcct cggccaggtc 120cttccccggg ccctggccct tcccctggag
ccatgctggg ccctagcccg ggtccctcgc 180cgggctccgc ccacagcatg
atggggccca gcccagggcc gccctcagca ggacacccca 240tccccaccca
ggggcctgga gggtaccctc aggacaacat gcaccagatg cacaagccca
300tggagtccat gcatgagaag ggcatgtcgg acgacccgcg ctacaaccag
atgaaaggaa 360tggggatgcg gtcagggggc catgctggga tggggccccc
gcccagcccc atggaccagc 420actcccaagg ttacccctcg cccctgggtg
gctctgagca tgcctctagt ccagttccag 480ccagtggccc gtcttcgggg
ccccagatgt cttccgggcc aggaggtgcc ccgctggatg 540gtgctgaccc
ccaggccttg gggcagcaga accggggccc aaccccattt aaccagaacc
600agctgcacca gctcagagct cagatcatgg cctacaagat gctggccagg
gggcagcccc 660tccccgacca cctgcagatg gcggtgcagg gcaagcggcc
gatgcccggg atgcagcagc 720agatgccaac gctacctcca ccctcggtgt
ccgcaacagg acccggccct ggccctggcc 780ctggccccgg cccgggtccc
ggcccggcac ctccaaatta cagcaggcct catggtatgg 840gagggcccaa
catgcctccc ccaggaccct cgggcgtgcc ccccgggatg ccaggccagc
900ctcctggagg gcctcccaag ccctggcctg aaggacccat ggcgaatgct
gctgccccca 960cgagcacccc tcagaagctg attcccccgc agccaacggg
ccgcccttcc cccgcgcccc 1020ctgccgtccc acccgccgcc tcgcccgtga
tgccaccgca gacccagtcc cccgggcagc 1080cggcccagcc cgcgcccatg
gtgccactgc accagaagca gagccgcatc acccccatcc 1140agaagccgcg
gggcctcgac cctgtggaga tcctgcagga gcgcgagtac aggctgcagg
1200ctcgcatcgc acaccgaatt caggaacttg aaaaccttcc cgggtccctg
gccggggatt 1260tgcgaaccaa agcgaccatt gagctcaagg ccctcaggct
gctgaacttc cagaggcagc 1320tgcgccagga ggtggtggtg tgcatgcgga
gggacacagc gctggagaca gccctcaatg 1380ctaaggccta caagcgcagc
aagcgccagt ccctgcgcga ggcccgcatc actgagaagc 1440tggagaagca
gcagaagatc gagcaggagc gcaagcgccg gcagaagcac caggaatacc
1500tcaatagcat tctccagcat gccaaggatt tcaaggaata tcacagatcc
gtcacaggca 1560aaatccagaa gctgaccaag gcagtggcca cgtaccatgc
caacacggag cgggagcaga 1620agaaagagaa cgagcggatc gagaaggagc
gcatgcggag gctcatggct gaagatgagg 1680aggggtaccg caagctcatc
gaccagaaga aggacaagcg cctggcctac ctcttgcagc 1740agacagacga
gtacgtggct aacctcacgg agctggtgcg gcagcacaag gctgcccagg
1800tcgccaagga gaaaaagaag aaaaagaaaa agaagaaggc agaaaatgca
gaaggacaga 1860cgcctgccat tgggccggat ggcgagcctc tggacgagac
cagccagatg agcgacctcc 1920cggtgaaggt gatccacgtg gagagtggga
agatcctcac aggcacagat gcccccaaag 1980ccgggcagct ggaggcctgg
ctcgagatga acccggggta tgaagtagct ccgaggtctg 2040atagtgaaga
aagtggctca gaagaagagg aagaggagga ggaggaagag cagccgcagg
2100cagcacagcc tcccaccctg cccgtggagg agaagaagaa gattccagat
ccagacagcg 2160atgacgtctc tgaggtggac gcgcggcaca tcattgagaa
tgccaagcaa gatgtcgatg 2220atgaatatgg cgtgtcccag gcccttgcac
gtggcctgca gtcctactat gccgtggccc 2280atgctgtcac tgagagagtg
gacaagcagt cagcgcttat ggtcaatggt gtcctcaaac 2340agtaccagat
caaaggtttg gagtggctgg tgtccctgta caacaacaac ctgaacggca
2400tcctggccga cgagatgggc ctggggaaga ccatccagac catcgcgctc
atcacgtacc 2460tcatggagca caaacgcatc aatgggccct tcctcatcat
cgtgcctctc tcaacgctgt 2520ccaactgggc gtacgagttt gacaagtggg
ccccctccgt ggtgaaggtg tcttacaagg 2580gatccccagc agcaagacgg
gcctttgtcc cccagctccg gagtgggaag ttcaacgtct 2640tgctgacgac
gtacgagtac atcatcaaag acaagcacat cctcgccaag atccgttgga
2700agtacatgat tgtggacgaa ggtcaccgca tgaagaacca ccactgcaag
ctgacgcagg 2760tgctcaacac gcactatgtg gcaccccgcc gcctgctgct
gacgggcaca ccgctgcaga 2820acaagcttcc cgagctctgg gcgctgctca
acttcctgct gcccaccatc ttcaagagct 2880gcagcacctt cgagcagtgg
tttaacgcac cctttgccat gaccggggaa aaggtggacc 2940tgaatgagga
ggaaaccatt ctcatcatcc ggcgtctcca caaagtgctg cggcccttct
3000tgctccgacg actcaagaag gaagtcgagg cccagttgcc cgaaaaggtg
gagtacgtca 3060tcaagtgcga catgtctgcg ctgcagcgag tgctctaccg
ccacatgcag gccaagggcg 3120tgctgctgac tgatggctcc gagaaggaca
agaagggcaa aggcggcacc aagaccctga 3180tgaacaccat catgcagctg
cggaagatct gcaaccaccc ctacatgttc cagcacatcg 3240aggagtcctt
ttccgagcac ttggggttca ctggcggcat tgtccaaggg ctggacctgt
3300accgagcctc gggtaaattt gagcttcttg atagaattct tcccaaactc
cgagcaacca 3360accacaaagt gctgctgttc tgccaaatga cctccctcat
gaccatcatg gaagattact 3420ttgcgtatcg cggctttaaa tacctcaggc
ttgatggaac cacgaaggcg gaggaccggg 3480gcatgctgct gaaaaccttc
aacgagcccg gctctgagta cttcatcttc ctgctcagca 3540cccgggctgg
ggggctcggc ctgaacctcc agtcggcaga cactgtgatc atttttgaca
3600gcgactggaa tcctcaccag gacctgcaag cgcaggaccg agcccaccgc
atcgggcagc 3660agaacgaggt gcgtgtgctc cgcctctgca ccgtcaacag
cgtggaggag aagatcctag 3720ctgcagccaa gtacaagctc aacgtggacc
agaaggtgat ccaggccggc atgttcgacc 3780agaagtcctc cagccatgag
cggcgcgcct tcctgcaggc catcctggag cacgaggagc 3840aggatgagag
cagacactgc agcacgggca gcggcagtgc cagcttcgcc cacactgccc
3900ctccgccagc gggcgtcaac cccgacttgg aggagccacc tctaaaggag
gaagacgagg 3960tgcccgacga cgagaccgtc aaccagatga tcgcccggca
cgaggaggag tttgatctgt 4020tcatgcgcat ggacctggac cgcaggcgcg
aggaggcccg caaccccaag cggaagccgc 4080gcctcatgga ggaggacgag
ctcccctcgt ggatcatcaa ggacgacgcg gaggtggagc 4140ggctgacctg
tgaggaggag gaggagaaga tgttcggccg tggctcccgc caccgcaagg
4200aggtggacta cagcgactca ctgacggaga agcagtggct caagaaaatt
acaggaaaag 4260atatccatga cacagccagc agtgtggcac gtgggctaca
attccagcgt ggccttcagt 4320tctgcacacg tgcgtcaaag gccatcgagg
agggcacgct ggaggagatc gaagaggagg 4380tccggcagaa gaaatcatca
cggaagcgca agcgagacag cgacgccggc tcctccaccc 4440cgaccaccag
cacccgcagc cgcgacaagg acgacgagag caagaagcag aagaagcgcg
4500ggcggccgcc tgccgagaaa ctctccccta acccacccaa cctcaccaag
aagatgaaga 4560agattgtgga tgccgtgatc aagtacaagg acagcagcag
tggacgtcag ctcagcgagg 4620tcttcatcca gctgccctcg cgaaaggagc
tgcccgagta ctacgagctc atccgcaagc 4680ccgtggactt caagaagata
aaggagcgca ttcgcaacca caagtaccgc agcctcaacg 4740acctagagaa
ggacgtcatg ctcctgtgcc agaacgcaca gaccttcaac ctggagggct
4800ccctgatcta tgaagactcc atcgtcttgc agtcggtctt caccagcgtg
cggcagaaaa 4860tcgagaagga ggatgacagt gaaggcgagg agagtgagga
ggaggaagag ggcgaggagg 4920aaggctccga atccgaatct cggtccgtca
aagtgaagat caagcttggc cggaaggaga 4980aggcacagga ccggctgaag
ggcggccggc ggcggccgag ccgagggtcc cgagccaagc 5040cggtcgtgag
tgacgatgac agtgaggagg aacaagagga ggaccgctca ggaagtggca
5100gcgaagaaga ctgagccccg acattccagt ctcgaccccg agcccctcgt
tccagagctg 5160agatggcata ggccttagca gtaacgggta gcagcagatg
tagtttcaga cttggagtaa 5220aactgtataa acaaaagaat cttccatatt
tatacagcag agaagctgta ggactgtttg 5280tgactggccc tgtcctggca
tcagtagcat ctgtaacagc attaactgtc ttaaagagag 5340agagagagaa
ttccgaattg gggaacacac gatacctgtt tttcttttcc gttgctggca
5400gtactgttgc gccgcagttt ggagtcactg tagttaagtg tggatgcatg
tgcgtcaccg 5460tccactcctc ctactgtatt ttattggaca ggtcagactc
gccgggggcc cggcgagggt 5520atgtcagtgt cactggatgt caaacagtaa
taaattaaac caacaacaaa acgcacagcc 5580aaaaaaaaa 558921647PRTHomo
sapiens 2Met Ser Thr Pro Asp Pro Pro Leu Gly Gly Thr Pro Arg Pro
Gly Pro1 5 10 15Ser Pro Gly Pro Gly Pro Ser Pro Gly Ala Met Leu Gly
Pro Ser Pro 20 25 30Gly Pro Ser Pro Gly Ser Ala His Ser Met Met Gly
Pro Ser Pro Gly 35 40 45Pro Pro Ser Ala Gly His Pro Ile Pro Thr Gln
Gly Pro Gly Gly Tyr 50 55 60Pro Gln Asp Asn Met His Gln Met His Lys
Pro Met Glu Ser Met His65 70 75 80Glu Lys Gly Met Ser Asp Asp Pro
Arg Tyr Asn Gln Met Lys Gly Met 85 90 95Gly Met Arg Ser Gly Gly His
Ala Gly Met Gly Pro Pro Pro Ser Pro 100 105 110Met Asp Gln His Ser
Gln Gly Tyr Pro Ser Pro Leu Gly Gly Ser Glu 115 120 125His Ala Ser
Ser Pro Val Pro Ala Ser Gly Pro Ser Ser Gly Pro Gln 130 135 140Met
Ser Ser Gly Pro Gly Gly Ala Pro Leu Asp Gly Ala Asp Pro Gln145 150
155 160Ala Leu Gly Gln Gln Asn Arg Gly Pro Thr Pro Phe Asn Gln Asn
Gln 165 170 175Leu His Gln Leu Arg Ala Gln Ile Met Ala Tyr Lys Met
Leu Ala Arg 180 185 190Gly Gln Pro Leu Pro Asp His Leu Gln Met Ala
Val Gln Gly Lys Arg 195 200 205Pro Met Pro Gly Met Gln Gln Gln Met
Pro Thr Leu Pro Pro Pro Ser 210 215 220Val Ser Ala Thr Gly Pro Gly
Pro Gly Pro Gly Pro Gly Pro Gly Pro225 230 235 240Gly Pro Gly Pro
Ala Pro Pro Asn Tyr Ser Arg Pro His Gly Met Gly 245 250 255Gly Pro
Asn Met Pro Pro Pro Gly Pro Ser Gly Val Pro Pro Gly Met 260 265
270Pro Gly Gln Pro Pro Gly Gly Pro Pro Lys Pro Trp Pro Glu Gly Pro
275 280 285Met Ala Asn Ala Ala Ala Pro Thr Ser Thr Pro Gln Lys Leu
Ile Pro 290 295 300Pro Gln Pro Thr Gly Arg Pro Ser Pro Ala Pro Pro
Ala Val Pro Pro305 310 315 320Ala Ala Ser Pro Val Met Pro Pro Gln
Thr Gln Ser Pro Gly Gln Pro 325 330 335Ala Gln Pro Ala Pro Met Val
Pro Leu His Gln Lys Gln Ser Arg Ile 340 345 350Thr Pro Ile Gln Lys
Pro Arg Gly Leu Asp Pro Val Glu Ile Leu Gln 355 360 365Glu Arg Glu
Tyr Arg Leu Gln Ala Arg Ile Ala His Arg Ile Gln Glu 370 375 380Leu
Glu Asn Leu Pro Gly Ser Leu Ala Gly Asp Leu Arg Thr Lys Ala385 390
395 400Thr Ile Glu Leu Lys Ala Leu Arg Leu Leu Asn Phe Gln Arg Gln
Leu 405 410 415Arg Gln Glu Val Val Val Cys Met Arg Arg Asp Thr Ala
Leu Glu Thr 420 425 430Ala Leu Asn Ala Lys Ala Tyr Lys Arg Ser Lys
Arg Gln Ser Leu Arg 435 440 445Glu Ala Arg Ile Thr Glu Lys Leu Glu
Lys Gln Gln Lys Ile Glu Gln 450 455 460Glu Arg Lys Arg Arg Gln Lys
His Gln Glu Tyr Leu Asn Ser Ile Leu465 470 475 480Gln His Ala Lys
Asp Phe Lys Glu Tyr His Arg Ser Val Thr Gly Lys 485 490 495Ile Gln
Lys Leu Thr Lys Ala Val Ala Thr Tyr His Ala Asn Thr Glu 500 505
510Arg Glu Gln Lys Lys Glu Asn Glu Arg Ile Glu Lys Glu Arg Met Arg
515 520 525Arg Leu Met Ala Glu Asp Glu Glu Gly Tyr Arg Lys Leu Ile
Asp Gln 530 535 540Lys Lys Asp Lys Arg Leu Ala Tyr Leu Leu Gln Gln
Thr Asp Glu Tyr545 550 555 560Val Ala Asn Leu Thr Glu Leu Val Arg
Gln His Lys Ala Ala Gln Val 565 570 575Ala Lys Glu Lys Lys Lys Lys
Lys Lys Lys Lys Lys Ala Glu Asn Ala 580 585 590Glu Gly Gln Thr Pro
Ala Ile Gly Pro Asp Gly Glu Pro Leu Asp Glu 595 600 605Thr Ser Gln
Met Ser Asp Leu Pro Val Lys Val Ile His Val Glu Ser 610 615 620Gly
Lys Ile Leu Thr Gly Thr Asp Ala Pro Lys Ala Gly Gln Leu Glu625 630
635 640Ala Trp Leu Glu Met Asn Pro Gly Tyr Glu Val Ala Pro Arg Ser
Asp 645 650 655Ser Glu Glu Ser Gly Ser Glu Glu Glu Glu Glu Glu Glu
Glu Glu Glu 660 665 670Gln Pro Gln Ala Ala Gln Pro Pro Thr Leu Pro
Val Glu Glu Lys Lys 675 680 685Lys Ile Pro Asp Pro Asp Ser Asp Asp
Val Ser Glu Val Asp Ala Arg 690 695 700His Ile Ile Glu Asn Ala Lys
Gln Asp Val Asp Asp Glu Tyr Gly Val705 710 715 720Ser Gln Ala Leu
Ala Arg Gly Leu Gln Ser Tyr Tyr Ala Val Ala His 725 730 735Ala Val
Thr Glu Arg Val Asp Lys Gln Ser Ala Leu Met Val Asn Gly 740 745
750Val Leu Lys Gln Tyr Gln Ile Lys Gly Leu Glu Trp Leu Val Ser Leu
755 760 765Tyr Asn Asn Asn Leu Asn Gly Ile Leu Ala Asp Glu Met Gly
Leu Gly 770 775 780Lys Thr Ile Gln Thr Ile Ala Leu Ile Thr Tyr Leu
Met Glu His Lys785 790 795 800Arg Ile Asn Gly Pro Phe Leu Ile Ile
Val Pro Leu Ser Thr Leu Ser 805 810 815Asn Trp Ala Tyr Glu Phe Asp
Lys Trp Ala Pro Ser Val Val Lys Val 820 825 830Ser Tyr Lys Gly Ser
Pro Ala Ala Arg Arg Ala Phe Val Pro Gln Leu 835 840 845Arg Ser Gly
Lys Phe Asn Val Leu Leu Thr Thr Tyr Glu Tyr Ile Ile 850 855 860Lys
Asp Lys His Ile Leu Ala Lys Ile Arg Trp Lys Tyr Met Ile Val865 870
875 880Asp Glu Gly His Arg Met Lys Asn His His Cys Lys Leu Thr Gln
Val 885 890 895Leu Asn Thr His Tyr Val Ala Pro Arg Arg Leu Leu Leu
Thr Gly Thr 900 905 910Pro Leu Gln Asn Lys Leu Pro Glu Leu Trp Ala
Leu Leu Asn Phe Leu 915 920 925Leu Pro Thr Ile Phe Lys Ser Cys Ser
Thr Phe Glu Gln Trp Phe Asn 930 935 940Ala Pro Phe Ala Met Thr Gly
Glu Lys Val Asp Leu Asn Glu Glu Glu945 950 955 960Thr Ile Leu Ile
Ile Arg Arg Leu His Lys Val Leu Arg Pro Phe Leu 965 970 975Leu Arg
Arg Leu Lys Lys Glu Val Glu Ala Gln Leu Pro Glu Lys Val 980 985
990Glu Tyr Val Ile Lys Cys Asp Met Ser Ala Leu Gln Arg Val Leu Tyr
995 1000 1005Arg His Met Gln Ala Lys Gly Val Leu Leu Thr Asp Gly
Ser Glu 1010 1015 1020Lys Asp Lys Lys Gly Lys Gly Gly Thr Lys Thr
Leu Met Asn Thr 1025 1030 1035Ile Met Gln Leu Arg Lys Ile Cys Asn
His Pro Tyr Met Phe Gln 1040 1045 1050His Ile Glu Glu Ser Phe Ser
Glu His Leu Gly Phe Thr Gly Gly 1055 1060 1065Ile Val Gln Gly Leu
Asp Leu Tyr Arg Ala Ser Gly Lys Phe Glu 1070 1075 1080Leu Leu Asp
Arg Ile Leu Pro Lys Leu Arg Ala Thr Asn His Lys 1085 1090 1095Val
Leu Leu Phe Cys Gln Met Thr Ser Leu Met Thr Ile Met Glu 1100 1105
1110Asp Tyr Phe Ala Tyr Arg Gly Phe Lys Tyr Leu Arg Leu Asp Gly
1115 1120 1125Thr Thr Lys Ala Glu Asp Arg Gly Met Leu Leu Lys Thr
Phe Asn 1130 1135 1140Glu Pro Gly Ser Glu Tyr Phe Ile Phe Leu Leu
Ser Thr Arg Ala 1145 1150 1155Gly Gly Leu Gly Leu Asn Leu Gln Ser
Ala Asp Thr Val Ile Ile 1160 1165 1170Phe Asp Ser Asp Trp Asn Pro
His Gln Asp Leu Gln Ala Gln Asp 1175 1180 1185Arg Ala His Arg Ile
Gly Gln Gln Asn Glu Val Arg Val Leu Arg 1190 1195 1200Leu Cys Thr
Val Asn Ser Val Glu Glu Lys Ile Leu Ala Ala Ala 1205 1210 1215Lys
Tyr Lys Leu Asn Val Asp Gln Lys Val Ile Gln Ala Gly Met 1220 1225
1230Phe Asp Gln Lys Ser Ser Ser His Glu Arg Arg Ala Phe Leu Gln
1235 1240 1245Ala Ile Leu Glu His Glu Glu Gln Asp Glu Ser Arg His
Cys Ser 1250 1255 1260Thr Gly Ser Gly Ser Ala Ser Phe Ala His Thr
Ala Pro Pro Pro 1265 1270 1275Ala Gly Val Asn Pro Asp Leu Glu Glu
Pro Pro Leu Lys Glu Glu 1280 1285 1290Asp Glu Val Pro Asp Asp Glu
Thr Val Asn Gln Met Ile Ala Arg 1295 1300 1305His Glu Glu Glu Phe
Asp Leu Phe Met Arg Met Asp Leu Asp Arg 1310 1315 1320Arg Arg Glu
Glu Ala Arg Asn Pro Lys Arg Lys Pro Arg Leu Met 1325 1330 1335Glu
Glu Asp Glu Leu Pro Ser Trp Ile Ile Lys Asp Asp Ala Glu 1340 1345
1350Val Glu Arg Leu Thr Cys Glu Glu Glu Glu Glu Lys Met Phe Gly
1355 1360 1365Arg Gly Ser Arg His Arg Lys Glu Val Asp Tyr Ser Asp
Ser Leu 1370 1375 1380Thr Glu Lys Gln Trp Leu Lys Ala Ile Glu Glu
Gly Thr Leu Glu 1385 1390 1395Glu Ile Glu Glu Glu Val Arg Gln Lys
Lys Ser Ser Arg Lys Arg 1400 1405 1410Lys Arg Asp Ser Asp Ala Gly
Ser Ser Thr Pro Thr Thr Ser Thr 1415 1420 1425Arg Ser Arg Asp Lys
Asp Asp Glu Ser Lys Lys Gln Lys Lys Arg 1430 1435 1440Gly Arg Pro
Pro Ala Glu Lys Leu Ser Pro Asn Pro Pro Asn Leu 1445 1450 1455Thr
Lys Lys Met Lys Lys Ile Val Asp Ala Val Ile Lys Tyr Lys 1460 1465
1470Asp Ser Ser Ser Gly Arg Gln Leu Ser Glu Val Phe Ile Gln Leu
1475 1480 1485Pro Ser Arg Lys Glu Leu Pro Glu Tyr Tyr Glu Leu Ile
Arg Lys 1490 1495 1500Pro Val Asp Phe Lys Lys Ile Lys Glu Arg Ile
Arg Asn His Lys 1505 1510 1515Tyr Arg Ser Leu Asn Asp Leu Glu Lys
Asp Val Met Leu Leu Cys 1520 1525
1530Gln Asn Ala Gln Thr Phe Asn Leu Glu Gly Ser Leu Ile Tyr Glu
1535 1540 1545Asp Ser Ile Val Leu Gln Ser Val Phe Thr Ser Val Arg
Gln Lys 1550 1555 1560Ile Glu Lys Glu Asp Asp Ser Glu Gly Glu Glu
Ser Glu Glu Glu 1565 1570 1575Glu Glu Gly Glu Glu Glu Gly Ser Glu
Ser Glu Ser Arg Ser Val 1580 1585 1590Lys Val Lys Ile Lys Leu Gly
Arg Lys Glu Lys Ala Gln Asp Arg 1595 1600 1605Leu Lys Gly Gly Arg
Arg Arg Pro Ser Arg Gly Ser Arg Ala Lys 1610 1615 1620Pro Val Val
Ser Asp Asp Asp Ser Glu Glu Glu Gln Glu Glu Asp 1625 1630 1635Arg
Ser Gly Ser Gly Ser Glu Glu Asp 1640 164535892RNAHomo sapiens
3gcgtcttccg gcgcccgcgg aggaggcgag ggtgggacgc tgggcggagc ccgagtttag
60gaagaggagg ggacggctgt catcaatgaa gtcatattca taatctagtc ctctctccct
120ctgtttctgt actctgggtg actcagagag ggaagagatt cagccagcac
actcctcgcg 180agcaagcatt actctactga ctggcagaga caggagaggt
agatgtccac gcccacagac 240cctggtgcga tgccccaccc agggccttcg
ccggggcctg ggccttcccc tgggccaatt 300cttgggccta gtccaggacc
aggaccatcc ccaggttccg tccacagcat gatggggcca 360agtcctggac
ctccaagtgt ctcccatcct atgccgacga tggggtccac agacttccca
420caggaaggca tgcatcaaat gcataagccc atcgatggta tacatgacaa
ggggattgta 480gaagacatcc attgtggatc catgaagggc actggtatgc
gaccacctca cccaggcatg 540ggccctcccc agagtccaat ggatcaacac
agccaaggtt atatgtcacc acacccatct 600ccattaggag ccccagagca
cgtctccagc cctatgtctg gaggaggccc aactccacct 660cagatgccac
caagccagcc gggggccctc atcccaggtg atccgcaggc catgagccag
720cccaacagag gtccctcacc tttcagtcct gtccagctgc atcagcttcg
agctcagatt 780ttagcttata aaatgctggc ccgaggccag cccctccccg
aaacgctgca gcttgcagtc 840caggggaaaa ggacgttgcc tggcttgcag
caacaacagc agcagcaaca gcagcagcag 900cagcagcagc agcagcagca
gcagcagcaa cagcagccgc agcagcagcc gccgcaacca 960cagacgcagc
aacaacagca gccggccctt gttaactaca acagaccatc tggcccgggg
1020ccggagctga gcggcccgag caccccgcag aagctgccgg tgcccgcgcc
cggcggccgg 1080ccctcgcccg cgccccccgc agccgcgcag ccgcccgcgg
ccgcagtgcc cgggccctca 1140gtgccgcagc cggccccggg gcagccctcg
cccgtcctcc agctgcagca gaagcagagc 1200cgcatcagcc ccatccagaa
accgcaaggc ctggaccccg tggaaattct gcaagagcgg 1260gaatacagac
ttcaggcccg catagctcat aggatacaag aactggaaaa tctgcctggc
1320tctttgccac cagatttaag aaccaaagca accgtggaac taaaagcact
tcggttactc 1380aatttccagc gtcagctgag acaggaggtg gtggcctgca
tgcgcaggga cacgaccctg 1440gagacggctc tcaactccaa agcatacaaa
cggagcaagc gccagactct gagagaagct 1500cgcatgaccg agaagctgga
gaagcagcag aagattgagc aggagaggaa acgccgtcag 1560aaacaccagg
aatacctgaa cagtattttg caacatgcaa aagattttaa ggaatatcat
1620cggtctgtgg ccggaaagat ccagaagctc tccaaagcag tggcaacttg
gcatgccaac 1680actgaaagag agcagaagaa ggagacagag cggattgaaa
aggagagaat gcggcgactg 1740atggctgaag atgaggaggg ttatagaaaa
ctgattgatc aaaagaaaga caggcgttta 1800gcttaccttt tgcagcagac
cgatgagtat gtagccaatc tgaccaatct ggtttgggag 1860cacaagcaag
cccaggcagc caaagagaag aagaagagga ggaggaggaa gaagaaggct
1920gaggagaatg cagagggtgg ggagtctgcc ctgggaccgg atggagagcc
catagatgag 1980agcagccaga tgagtgacct ccctgtcaaa gtgactcaca
cagaaaccgg caaggttctg 2040ttcggaccag aagcacccaa agcaagtcag
ctggacgcct ggctggaaat gaatcctggt 2100tatgaagttg cccctagatc
tgacagtgaa gagagtgatt ctgattatga ggaagaggat 2160gaggaagaag
agtccagtag gcaggaaacc gaagagaaaa tactcctgga tccaaatagc
2220gaagaagttt ctgagaagga tgctaagcag atcattgaga cagctaagca
agacgtggat 2280gatgaataca gcatgcagta cagtgccagg ggctcccagt
cctactacac cgtggctcat 2340gccatctcgg agagggtgga gaaacagtct
gccctcctaa ttaatgggac cctaaagcat 2400taccagctcc agggcctgga
atggatggtt tccctgtata ataacaactt gaacggaatc 2460ttagccgatg
aaatggggct tggaaagacc atacagacca ttgcactcat cacttatctg
2520atggagcaca aaagactcaa tggcccctat ctcatcattg ttcccctttc
gactctatct 2580aactggacat atgaatttga caaatgggct ccttctgtgg
tgaagatttc ttacaagggt 2640actcctgcca tgcgtcgctc ccttgtcccc
cagctacgga gtggcaaatt caatgtcctc 2700ttgactactt atgagtatat
tataaaagac aagcacattc ttgcaaagat tcggtggaaa 2760tacatgatag
tggacgaagg ccaccgaatg aagaatcacc actgcaagct gactcaggtc
2820ttgaacactc actatgtggc ccccagaagg atcctcttga ctgggacccc
gctgcagaat 2880aagctccctg aactctgggc cctcctcaac ttcctcctcc
caacaatttt taagagctgc 2940agcacatttg aacaatggtt caatgctcca
tttgccatga ctggtgaaag ggtggactta 3000aatgaagaag aaactatatt
gatcatcagg cgtctacata aggtgttaag accattttta 3060ctaaggagac
tgaagaaaga agttgaatcc cagcttcccg aaaaagtgga atatgtgatc
3120aagtgtgaca tgtcagctct gcagaagatt ctgtatcgcc atatgcaagc
caaggggatc 3180cttctcacag atggttctga gaaagataag aaggggaaag
gaggtgctaa gacacttatg 3240aacactatta tgcagttgag aaaaatctgc
aaccacccat atatgtttca gcacattgag 3300gaatcctttg ctgaacacct
aggctattca aatggggtca tcaatggggc tgaactgtat 3360cgggcctcag
ggaagtttga gctgcttgat cgtattctgc caaaattgag agcgactaat
3420caccgagtgc tgcttttctg ccagatgaca tctctcatga ccatcatgga
ggattatttt 3480gcttttcgga acttccttta cctacgcctt gatggcacca
ccaagtctga agatcgtgct 3540gctttgctga agaaattcaa tgaacctgga
tcccagtatt tcattttctt gctgagcaca 3600agagctggtg gcctgggctt
aaatcttcag gcagctgata cagtggtcat ctttgacagc 3660gactggaatc
ctcatcagga tctgcaggcc caagaccgag ctcaccgcat cgggcagcag
3720aacgaggtcc gggtactgag gctctgtacc gtgaacagcg tggaggaaaa
gatcctcgcg 3780gccgcaaaat acaagctgaa cgtggatcag aaagtgatcc
aggcgggcat gtttgaccaa 3840aagtcttcaa gccacgagcg gagggcattc
ctgcaggcca tcttggagca tgaggaggaa 3900aatgaggaag aagatgaagt
accggacgat gagactctga accaaatgat tgctcgacga 3960gaagaagaat
ttgacctttt tatgcggatg gacatggacc ggcggaggga agatgcccgg
4020aacccgaaac ggaagccccg tttaatggag gaggatgagc tgccctcctg
gatcattaag 4080gatgacgctg aagtagaaag gctcacctgt gaagaagagg
aggagaaaat atttgggagg 4140gggtcccgcc agcgccgtga cgtggactac
agtgacgccc tcacggagaa gcagtggcta 4200agggccatcg aagacggcaa
tttggaggaa atggaagagg aagtacggct taagaagcga 4260aaaagacgaa
gaaatgtgga taaagatcct gcaaaagaag atgtggaaaa agctaagaag
4320agaagaggcc gccctcccgc tgagaaactg tcaccaaatc cccccaaact
gacaaagcag 4380atgaacgcta tcatcgatac tgtgataaac tacaaagata
ggtgtaacgt ggagaaggtg 4440cccagtaatt ctcagttgga aatagaagga
aacagttcag ggcgacagct cagtgaagtc 4500ttcattcagt taccttcaag
gaaagaatta ccagaatact atgaattaat taggaagcca 4560gtggatttca
aaaaaataaa ggaaaggatt cgtaatcata agtaccggag cctaggcgac
4620ctggagaagg atgtcatgct tctctgtcac aacgctcaga cgttcaacct
ggagggatcc 4680cagatctatg aagactccat cgtcttacag tcagtgttta
agagtgcccg gcagaaaatt 4740gccaaagagg aagagagtga ggatgaaagc
aatgaagagg aggaagagga agatgaagaa 4800gagtcagagt ccgaggcaaa
atcagtcaag gtgaaaatta agctcaataa aaaagatgac 4860aaaggccggg
acaaagggaa aggcaagaaa aggccaaatc gaggaaaagc caaacctgta
4920gtgagcgatt ttgacagcga tgaggagcag gatgaacgtg aacagtcaga
aggaagtggg 4980acggatgatg agtgatcagt atggaccttt ttccttggta
gaactgaatt ccttcctccc 5040ctgtctcatt tctacccagt gagttcattt
gtcatatagg cactgggttg tttctatatc 5100atcatcgtct ataaactagc
tttaggatag tgccagacaa acatatgata tcatggtgta 5160aaaaacacac
acatacacaa atatttgtaa catattgtga ccaaatgggc ctcaaagatt
5220cagattgaaa caaacaaaaa gcttttgatg gaaaatatgt gggtggatag
tatatttcta 5280tgggtgggtc taatttggta acggtttgat tgtgcctggt
tttatcacct gttcagatga 5340gaagattttt gtcttttgta gcactgataa
ccaggagaag ccattaaaag ccactggtta 5400ttttattttt catcaggcaa
ttttcgaggt ttttatttgt tcggtattgt ttttttacac 5460tgtggtacat
ataagcaact ttaataggtg ataaatgtac agtagttaga tttcacctgc
5520atatacattt ttccatttta tgctctatga tctgaacaaa agctttttga
attgtataag 5580atttatgtct actgtaaaca ttgcttaatt tttttgctct
tgatttaaaa aaaagttttg 5640ttgaaagcgc tattgaatat tgcaatctat
atagtgtatt ggatggcttc ttttgtcacc 5700ctgatctcct atgttaccaa
tgtgtatcgt ctccttctcc ctaaagtgta cttaatcttt 5760gctttctttg
cacaatgtct ttggttgcaa gtcataagcc tgaggcaaat aaaattccag
5820taatttcgaa gaatgtggtg ttggtgcttt cctaataaag aaataattta
gcttgacaaa 5880aaaaaaaaaa aa 589241590PRTHomo sapiens 4Met Ser Thr
Pro Thr Asp Pro Gly Ala Met Pro His Pro Gly Pro Ser1 5 10 15Pro Gly
Pro Gly Pro Ser Pro Gly Pro Ile Leu Gly Pro Ser Pro Gly 20 25 30Pro
Gly Pro Ser Pro Gly Ser Val His Ser Met Met Gly Pro Ser Pro 35 40
45Gly Pro Pro Ser Val Ser His Pro Met Pro Thr Met Gly Ser Thr Asp
50 55 60Phe Pro Gln Glu Gly Met His Gln Met His Lys Pro Ile Asp Gly
Ile65 70 75 80His Asp Lys Gly Ile Val Glu Asp Ile His Cys Gly Ser
Met Lys Gly 85 90 95Thr Gly Met Arg Pro Pro His Pro Gly Met Gly Pro
Pro Gln Ser Pro 100 105 110Met Asp Gln His Ser Gln Gly Tyr Met Ser
Pro His Pro Ser Pro Leu 115 120 125Gly Ala Pro Glu His Val Ser Ser
Pro Met Ser Gly Gly Gly Pro Thr 130 135 140Pro Pro Gln Met Pro Pro
Ser Gln Pro Gly Ala Leu Ile Pro Gly Asp145 150 155 160Pro Gln Ala
Met Ser Gln Pro Asn Arg Gly Pro Ser Pro Phe Ser Pro 165 170 175Val
Gln Leu His Gln Leu Arg Ala Gln Ile Leu Ala Tyr Lys Met Leu 180 185
190Ala Arg Gly Gln Pro Leu Pro Glu Thr Leu Gln Leu Ala Val Gln Gly
195 200 205Lys Arg Thr Leu Pro Gly Leu Gln Gln Gln Gln Gln Gln Gln
Gln Gln 210 215 220Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
Gln Gln Pro Gln225 230 235 240Gln Gln Pro Pro Gln Pro Gln Thr Gln
Gln Gln Gln Gln Pro Ala Leu 245 250 255Val Asn Tyr Asn Arg Pro Ser
Gly Pro Gly Pro Glu Leu Ser Gly Pro 260 265 270Ser Thr Pro Gln Lys
Leu Pro Val Pro Ala Pro Gly Gly Arg Pro Ser 275 280 285Pro Ala Pro
Pro Ala Ala Ala Gln Pro Pro Ala Ala Ala Val Pro Gly 290 295 300Pro
Ser Val Pro Gln Pro Ala Pro Gly Gln Pro Ser Pro Val Leu Gln305 310
315 320Leu Gln Gln Lys Gln Ser Arg Ile Ser Pro Ile Gln Lys Pro Gln
Gly 325 330 335Leu Asp Pro Val Glu Ile Leu Gln Glu Arg Glu Tyr Arg
Leu Gln Ala 340 345 350Arg Ile Ala His Arg Ile Gln Glu Leu Glu Asn
Leu Pro Gly Ser Leu 355 360 365Pro Pro Asp Leu Arg Thr Lys Ala Thr
Val Glu Leu Lys Ala Leu Arg 370 375 380Leu Leu Asn Phe Gln Arg Gln
Leu Arg Gln Glu Val Val Ala Cys Met385 390 395 400Arg Arg Asp Thr
Thr Leu Glu Thr Ala Leu Asn Ser Lys Ala Tyr Lys 405 410 415Arg Ser
Lys Arg Gln Thr Leu Arg Glu Ala Arg Met Thr Glu Lys Leu 420 425
430Glu Lys Gln Gln Lys Ile Glu Gln Glu Arg Lys Arg Arg Gln Lys His
435 440 445Gln Glu Tyr Leu Asn Ser Ile Leu Gln His Ala Lys Asp Phe
Lys Glu 450 455 460Tyr His Arg Ser Val Ala Gly Lys Ile Gln Lys Leu
Ser Lys Ala Val465 470 475 480Ala Thr Trp His Ala Asn Thr Glu Arg
Glu Gln Lys Lys Glu Thr Glu 485 490 495Arg Ile Glu Lys Glu Arg Met
Arg Arg Leu Met Ala Glu Asp Glu Glu 500 505 510Gly Tyr Arg Lys Leu
Ile Asp Gln Lys Lys Asp Arg Arg Leu Ala Tyr 515 520 525Leu Leu Gln
Gln Thr Asp Glu Tyr Val Ala Asn Leu Thr Asn Leu Val 530 535 540Trp
Glu His Lys Gln Ala Gln Ala Ala Lys Glu Lys Lys Lys Arg Arg545 550
555 560Arg Arg Lys Lys Lys Ala Glu Glu Asn Ala Glu Gly Gly Glu Ser
Ala 565 570 575Leu Gly Pro Asp Gly Glu Pro Ile Asp Glu Ser Ser Gln
Met Ser Asp 580 585 590Leu Pro Val Lys Val Thr His Thr Glu Thr Gly
Lys Val Leu Phe Gly 595 600 605Pro Glu Ala Pro Lys Ala Ser Gln Leu
Asp Ala Trp Leu Glu Met Asn 610 615 620Pro Gly Tyr Glu Val Ala Pro
Arg Ser Asp Ser Glu Glu Ser Asp Ser625 630 635 640Asp Tyr Glu Glu
Glu Asp Glu Glu Glu Glu Ser Ser Arg Gln Glu Thr 645 650 655Glu Glu
Lys Ile Leu Leu Asp Pro Asn Ser Glu Glu Val Ser Glu Lys 660 665
670Asp Ala Lys Gln Ile Ile Glu Thr Ala Lys Gln Asp Val Asp Asp Glu
675 680 685Tyr Ser Met Gln Tyr Ser Ala Arg Gly Ser Gln Ser Tyr Tyr
Thr Val 690 695 700Ala His Ala Ile Ser Glu Arg Val Glu Lys Gln Ser
Ala Leu Leu Ile705 710 715 720Asn Gly Thr Leu Lys His Tyr Gln Leu
Gln Gly Leu Glu Trp Met Val 725 730 735Ser Leu Tyr Asn Asn Asn Leu
Asn Gly Ile Leu Ala Asp Glu Met Gly 740 745 750Leu Gly Lys Thr Ile
Gln Thr Ile Ala Leu Ile Thr Tyr Leu Met Glu 755 760 765His Lys Arg
Leu Asn Gly Pro Tyr Leu Ile Ile Val Pro Leu Ser Thr 770 775 780Leu
Ser Asn Trp Thr Tyr Glu Phe Asp Lys Trp Ala Pro Ser Val Val785 790
795 800Lys Ile Ser Tyr Lys Gly Thr Pro Ala Met Arg Arg Ser Leu Val
Pro 805 810 815Gln Leu Arg Ser Gly Lys Phe Asn Val Leu Leu Thr Thr
Tyr Glu Tyr 820 825 830Ile Ile Lys Asp Lys His Ile Leu Ala Lys Ile
Arg Trp Lys Tyr Met 835 840 845Ile Val Asp Glu Gly His Arg Met Lys
Asn His His Cys Lys Leu Thr 850 855 860Gln Val Leu Asn Thr His Tyr
Val Ala Pro Arg Arg Ile Leu Leu Thr865 870 875 880Gly Thr Pro Leu
Gln Asn Lys Leu Pro Glu Leu Trp Ala Leu Leu Asn 885 890 895Phe Leu
Leu Pro Thr Ile Phe Lys Ser Cys Ser Thr Phe Glu Gln Trp 900 905
910Phe Asn Ala Pro Phe Ala Met Thr Gly Glu Arg Val Asp Leu Asn Glu
915 920 925Glu Glu Thr Ile Leu Ile Ile Arg Arg Leu His Lys Val Leu
Arg Pro 930 935 940Phe Leu Leu Arg Arg Leu Lys Lys Glu Val Glu Ser
Gln Leu Pro Glu945 950 955 960Lys Val Glu Tyr Val Ile Lys Cys Asp
Met Ser Ala Leu Gln Lys Ile 965 970 975Leu Tyr Arg His Met Gln Ala
Lys Gly Ile Leu Leu Thr Asp Gly Ser 980 985 990Glu Lys Asp Lys Lys
Gly Lys Gly Gly Ala Lys Thr Leu Met Asn Thr 995 1000 1005Ile Met
Gln Leu Arg Lys Ile Cys Asn His Pro Tyr Met Phe Gln 1010 1015
1020His Ile Glu Glu Ser Phe Ala Glu His Leu Gly Tyr Ser Asn Gly
1025 1030 1035Val Ile Asn Gly Ala Glu Leu Tyr Arg Ala Ser Gly Lys
Phe Glu 1040 1045 1050Leu Leu Asp Arg Ile Leu Pro Lys Leu Arg Ala
Thr Asn His Arg 1055 1060 1065Val Leu Leu Phe Cys Gln Met Thr Ser
Leu Met Thr Ile Met Glu 1070 1075 1080Asp Tyr Phe Ala Phe Arg Asn
Phe Leu Tyr Leu Arg Leu Asp Gly 1085 1090 1095Thr Thr Lys Ser Glu
Asp Arg Ala Ala Leu Leu Lys Lys Phe Asn 1100 1105 1110Glu Pro Gly
Ser Gln Tyr Phe Ile Phe Leu Leu Ser Thr Arg Ala 1115 1120 1125Gly
Gly Leu Gly Leu Asn Leu Gln Ala Ala Asp Thr Val Val Ile 1130 1135
1140Phe Asp Ser Asp Trp Asn Pro His Gln Asp Leu Gln Ala Gln Asp
1145 1150 1155Arg Ala His Arg Ile Gly Gln Gln Asn Glu Val Arg Val
Leu Arg 1160 1165 1170Leu Cys Thr Val Asn Ser Val Glu Glu Lys Ile
Leu Ala Ala Ala 1175 1180 1185Lys Tyr Lys Leu Asn Val Asp Gln Lys
Val Ile Gln Ala Gly Met 1190 1195 1200Phe Asp Gln Lys Ser Ser Ser
His Glu Arg Arg Ala Phe Leu Gln 1205 1210 1215Ala Ile Leu Glu His
Glu Glu Glu Asn Glu Glu Glu Asp Glu Val 1220 1225 1230Pro Asp Asp
Glu Thr Leu Asn Gln Met Ile Ala Arg Arg Glu Glu 1235 1240 1245Glu
Phe Asp Leu Phe Met Arg Met Asp Met Asp Arg Arg Arg Glu 1250 1255
1260Asp Ala Arg Asn Pro Lys Arg Lys Pro Arg Leu Met Glu Glu Asp
1265 1270 1275Glu Leu Pro Ser Trp Ile Ile Lys Asp Asp Ala Glu Val
Glu Arg 1280 1285 1290Leu Thr Cys Glu Glu Glu Glu Glu Lys Ile Phe
Gly Arg Gly Ser 1295 1300 1305Arg Gln Arg Arg Asp Val Asp Tyr Ser
Asp Ala Leu Thr Glu Lys 1310 1315 1320Gln Trp Leu Arg Ala Ile Glu
Asp Gly Asn Leu Glu Glu Met Glu 1325 1330 1335Glu Glu Val Arg Leu
Lys Lys Arg Lys Arg Arg Arg Asn Val Asp 1340 1345 1350Lys Asp Pro
Ala Lys Glu Asp Val Glu Lys Ala Lys Lys Arg Arg 1355 1360
1365Gly Arg Pro Pro Ala Glu Lys Leu Ser Pro Asn Pro Pro Lys Leu
1370 1375 1380Thr Lys Gln Met Asn Ala Ile Ile Asp Thr Val Ile Asn
Tyr Lys 1385 1390 1395Asp Arg Cys Asn Val Glu Lys Val Pro Ser Asn
Ser Gln Leu Glu 1400 1405 1410Ile Glu Gly Asn Ser Ser Gly Arg Gln
Leu Ser Glu Val Phe Ile 1415 1420 1425Gln Leu Pro Ser Arg Lys Glu
Leu Pro Glu Tyr Tyr Glu Leu Ile 1430 1435 1440Arg Lys Pro Val Asp
Phe Lys Lys Ile Lys Glu Arg Ile Arg Asn 1445 1450 1455His Lys Tyr
Arg Ser Leu Gly Asp Leu Glu Lys Asp Val Met Leu 1460 1465 1470Leu
Cys His Asn Ala Gln Thr Phe Asn Leu Glu Gly Ser Gln Ile 1475 1480
1485Tyr Glu Asp Ser Ile Val Leu Gln Ser Val Phe Lys Ser Ala Arg
1490 1495 1500Gln Lys Ile Ala Lys Glu Glu Glu Ser Glu Asp Glu Ser
Asn Glu 1505 1510 1515Glu Glu Glu Glu Glu Asp Glu Glu Glu Ser Glu
Ser Glu Ala Lys 1520 1525 1530Ser Val Lys Val Lys Ile Lys Leu Asn
Lys Lys Asp Asp Lys Gly 1535 1540 1545Arg Asp Lys Gly Lys Gly Lys
Lys Arg Pro Asn Arg Gly Lys Ala 1550 1555 1560Lys Pro Val Val Ser
Asp Phe Asp Ser Asp Glu Glu Gln Asp Glu 1565 1570 1575Arg Glu Gln
Ser Glu Gly Ser Gly Thr Asp Asp Glu 1580 1585 1590
* * * * *
References